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The purpose of this study was to estimate the cost of illness of Parkinson’s disease in the United States.
Direct medical expenditures, with the exception of nursing home costs, were estimated using data from
the 1999-2003 Medical Expenditures Panel Survey Household Component (MEPS-HC). Nursing home
costs were estimated using the Medical Expenditures Panel Survey Nursing Home Component (MEPSNHC). Indirect costs for lost productivity due to missed work or bed-days (morbidity) were estimated
using the MEPS-HC and the Bureau of Labor Statistics (BLS). Indirect costs for lost productivity due to
death (mortality) were estimated using the National Vital Statistics System.
Direct and indirect costs of Parkinson’s disease in the United States were estimated at $39,661,102,321
for the five year period of 1999-2003. Direct medical costs totaled $25,686,503,575 and direct nonmedical expenditures accounted for $328,048,817. The majority of direct medical costs were found to be
associated with nursing home care for patients with Parkinson’s disease and prescription medications for
the treatment of Parkinson’s disease. Indirect costs resulting from lost workdays, bed-days, and mortality
totaled $10,870,870,402. The majority of indirect costs was due to bed days ($9,619,603,534), followed by
mortality costs ($861,530,870) and lost workdays ($389,735,998).
There were no statistically significant differences in total cost of illness between gender, education, age,
marital status, income level and region of residence found in this study for patients with Parkinson’s
disease. This study concluded that there are statistically significant differences in direct medical costs for
male and female patients v with Parkinson’s disease. This study also concluded that there are statistically
significant differences in direct medical costs for patients who live in the South compared to patients in
the Northeast. Direct non-medical costs were the least frequently reported cost by patient’s with
Parkinson’s disease in this study. Patients who live in the South reported the largest proportion of indirect
costs due to morbidity. However, there were no statistically significant differences in selected
demographic characteristics and morbidity costs for patients with Parkinson’s disease.
The overall total cost of illness was estimated by this study to be over six billion dollars annually for
patients with Parkinson’s disease. While not as costly a disease state as Alzheimer’s, Parkinson’s disease
is a more costly disease when compared to Multiple Sclerosis, a disease state with a similar prevalence.
This cost of illness estimate has provided an initial understanding of the costs associated with
Parkinson’s disease. Forthcoming research of the cost of illness of Parkinson’s disease will now have a
solid foundation to expand upon.
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ABSTRACT

The purpose of this study was to estimate the cost of illness of Parkinson’s disease in
the United States. Direct medical expenditures, with the exception of nursing home
costs, were estimated using data from the 1999-2003 Medical Expenditures Panel Survey
Household Component (MEPS-HC). Nursing home costs were estimated using the
Medical Expenditures Panel Survey Nursing Home Component (MEPS-NHC). Indirect
costs for lost productivity due to missed work or bed-days (morbidity) were estimated
using the MEPS-HC and the Bureau of Labor Statistics (BLS). Indirect costs for lost
productivity due to death (mortality) were estimated using the National Vital Statistics
System.
Direct and indirect costs of Parkinson’s disease in the United States were estimated at
$39,661,102,321 for the five year period of 1999-2003. Direct medical costs totaled
$25,686,503,575 and direct non-medical expenditures accounted for $328,048,817. The
majority of direct medical costs were found to be associated with nursing home care for
patients with Parkinson’s disease and prescription medications for the treatment of
Parkinson’s disease. Indirect costs resulting from lost workdays, bed-days, and mortality
totaled $10,870,870,402. The majority of indirect costs was due to bed days
($9,619,603,534), followed by mortality costs ($861,530,870) and lost workdays
($389,735,998).
There were no statistically significant differences in total cost of illness between
gender, education, age, marital status, income level and region of residence found in this
study for patients with Parkinson’s disease. This study concluded that there are
statistically significant differences in direct medical costs for male and female patients
v

with Parkinson’s disease. This study also concluded that there are statistically significant
differences in direct medical costs for patients who live in the South compared to patients
in the Northeast. Direct non-medical costs were the least frequently reported cost by
patient’s with Parkinson’s disease in this study. Patients who live in the South reported
the largest proportion of indirect costs due to morbidity. However, there were no
statistically significant differences in selected demographic characteristics and morbidity
costs for patients with Parkinson’s disease.
The overall total cost of illness was estimated by this study to be over six billion
dollars annually for patients with Parkinson’s disease. While not as costly a disease state
as Alzheimer’s, Parkinson’s disease is a more costly disease when compared to Multiple
Sclerosis, a disease state with a similar prevalence. This cost of illness estimate has
provided an initial understanding of the costs associated with Parkinson’s disease.
Forthcoming research of the cost of illness of Parkinson’s disease will now have a solid
foundation to expand upon.
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CHAPTER L INTRODUCTION

Data on the economic burden of Parkinson’s disease is limited, but it is considered to
be one of the most expensive neurological disorders to treat.1 Parkinson’s disease is a
common chronic neurodegenerative disease for which there is currently no cure.2'3 In the
United States, an estimated 500,000 to 1.5 million people have Parkinson’s disease, with
approximately 50,000 new cases are diagnosed each year 4-6 Existing estimates of
medical expenses for Parkinson’s disease range between $5.6 billion and $25 billion
dollars annually.7’8 Parkinson’s disease has a dramatic impact on a person’s quality of life
and results in severe disability despite the availability of a variety of pharmacological and
surgical treatments.3

Definition of Parkinson’s Disease
Parkinson’s disease is the most common form of Parkinsonism and was originally
referred to in 1817 as “Shaking Palsy.”9 During the 1960s, research on Parkinson’s
disease revealed the pathology and biology of the disease.9 The physiological causes of
Parkinson’s disease are generally agreed upon. In the substantia nigra, the brain cells or
neurons of persons with Parkinson’s disease become impaired or die.10 These neurons are
responsible for the production of the chemical messenger dopamine that enters nerve
cells.10 Patients with Parkinson’s disease experience a loss of more than 80% of neurons
that produce dopamine.10 The lack of dopamine causes nerve cells to fire out of control,
leaving patients with Parkinson’s disease unable to control movements normally.10
Most people diagnosed with Parkinson’s disease are over the age of 65; however,
approximately 10% of cases occur in persons under the age of 50.11 The prevalence of
1

Parkinson’s disease increases with age.12 Prevalence of the disease is estimated to be 1
out of 100 people over the age of 65, and 3 out of 100 for those over 85.11 The average
age of individuals at diagnosis of Parkinson’s disease ranges between 55 and 60 years.

10

In the United States, there are varying estimates on the number of persons with
Parkinson’s disease, ranging from 500,000 to 1.5 million.6 Currently more males than
females suffer from Parkinson’s disease. Specifically, males have a relative risk 1.5
times higher than that of females for developing Parkinson’s disease.13

Description of the Problem
In 1900, only 3 million persons in the United States were over the age of 65.14
However, by the year 2000, 39 million persons were 65 years or older.15 In 2002,
healthcare expenditures accounted for 14.9% of the gross domestic product, with older
persons accounting for the highest percentage of healthcare resources and services.16 By
the year 2030, population estimates predict that one in five Americans will be 65 years or
older, with the most rapidly growing population segment being those 85 and older.15
Given the increasing prevalence of Parkinson’s disease with advancing age, the number
of persons developing Parkinson’s disease will increase dramatically over the next
several decades.17 Between the years of 1990 and 2040, neurodegenerative disease
mortality is expected to increase in the United States by 166%.5
Parkinson’s disease has no cure and is considered one of the most expensive
neurodegenerative diseases to treat .1’2,18 While a variety of pharmaceutical options exist
to reduce symptoms, no treatment exists to slow the progression of Parkinson’s disease.
Patients with Parkinson’s disease require increasing amounts of care as the disease
progresses, increasing amounts of assistance from informal (unpaid) caregivers, and in
2

the latter stages of the disease, a high level of formal care.18 Although Parkinson’s
disease is the second most common neurodegenerative disease, there are only limited
data on the economic impact of Parkinson’s disease.18
Based on a review of the peer reviewed literature, a detailed national estimate of the
burden of Parkinson’s disease does not exist.18'20 Existing cost of illness estimates
published on the Internet or by foundations for Parkinson’s disease lack a clear
explanation of the methodology used to obtain the estimates. These existing estimates
vary between $5.6 billion and $25 billion- a $20 billion range in cost of illness for
Parkinson’s disease.7,8 Because of the wide variation and lack of peer review in these
estimates, there is a need for conducting a detailed analysis of the cost of illness, or more
specifically the direct and indirect costs of Parkinson’s disease.18'20
Other medical conditions have been previously studied and the results used for the
healthcare policy setting. In 2002, Druss used the Medical Expenditures Panel Survey
(MEPS) database to compare the costs of 15 different medical conditions and then used
these findings to discuss how cost of illness studies and economic burden studies may be
used in setting healthcare priorities.21 The Druss study revealed that, ischemic heart
disease, which affects 3.4 million persons, was the most expensive at $21.5 billion
annually. Druss also studied congestive heart failure, a condition which affects
approximately the same number of people as Parkinson’s disease. The annual cost for
the 1.1 million people with congestive heart failure was $5.2 billion.21 Having a baseline
estimate of the costs for Parkinson’s disease would be useful for comparison and ranking
the disease with other medical conditions to set priorities given our limited healthcare
dollars.
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With the aging of the population and the increasing importance of healthcare
expenditures, it would be valuable to have the cost of illness (i.e., economic outcomes)
information specific to the United States. Several reasons exist regarding why the initial
focus should be on cost of illness. First, 3 out of every 100 people over the age of 85
have Parkinson’s disease.11,22 Second, the population of people living over 85 continues
to rise.23 Third, drug treatments for Parkinson’s disease are already expensive and as new,
more expensive treatments are released, total drug-related costs will continue to rise.
Fourth, the available healthcare dollars are limited, and finally, cost of illness studies are
useful in defining the magnitude of disease in monetary terms, assisting in the allocation
of resources, providing a foundation for policy, and serving as an economic framework
for program evaluation.24'25

Description of Cost of Illness
A branch of health economics, pharmacoeconomics is the study of the application of
economic theory to drugs and pharmaceutical services.

A pharmacoeconomic analysis

seeks to identify and measure the costs and consequences of drug use. Specifically,
pharmacoeconomic analyses measure clinical health, quality of life, and economic
outcomes related to drug therapy.27 Phamacoeconomic methods are increasingly being
used by researchers and practitioners to study the impact of the use of pharmaceuticals on
the health of patients. Information obtained from pharmacoeconomic studies is used by a
variety of individuals and organizations, including consumers, physicians, payers, federal
and state governments, and healthcare analysts. One pharmacoeconomic model is the
cost of illness analysis. Theoretically, a cost of illness analysis examines the total costs
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that are the result of a specific disease.26 A cost of illness model may take into account
direct medical, direct non-medical, indirect, and intangible expenses.

28

In 1966, Rice introduced cost of illness as a methodology that measures the economic
burden placed on society due to disease or illness.28 The cost of illness framework has
been popular among researchers and policy makers, and the number of cost of illness
studies has proliferated. Typically, cost of illness studies are used to compare the
economic impact of various health problems, either on a national or international level.29
Cost of illness studies were initially used to support the need for additional healthcare
resources.25 In the early 1990s, the pharmaceutical industry started using cost of illness
information to support the idea that if a disease has a large impact on the economy, it
should receive more resources in research and development. 25
Cost of illness studies provide insight into diseases and resource allocation in a way
that morbidity and mortality rates do not.25 Morbidity and mortality data provide a
measure of the physical impact of a disease. With costs being an important component of
health care in the United States, a cost of illness study serves an important role. A
condition such as arthritis may contribute to significant healthcare resource use but is not
a life-threatening disease. Drummond suggests that using mortality and morbidity data
alone to allocate resources could overlook many chronic diseases that require significant
healthcare resources.
Two approaches exist for conducting a cost of illness study. The first approach is
referred to as incidence based and calculates the lifetime cost of an illness.28,30 The
second approach is referred to as prevalence based and estimates the costs during any
given year.31
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The cost of caring for patients can be separated into three categories: 1) direct costs, 2)
indirect costs, and 3) intangible costs.26,28 Direct costs are those that are directly related
to the illness and for which there is a monetary exchange.28'31 Direct costs may be further
divided into direct medical and direct non-medical costs.31 Direct medical costs are
defined as costs that are related to medical care, including treatment, diagnosis and
continuity of care26 Examples of direct medical costs include hospitalization, emergency
department visits, medications, rehabilitation, nursing home care, and treatment by
medical professionals. Depending on an individual’s geographic location, direct medical
costs associated with a particular disease may vary.
A second component of direct costs is non-medical costs. Direct non-medical costs are
those incurred by the patient to access medical care.26 Examples of direct non-medical
costs are transportation to access the healthcare system, child care, and household
expenses related to managing the illness.31 These costs are not accounted for as
consistently in cost of illness studies as the direct medical costs.31
Indirect costs are those not related to the delivery of health care and where there is no
monetary exchange.28,30 Indirect costs are primarily related to a loss in productivity by
the individual or by family members caring for the individual.26,31 Given the impact of
Parkinson’s disease on a patient’s ability to function, these costs may be substantial.
Indirect costs are the loss of output by an individual with an illness or disability because
they are no longer being able to perform their job (morbidity costs) or because they have
died due to the illness (mortality costs). Both indirect morbidity and mortality costs
should include considerations for age and gender.
Intangible costs are associated with emotional pain and suffering, and measure the
effect of a disease on a person’s quality of life.26 Intangible costs are hard to quantify
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because of the difficulty associated with assigning a dollar value to emotional stress.
Because of this, intangible costs are typically excluded from cost of illness estimates.31,32
Figure 1-1 depicts visually the components of a cost of illness model, as outlined by
Rice.28
Figure 1-2 depicts the components of the Parkinson’s disease cost of illness model
that was used in this study with an expanded description of each of the included
components and the data source used. One entire component of the cost of illness model,
intangible costs, was not included in this study. At present, no one has successfully
quantified this component of cost of illness.33,34
The primary research question to be investigated in this exploratory descriptive study
was: What is the cost of illness of Parkinson’s disease in the United States?

Purpose of the Study
The purpose of this study was to provide a prevalence-based retrospective national
estimate of the cost of illness (direct and indirect costs) of Parkinson’s disease in the
United States in 2003.

Objectives of the Study
The objectives of this study were to:
1. Use a national database to estimate the direct and indirect costs (cost of illness)
for persons with Parkinson’s disease in the United States.
2. Describe healthcare resource utilization for persons with Parkinson’s disease in
the United States.
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Figure 1-1. Cost of Illness Model. A Visual Representation of the Components Outlined
by Rice.
Source: Rice DP. Estimating the Cost of Illness. 6, 3-19. 1966. Washington, DC, U.S.
Department of Health, Education and Welfare. Health Economics Series.
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Figure 1-2. Cost of Illness Model for Parkinson’s Disease. A visual representation of the
components outlined by Rice and the categories of cost used to measure direct and
indirect costs of Parkinson’s disease used in this study.
Dotted line (—) = not measured.
Italicized - not captured by any of the databases
*Data from the National Vital Statistics Survey (NVSS) and Bureau of Labor Statistics
(BLS).
MEPS = Medical Expenditures Panel Survey, the database used for collecting direct and
indirect costs.
Adapted with permission from: Rice DP. Estimating the Cost of Illness. 6, 3-19. 1966.
Washington, DC, US. Department of Health, Education and Welfare. Health Economics
Series.
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3. Determine if there is a statistically significant relationship between gender and
cost of illness for Parkinson’s disease.
4. Determine if there is a statistically significant relationship between education
level and cost of illness for Parkinson’s disease.
5. Determine if there is a statistically significant relationship between age and cost
of illness for Parkinson’s disease in the United States.
6. Determine if there is a statistically significant relationship between marital status
and cost of illness for Parkinson’s disease.
7. Determine if there is a statistically significant relationship between income level
and cost of illness for Parkinson’s disease.
8. Determine if there is a statistically significant relationship between region of
residence and cost of illness for Parkinson’s disease.
9. Determine if there is a statistically significant relationship when adjusting for
demographic characteristics (gender, education level, age, marital status, income
level, and region of residence) jointly and cost of illness for Parkinson’s disease.

Definitions of Terms and Concepts
The following is a list of terms and concepts utilized throughout this study.
1. Bureau o f Labor Statistics (BLS) —Government agency that supplies labor force
data and information on the demographics, productivity, wages, and employment
rates for persons in the Untied States.
2. Current Population Survey (CPS) —A monthly survey conducted by the Bureau of
Census for the Bureau of Labor Statistics that provides data on the labor force,
employment, unemployment, and persons not in the labor force.
10

3. Cost o f illness—A measurement of economic burden placed on society because of
a disease or illness.28 Cost of illness is determined by the following equation:
direct costs (DC) + indirect costs (IC) + intangible costs = cost of illness (COI).
4. Direct medical costs—Costs related to the provision of medical care, including the
screening, prevention, diagnosis, and treatment of diseases. Direct costs include
costs for emergency room visits, hospital inpatient visits, hospital outpatient visits,
nursing home care, (prescription and over-the-counter) medications/treatments,
and treatment by medical professionals.
5. Direct non-medical costs—Costs related to the illness borne by the patient that do
not involve treatment. Examples of direct non-medical costs are transportation or
lodging in order to access the healthcare system and childcare while obtaining
medical treatment. Household expenses such as home modifications because of a
medical condition are also contained in the category of direct non-medical
costs.26,28
6. Emergency room services—Includes visits to healthcare providers in an
emergency room. These charges are only for patients who were seen and
discharged from the emergency room. The expenses in this category include both
payments for services covered under the general facility charge and separately
billed physician services. If a patient is admitted to the hospital, emergency room
services are not included in this category. Emergency room charges for patients
admitted to the hospital through the emergency are included in the hospital
inpatient services category.
7. Home health visits—Expenses for care that was provided by home health agencies
and independent home health providers.
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8. Hospital inpatient services—Room, board, and all hospital diagnostic and
laboratory expenses associated with the basic facility charges. Separately billed
physician services and emergency room expenses that occurred immediately prior
to admission are also included in this category. Charges from the emergency
room are only included in this category if the patient was admitted. If the patient
was seen in the emergency room and discharged, those charges appear in
emergency room services.
9. Hospital outpatient services—Expenses for visits to physicians and other medical
providers seen in hospital outpatient departments. Separately billed physician
services and facility charges are also included in this category.
10. Household expenses—Any expenses related to home modifications that are
necessary because of a specific disease or medical condition. An example of a
home modification would be the addition of hand rails near the bathtub.
11. Human capital method—Technique that quantifies indirect costs by calculating
non-medical costs associated with a particular disease state. The human capital
method calculates the value of lost productivity due to absence from the work
place caused by disability (morbidity) or death (mortality).
12. Indirect costs—Costs of illness related to loss in productivity by the individual
who is ill and by family members who care for that individual.26,28 Two
components of indirect costs are morbidity and mortality costs. Morbidity costs
are those costs associated with a loss in productivity, and mortality costs are
calculated using the present value of future earnings lost.
13. Institutionalized population—Population under formally authorized, supervised
care or custody. Population restricted to an institution, under the care or
12

supervision of trained staff, and includes individuals who are patients in health
care facilities or inmates in prison or jail.36 For the purposes of this study,
institutionalized population refers to patients in nursing home facilities who were
part of the Medical Expenditures Panel Survey Nursing Home Component
(MEPS-NHC).
14. Intangible costs—Costs of illness related to emotional pain and suffering and
measure the effect of a disease on a person’s quality of life.26 Intangible costs
were not addressed in this study.
15. MedicalExpenditures Panel Survey (MEPS)—A national healthcare database that
collects data on specific health services that Americans use, the cost of these
services, and frequency of use.37 Data on the cost, scope, and breadth of health
insurance in the United States are also collected.37
16. Morbidity costs—Costs associated with the loss of paid or unpaid productivity due
to an illness.
17.Mortality costs—Costs associated with the loss of paid or unpaid productivity due
to death from an illness or disease. Mortality costs are calculated using the
present value of future earnings lost.
18. National Vital Statistics System (NVSS)—Data provided through the National
Center for Health Statistics (NCHS) and vital registration systems that are
responsible for the registration of vital events (births, deaths, marriages, divorces,
and fetal deaths).38
19. Non-Institutionalized Population—Civilian population who live in the United
States and reside somewhere other than an institution.39 For the purposes of this
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study, non-institutionalized population refers to patients who were in the Medical
Expenditures Panel Survey Household Component (MEPS-HC).
20. Nursing home care—A facility that specializes in providing care to people who
are chronically ill and/or who are unable to take care of necessary daily living
needs.
21. Office-based medical provider services—Included in this category are expenses
for visits to medical providers that were seen in either office-based settings or
clinics.
22. Parkinson’s disease—The most common form of Parkinsonism; it is a chronic,
progressive, neurological disease resulting from a loss of dopamine-producing
brain cells. Parkinson’s disease affects different areas of the body and causes
difficulty with starting movements. Known also as a motor system disorder,
stiffness, slowness, and tremors are all symptoms associated with Parkinson’s
disease. The International Classification of Diseases, Ninth Revision, Clinical
Modification Code (ICD-9-CM) for Parkinson’s disease is 332.0-332.1.
23 Prescription medicines—Any medication that requires an order (prescription)
from a physician to be obtained. This category includes expenses for all
prescription medications (i.e., initial purchases of prescribed medications and
refills of them).
24. Treatment by medical professionals—Treatment received from any type of
healthcare worker in either a healthcare setting or the home. The types of
healthcare provider, as specified in the Home Health Services database, includes
(among others): certified nursing assistant, dietitian, home-health aide, hospice
worker, homemaker, IV therapist, medical doctor, nurse’s aide, nurse practitioner,
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occupational therapist, personal care attendant, physical therapist, respiratory
therapist, social worker, and speech therapist.

Assumptions
The following assumptions were made regarding this research:
1. The data in the MEPS database are valid and reliable;
2. The model used is reliable and valid;
3. The national sample is representative of the U.S. population with Parkinson’s
disease; and
4. Direct and indirect costs are captured by the data sources.

Limitations of the Study
The limitations of this research were:
1. The data to be analyzed for this project might not provide a complete or accurate
estimate of the direct and indirect costs associated with Parkinson’s disease;
2. Respondents to the MEPS survey may inaccurately report the existence or non
existence of a condition.
3. Intangible costs are not measured as part of the study.

Relevance to Health Science Administration
A cost of illness analysis is an excellent tool for policy makers and legislatures to
determine where resource allocation occurs. MEPS is a resource that provides
comprehensive and timely information about direct and indirect healthcare costs in the
United States.40 It is currently used by policy makers and healthcare administrators to
15

formulate economic projections related to health care. A cost of illness analysis of
Parkinson’s disease using MEPS will provide understanding of how healthcare spending
(direct and indirect costs) for Parkinson’s disease is distributed in the United States. This
research will assist in determining if the existing health policies need to be changed, or if
new policies need to be created. By knowing that healthcare dollars for an illness such as
Parkinson’s disease were spent in a specific area, such as treatments, administrators can
make better financial plans for their organizations.

Organization of the Study
This dissertation is organized into five chapters. Chapter II provides a review of the
literature encompassing a description of Parkinson’s disease, the epidemiology of
Parkinson’s disease, as well as the economic, clinical and humanistic outcomes of
Parkinson’s disease. Chapter HI presents the methods used in the research, while Chapter
IV provides the results of the research. Chapter V is a discussion of findings and possible
future directions that the research may suggest.
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CHAPTER II. REVIEW OF LITERATURE

Introduction
The goal of this chapter is to provide a review of literature relevant to the purpose of
this research. The chapter is outlined as a brief history of Parkinson’s disease, followed
by an overview of the pathological and clinical features of Parkinson’s disease. The
literature review continues with a description of how Parkinson’s disease is diagnosed
and how the severity of Parkinson’s disease is assessed. The next section provides a
detailed description of the epidemiology of Parkinson’s disease. The etiology, incidence,
prevalence, risk factors, and protective factors for Parkinson’s disease are discussed.
Next, pharmaceutical treatments, surgical treatments, and ancillary treatments for
Parkinson’s disease are discussed. The remainder of this review focuses on cost of
illness, the Medical Expenditures Panel Survey (MEPS) database, and
pharmacoeconomic studies of Parkinson’s disease. The cost of illness section provides
the history and description of cost of illness. The MEPS database section provides a
description of MEPS and a review of other cost of illness studies that utilize the MEPS
database. The review of pharmacoeconomic studies of Parkinson’s disease covers
previous cost of illness studies of Parkinson’s disease, as well as economic studies of the
costs of treatment.

Description of Parkinson’s Disease
Parkinson’s disease is the most common form of Parkinsonism and was initially
referred to in 1817 as “Shaking Palsy.”9 Known as both chronic and progressive,
Parkinson’s disease has recently become more widely publicized. During the 1960s,
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research on Parkinson’s disease revealed the pathology and biology of the disease.41
Most people with Parkinson’s disease live an average of 10 years before dying, typically
from an infection.8 The most common type of infection causing death in a patient with
Parkinson’s disease is pneumonia. For a variety of reasons, Parkinson’s disease
symptoms become more severe after the first five years.8

Pathological Features
The physiological causes of Parkinson’s disease are generally agreed upon. The brain
cells or neurons in the substantia nigra of patients with Parkinson’s disease become
impaired or die.8 These neurons produce the chemical messenger dopamine that goes into
the nerve cells. Patients with Parkinson’s disease may experience a loss of more than
80% of neurons that produce dopamine.8 The loss of dopamine causes nerve cells to fire
out of control, thus destroying normally controlled movements.8

Clinical Features
Parkinson’s disease is characterized by four major neurological signs: resting tremor,
bradykinesia, cogwheel rigidity, and impaired postural reflexes.42 Typically a patient
may experience signs and symptoms of Parkinson’s disease for one year before being
evaluated by a doctor.42 The most common symptom of Parkinson’s disease is unilateral
tremor involving a single limb.42 However, it is often revealed, after taking the patient
history, that a patient may have also been experiencing difficulty buttoning shirts,
chewing food, and walking.42 Additional signs and symptoms include loss of facial
expressions, difficulty rising from a sitting position, and difficulty turning over in bed.42
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Diagnosis
The presentation of Parkinson’s disease varies, making it difficult to clinically
diagnose early in the disease process 43 Various guidelines have been created to assist in
the diagnosis of Parkinson’s disease 43 Typically the clinical diagnosis of Parkinson’s
disease is based on the detection of a combination of selected motor signs and
symptoms.43 The cardinal motor signs of Parkinson’s disease are rigidity, tremor,
bradykinesia, and postural instability.43 Symptoms of Parkinson’s disease include altered
gait, depression, constipation, and dementia.43
Currently, there is no clinical gold standard for diagnosing live patients. Autopsy
provides the only definitive method to diagnose Parkinson’s disease,12'43 since it can
reveal the pathological trait of Parkinson’s disease, the depigmentation of the substantia
nigra.43 The presence of Lewy bodies in the affected nerve cells is also a pathological
characteristic of Parkinson’s disease; however, Lewy bodies also appear in other
neurological disorders.44

Assessing Disease Severity
Parkinson’s is a chronic, progressive disease. After the clinical diagnosis is made,
assessment scales are used to monitor the progression of the disease.12 The United
Parkinson’s Disease Rating Scale (UPDRS) measures functional status, disease
progression, and the effectiveness of medication.45 The Hoehn and Yahr scale is a mutlistage system that focuses on the existence and severity of postural instability .12 The
Schwab and England Activities of Daily Living Scale assesses quality of life issues such
as speech, handwriting, walking, and pain.
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The UPDRS was developed in 1984 and is the most commonly used scale due to the
comprehensive list of Parkinson’s disease symptoms included.43’45"47 The scale runs from
0 to 199, with zero representing no disability and 199 representing total disability.45 Four
major subscales comprise the total score: 1) Mentation, Behavior, and Mood, 2)
Activities of Daily Living, 3) Motor Exam, and 4) Complications of Therapy During the
Previous Week.45 Each of these subscales is further broken down into subscales with a
range of 0 (normal) to 4 (most severe).45 The UPDRS is considered a validated tool to
monitor the progression of Parkinson’s disease and the patient’s response to medication
therapy.46,47
The Hoehn and Yahr scale ranks patients based on their level of clinical disability.48
Patients are assigned stages from 0 to 5, with 0 being no signs of the disease and 5 being
completely disabled.48 In stage 2, patients have bilateral movement without balance
problems.48 In stage 3, patients have impaired balance and body movements.48 In stage 4
the patients have very severe symptoms but are still able to stand or walk without
assistance.48
The Schwab and England Activities of Daily Living Scale ranges from 0 to 100%
and rates patient disability due to Parkinson’s disease.49 A rating of 0 indicates the
patient is bedridden with no swallowing, bladder, or bowel function. A rating of 100
indicates total independence.49

Epidemiology of Parkinson’s Disease
The cause of Parkinson’s disease is unknown. The clinical characteristics of
Parkinson’s disease include bradykinesia, resting tremor, postural reflex impairment, and
cogwheel rigidity.22 The chief pathological features of Parkinson’s disease are the loss of
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pigmented neurons, primarily in the substantia nigra, and the presence of Lewy bodies in
the affected nerve cells 22 Clinical symptoms are produced by the loss of the nerve
chemical dopamine.50 The levels of dopamine are usually reduced by approximately
80% before a patient begins to experience clinical symptoms of Parkinson’s disease.50

Incidence and Prevalence
Worldwide, the highest prevalence of Parkinson’s disease is reported in North
America, South America, and Europe.11 The lowest prevalence is reported in Japan,
China and Africa.11 In the United States, estimates for the prevalence of Parkinson’s
disease range from 100 to 300 per 100,000 persons.22'51 The annual incidence of
Parkinson’s disease in the United States is 20 per 100,000 lives.51 Estimates on the
number of persons with Parkinson’s disease in the United States, rang from 500,000 to
1.5 million.6

Risk Factors

Age
The average age for Parkinson’s disease to be diagnosed ranges between 55 and 60
years of age.12 The incidence and prevalence of Parkinson’s disease increases with
age.11’52 It is unknown why this relationship between increased age and increased
incidence and prevalence exists. One possible explanation for the correlation between
increased age and prevalence of Parkinson’s disease is age-related neurological
vulnerability.22 Another explanation is that a causal mechanism of Parkinson’s disease is
dependent on the passage of time.22
21

Gender
If risk were equal among men and women for developing Parkinson’s disease, one
would expect that because women live longer the prevalence of Parkinson’s disease
would be greater in women.22 Incidence rates for Parkinson’s disease increase with age
for both men and women; however, men have a higher incidence rate in all age groups.53
An increasing number of studies have shown that men have an increased age-adjusted
prevalence of Parkinson’s disease.22,53'56 Baldereschi reported in 2000 an age-adjusted
relative risk in men of 2.13 compared with women for Parkinson’s disease.53

Race
The highest prevalence of Parkinson’s disease is in North American and Europe.22
The prevalence rates in Africa, China, and Japan are significantly lower.

In the United

States and Africa, several studies have found the prevalence of Parkinson’s disease to be
much lower among blacks.56'59 The findings of these studies imply that whites are at
greater risk for Parkinson’s disease.

Genetics
Heredity is another risk factor for Parkinson’s disease.22 In 1991, Maraganore studied
relatives of 20 Parkinson’s patients in Britain and found that 13 of 69 living first-degree
relatives had idiopathic Parkinson’s disease.60 The authors proposed there was an
autosomal-dominant pattern of inheritance.60 Payami found the risk of developing
Parkinson’s disease among the relatives of patients with Parkinson’s disease to be 3.5
times higher than in relatives in the control group.61 While both of these studies are
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significant, neither of them used population-based methods and therefore, the results are
not generalizable.
While some studies have found a significant genetic link for Parkinson’s disease risk,
other studies report a less prominent role for genetic factors 62-64 Studies that use twins
support the less prominent role of genetic factors in Parkinson’s disease.65-68 Since
Parkinson’s disease is a disorder that occurs late in life it is possible that if one twin dies
before developing symptoms, that the twins would appear to be discordant.

Bum et al.

used positron emission tomography (PET) scan to demonstrate that 30-40% of
asymptomatic twins had a significantly lower uptake of F-dopa.69

Toxic Exposure
Research into exogenous agents causing Parkinson’s disease was triggered when
narcotic addicts injected methyl-tetrahydophridine (MPTP) and began experiencing
Parkinson’s symptoms. Until this discovery, Parkinson’s disease was known to result
from chemical injuries; however, MPTP-induced Parkinson’s strictly mimics anatomic
and clinical features without causing additional CNS injury. This discovery initiated the
research for naturally occurring environmental factors that may be related to Parkinson’s
disease.22 The symptoms induced by the MPTP exposure were immediate; however, the
symptoms from environmental causes are slower to develop. It is possible that mildly
toxic substances could take a longer time to accumulate in the brain and the significance
may be missed.70
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Trauma
Retrospective case control studies have shown a relationship between head trauma and
.

Parkinson’s disease. '

n r n r

However, prospective studies do not find this relationship. ’

The association between head trauma and Parkinson’s disease is thought to be due to
recall bias.22 In 1991, Goetz found that Parkinson’s patients who reported head trauma
had no change in the long-term course of their disease.77 Trauma should therefore not be
considered to increase the risk of Parkinson’s unless prospectively collected data show an
association.22

Protective Factors

Diet
It has been proposed that antioxidant vitamins protect against the development of
Parkinson’s disease. The consumption of foods rich in tocopherol in two case-control
studies demonstrated decreased risk of developing Parkinson’s.78-79 The use of vitamins,
vitamin E and cod liver oil have also been associated with a decreased risk for
Parkinson’s disease.80 While these studies are few, they do suggest that eating foods rich
in tocopheral may have a protective effect against Parkinson’s disease.22 These studies
also open another research avenue between environmental toxins and the protective
effects of diet22

Cigarette Smoking
Some studies have demonstrated an inverse relationship between smoking and
Parkinson’s disease. In the 1960s, a study o f U.S. military veterans demonstrated an
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inverse relationship between smoking and Parkinson’s disease.81 Additional studies have
confirmed this finding in the United States and Europe68’74,82'90 There are studies that
have found no relationship between smoking and Parkinson’s disease or raise questions
as to the protective effect of cigarette smoking.91'95 There is a potential for multiple
confounding factors related to smoking and Parkinson’s disease, including the possibility
that patients with Parkinson’s disease who smoke die before signs and symptoms of
Parkinson’s disease manifest93’96,97

Treatments for Parkinson’s Disease
The three categories of treatment modalities for Parkinson’s disease are medications,
surgery, and ancillary treatments. Originally, surgery was the only option for patients
with Parkinson’s disease.8 However, surgical intervention creates a variety of severe side
effects, including stroke, loss of vision, difficulty swallowing, confusion, and speech
problems.8 Since being introduced in the 1960s, levodopa has been the primary
pharmacological treatment for Parkinson’s disease 98 There are five categories of
ancillary treatments for Parkinson’s disease: psychological support, social support,
occupational therapy, physical therapy, and speech therapy.

Pharmaceutical Treatments
There is no cure for Parkinson’s disease; therefore, the goal of pharmacotherapy is to
control the signs and symptoms of the disease.1243’99 Research is lacking in multiple
areas of pharmaceutical treatment for Parkinson’s disease, and there exists a wide
variation in the management of the disease.43 Patients in the early stages of Parkinson’s
disease require a different pharmacotherapy regimen than patients who are in the later
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stages.43 In the early stages of Parkinson’s disease, the goal of pharmacotherapy is to
alleviate symptoms, keep the patient functioning independently, and use the smallest
amount of pharmaceutical therapy necessary .43 In the later stages of the disease, the goal
of treatment is to reduce medication-related issues such as motor fluctuations, psychiatric
problems, and dyskinesias.100
There are five categories of pharmaceutical treatments for Parkinson’s disease:
levodopa, cathechol-o-methyltransferase inhibitors, dopamine agonists, anticholinergic
drugs, and amantadine.43,101 The primary goals of these treatments are protection from
destruction by the degeneration process, the rescue of dying neurons, and replacement of
damaged pathways." To achieve symptom control, it is necessary to either replace or
mimic the replacement of dopamine or adjust the actions of other neurotransmitters
located within the basal ganglia "

Levodopa. Levodopa was introduced in the 1960s and remains the most effective
symptomatic pharmaceutical therapy for Parkinson’s disease 43,99 Since dopamine is
unable to cross the blood-brain barrier and causes nausea, levodopa is given with a
peripheral decarboxylase inhibitor (PDI)43 The PDI reduces nausea and allows for a
limited amount of levodopa to cross the blood-brain barrier intact.43 Once in the brain,
levodopa is then converted to dopamine by decarboxylase located in the dopaminergic
neurons in the substantia nigra.102
In the early stages of Parkinson’s disease, patients experience an excellent response to
levodopa 43 However, serious side-effects are associated with extended use of
levodopa.103 The most common side-effects are motor fluctuations and dyskinesias.103
Over time, the patient experiences a decline in the duration of effect for each dose.43 As
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the patient’s Parkinson’s disease advances, the medication stops working and begins
causing motor fluctuations which are unpredictable and debilitating.43
The primary reason for delaying use of levodopa is to limit the side effects and delay
dyskinesias, which are associated with continued use of levodopa.104 Dyskinesia is the
inability to control voluntary movements, which results in fragmented movements. Some
experts think that if the initiation of levodopa is delayed, the onset of dyskinesias will be
postponed.105 Other experts believe that combining levodopa with another antiParkinson’s drug will delay the dyskinesias.

Catechol-O-Methyltranserase Inhibitors. Catechol-o-methyltranserase inhibitors are
required for the catabolism of dopamine.43 When levodopa is taken orally with a
peripheral decarboxylase inhibitor (PDI), only 5 to 10% of the levodopa reaches the
central nervous system because of the presence of catechol-o-methyl transferase
(COMT).106 Entcapone and tolcapone are two drugs that inhibit COMT and allow for the
increased bioavailability and extended action of dopamine.43 By maintaining stable levels
of levodopa in the brain and plasma, the amount of time between “wearing off’ will be
extended.107 The amount of levodopa needed will be reduced as this time period is
extended.107 There are adverse events related to the use of COMT inhibitors, including
nausea, sleep disorders, and diarrhea.107

Dopamine Agonists. Dopamine agonists mimic endogenous dopamine by acting
directly on dopamine receptors.43 Introduced in 1974, dopamine agonists can be used as
either a mono-therapy or in combination with levodopa.43,108 There are two advantages to
using dopamine agonists in the treatment o f Parkinson’s. First, when dopamine agonists
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are used early in the onset of Parkinson’s disease, the need for levodopa may be
delayed.108 Second, when used in combination therapy, dopamine agonists allow patients
to take lower doses of levodopa.43

Anticholinergic Aeents. Anticholinergic agents were prescribed and used to treat
Parkinson’s disease before levodopa and dopamine agonists became available.109,110
Anticholinergic agents relieve tremor and stiffness associated with Parkinson’s disease.43
The side effects of anticholinergic medications limit their use.43 The side effects include
dry mouth, blurred vision, constipation, urinary retention, and mental confusion.43
Because of the adverse events related to anticholinergics, their use is limited to younger
patients with Parkinson’s disease.102

Amantadine. Amantadine can be used in combination with anticholinergic
medications and levodopa.43 The mechanism of action of amantadine is unknown;
however, it is effective at reducing or eliminating drug-induced dystonia and akathisia. It
is unknown whether amantadine is effective at reducing levodopa-induced dyskinesias.43
There are numerous side effects associated with amantadine; including hallucinations,
insomnia, confusion, ankle edema, and nightmares.111

Surgical Treatments
The purpose of the surgical treatment of Parkinson’s disease has changed considerably
over the last fifty years.43 Pallidotomies and thalamotomies were performed in the 1940s
and 1950s as a way to treat the tremor associated with Parkinson’s.112 Once drug therapy
was developed, surgery for Parkinson’s disease virtually halted.8 Today, surgery is
28

generally used only when patients have severe side effects from drug therapy.103,113 The
decision to perform a surgical procedure is determined by the severity of the patient’s
symptoms and the availability of an appropriate surgical procedure.114,115

Pallidotomy. Pallidotomy is a surgical procedure that may reduce some of the
symptoms of Parkinson’s disease. The procedure reduces the dyskinesias caused by drug
therapy.116 In this procedure, a small lesion is made using heat to correct the nerve cells
that are discharging abnormally in the globus pallidus intemus.42 Candidates for this
procedure are patients who have responded well to levodopa.
Pallidotomy can be done on one or both sides of the brain. A unilateral pallidotomy
improves symptoms on the opposite side.113 In other words, if the patient has dyskinesias
on the left side, the unilateral pallidotomy is done on the right side of the brain.113 It is
recommended that pallidotomies only be done on one side of the brain .113 Bilateral
pallidotomy is controversial, and its safety has not been established.103

Thalamotomy. Thalamotomy was introduced in the 1950s as a surgical procedure to
treat Parkinson’s tremor.43 This treatment is for patients with benign essential tremor and
dystonia. A lesion is made on the ventro-lateral thalamus to relieve the tremor.
Thalamotomy may improve rigidity and dyskinesias. Thalamotomy does not improve
bradykinesia and gait problems and may even cause those symptoms to worsen.43

Deep Brain Stimulation. Deep Brain Stimulation (DBS) is used to control tremors in
patients with Parkinson’s disease. The target areas for DBS are dependent on where the
patient is experiencing a predominant amount of symptoms.117 A multi-electrode lead is
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inserted into a portion of the nucleus in the thalamus. The other end of the lead is
attached to a generator that is implanted in the upper chest. The generator can be turned
on and off by the patient with the use of a hand-held magnet that is passed over the chest
area.42 DBS has been shown to effectively reduce tremor; however, it does not relieve
bradykinesia.43

Ancillary Treatments
Many areas of a patient’s life are disrupted because of Parkinson’s disease.118 The
treatment and care for patients with Parkinson’s disease requires both an individualized
and multidisciplinary strategy. Patients frequently need psychological and social
support, speech therapy, physical therapy, and occupational therapy to maintain their
safety and independence.103119 Research is needed to determine the efficacy of ancillary
treatments. If ancillary treatments are proven to be effective, physicians could make
appropriate referrals to patients with Parkinson’s.

New Treatments
The estimate presented in this cost of illness for Parkinson’s disease covers the years
1999-2003; however, since 2003, four new medications have been approved by the FDA
for treatment of Parkinson’s disease. The first medication that was approved since 2003
by the FDA for patients with Parkinson’s disease is Apomorphine Hydrochloride
(Apokyn). This medication was approved for use in the treatment of Parkinson’s disease
in 2004 and is indicated to treat the approximately 10 percent of patients who are
unresponsive to standard Parkinson’s disease medications.
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This medication is also

used in patients with Parkinson’s disease who have reached stage 4 of Parkinson’s
disease and are experiencing severe on/off motor fluctuations.
Other medications that have been approved by the FDA since 2003 include Stalevo,
Parcopa, and Azilect. Stalevo and Parcopa were both approved in 2004 and Azilect was
approved in 2006 for the treatment of Parkinson’s disease. Stalevo is a combination of
levodopa, carbidopa and entacapone.121 Stalevo allows some patients with Parkinson’s
disease to take only one pill per day instead of two.121 Stalevo is also less expensive than
taking the same medications (carbidopa, levodopa, and entacapone) separately.
Parcopa is another medication that was approved by the FDA since 2003 for the
treatment of Parkinson’s disease. Parcopa is a combination of carbidopa and levodopa
that dissolves on the tongue and can be taken without water.122 Since being released in
2004, some doctors have reported that Parcopa may be beneficial to patients with
gastrointestinal issues.123 Parcopa may be of practical use when patients with
Parkinson’s disease are having swallowing problems or patients that are undergoing
procedures that do not allow anything to be taken by mouth.123 Currently there are no
published studies of Parcopa and it is more expensive than the existing generic and brand
name combinations of carbidopa and levodopa.
Azilect is a mono-therapy that was approved in May 2006 by the FDA for the
treatment of Parkinson’s disease.124 Because this medication was recently approved by
FDA, there are no published studies on the cost-effectiveness of Azilect. However,
Azilect has been shown to significantly improve Unified Parkinson’s Disease Rating
Scale (UPDRS) total score in clinical trials.125 In summary, treatments for Parkinson’s
disease include pharmaceutical, surgical, and ancillary treatments. Figure 2-1 provides a
visual explanation of the various ways in which Parkinson’s disease is treated.
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Figure 2-1. The Management of Parkinson’s Disease.
COMT = catechol-O-methyltransferase; CR = controlled release; MAO-B =
monoamine oxidase B; tid = 3 times daily; f = increase.
Used with permission from Olanow C, Koller W. An algorithm (decision tree) for the
management of Parkinson’s disease: Treatment guidelines. Neurology 1998; 50(3
(Supplement 3)):S1.
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Cost of Illness Overview

History o f Cost o f Illness
Cost of illness studies first appeared in the literature in 1913 and were among the first
economic studies.126 In the 1950s and 1960s, cost of illness was developed further by
Mushkin, Fein, and Rice.28,127’128 In 1959, Mushkin outlined a classification of costs inan
attempt to clarify the cost concepts of the time.127 Mushkin wanted to determine what the
impact of an illness was on economic resources.127 Specifically, he wanted to classify
costs based on their effects on the use, distribution, and quantity of economic resources to
determine the true economic impact of disease.127 In 1966, Dorothy Rice developed a
method for estimating cost of illness using existing data sets.28 This method would later
become the de facto standard for cost of illness studies. Since 1966, Rice has updated and
refined the cost of illness methodology.32
In the 1970s and 1980s, cost of illness studies were initially used in health economics
to win support for more resources being devoted to health care.

By calculating the cost

of illness, health economists could provide an actual dollar amount associated with letting
a disease run its course. In the early 1990s, cost of illness studies started being used by
pharmaceutical companies to highlight specific diseases.25 For pharmaceutical
companies, the cost of illness is used to justify that more resources should be dedicated to
a given disease if that particular disease has an enormous economic burden.25 Currently,
health economists, pharmaceutical companies, clinicians, and policy makers use the cost
of illness approach to set research agendas and allocate resources.25,129
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Description o f Cost o f Illness
The cost of illness methodology places economic costs into two categories: direct
costs and indirect costs. Direct costs of an illness include two separate categories, direct
medical and direct non-medical.130 Examples of direct medical costs are expenditures for
hospitalizations, nursing home care, home health services, medications, physician
services, etc.130 Direct non-medical costs involve costs associated with travel to and from
the doctor, family time that is spent directly caring for the illness, and community time
in

1^ 0

spent caring for the illness. ’

Retrospective Database: Medical Expenditures Panel Survey (MEPS)
The MEPS survey is a longitudinal study utilizing an overlapping panel design to
collect healthcare expenditure and utilization data at both the person and household
levels.131 The four components of the MEPS survey are the household component (HC),
insurance component (IC), nursing home component (NHC), and medical provider
component (MPC).131
The HC portion of the survey provides estimates of national healthcare use and
expenditures.131 The HC portion also provides estimates on insurance coverage and
payment sources for the United States population.

111

The IC portion of MEPS has two

components: the household sample and the list sample.131 The household sample
contains information on health insurance coverage carried by and offered to
respondents.131 The list sample portion of the survey allows for national-, regional-, and
state-level estimates to be made on the amount, type, and costs of health insurance
available in the workplace.131
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The NHC portion of the MEPS survey gathers information on three components of
nursing home care.131 The first component of the NHC survey gathers information on the
facilities and services of a particular nursing home.131 The second component of the
NHC survey gathers information on expenditures and sources of payment .131 The third
component looks at the characteristics of the residents.131 This section gathers
information on the functional and cognitive limitations of patients as well as their age,
income, and insurance coverage.131
The MPC portion of the survey serves as a supplement to the HC portion of the
MEPS.131 The MPC provides information on hospitals, physicians, and home healthcare
providers.131 This component also gathers information to estimate the expenses of people
enrolled in either a health maintenance organization or another type of managed care
plan.131

Cost of Illness Studies Using MEPS
A review of the literature found a number of studies that measured economic burden
or cost of illness using the MEPS database. The studies focused on obesity, cancer, back
pain, asthma, childhood disabilities, arthritis, musculoskeletal disorders and chronic
conditions.33,34,132'137 Eight of the 17 studies found measured both direct and indirect
costs, with none of the studies estimating intangible costs. Two of the 17 studies used
MEPS data in combination with the California Patient Discharge dataset.33’34
Max and colleagues provided a prevalence-based estimate of the cost of prostate
cancer in Califonia.34 This 1998 study estimated direct and indirect healthcare
expenditures for individuals with prostate cancer in California to be $360 million.34
Hospitalization costs for this study were derived from the California Hospital Discharge
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dataset (CHDS), and other direct costs were derived from MEPS.34 Indirect costs were
calculated by multiplying the number of deaths due to prostate cancer and the expected
value of future earnings.34 This study concluded that due to the high costs of prostate
cancer it is critical to identify cost-effective early prostate cancer detection methods.34
Max and colleagues also provided a prevalence-based estimate of the cost of
gynecologic cancers in California.33 This study estimated direct and indirect healthcare
expenditures in California for cervical, ovarian, and uterine cancers to be $624 million in
1998.33 Indirect costs were estimated to be twice the direct medical care costs.
Hospitalization costs accounted for more than half of the total direct costs for cervical,
ovarian, and uterine cancers.33 This study concluded that total costs of ovarian cancer are
highest among gynecologic cancers in California.
Liu et al. estimated the direct costs of back pain in the United States using MEPS as
the only data source.134 This national estimate compared expenses among people with
back pain and people without back pain.134 This study was done because despite the high
prevalence of back pain, there were no recent studies using a nationally representative
database.134 This study found that total incremental expenditures due to back pain were
approximately $26.3 billion. This study concluded that expenditures for back pain have a
wide variation among individuals with different demographic and socioeconomic
characteristics.
Three studies examined the costs of health care for children with special needs,
disabilities, or behavioral disorders.138'140 Newacheck and colleagues used the 2000
MEPS dataset to estimate the healthcare utilization and direct costs for children with
special healthcare needs.138 Children with special healthcare needs were found to have
healthcare costs three times higher per year ($2,099 compared to $628) than children
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without special healthcare needs.138 Using the MEPS data, the authors were able to
determine that children with special healthcare needs had about four times the number of
hospitalizations of other children.138 The study also found that children with special
healthcare needs spent an average of 7 more days per year in the hospital.138 This study
concluded that families have much higher out-of-pocket expenditures when there is a
child in the home with special healthcare needs.138 This study did not specify which
ICD-9-CM codes were used to define a child as having special needs.
Prior to the study on children with special healthcare needs, Newacheck and
colleagues used the MEPS databases to estimate health services use and healthcare
expenditures for children with disabilities.139 This study did not specify the ICD-9-CM
codes that were used to define disability.139 The study reported only the direct costs for
children with disabilities compared to children without disabilities. An estimated 5
million children (7.3%) in the United States reported a disability between 1999 and
2000.139 The authors defined disability as “the presence of a limitation in age-appropriate
social role activities, such as school or play, or receipt of specialized services through
early intervention or special education programs.” 139 Children with disabilities had an
annual average of $2,669 in healthcare expenditures compared to $676 for children
without disabilities. After controlling for insurance status, this study concluded that
lower-income families encountered more out of pocket expenses than higher-income
families.
The third study on children with special needs focused on behavioral disorders.140
Guevara and colleagues estimated the annual direct costs of various behavioral disorders
of $1,492 per child compared to $834 for children without behavioral disorders.140 This
study also compared children with behavioral disorders to children with physical
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conditions, and found that the overall healthcare costs were similar in these two groups
($1,492 compared to $1,245).140 Children who were classified as having an emotional
condition had twice the healthcare costs of children with disruptive disorders.140 MEPS
has been used in two studies to assess the direct medical costs of adults who are
obese.132,133 Wang used the 1996 MEPS data to estimate the direct medical costs of
cardiovascular disease (CVD) associated with excess body weight (EBW).132 The study
included subjects that were adults age 25 or older, excluding pregnant women.132 Body
mass index (BMI) was used as the marker for assessing obesity.132 In 2001 dollars, EBW
led to $22.17 billion in direct medical costs.132 The authors concluded that there is
economic impact due to EBW associated with CVD and that there is a need to prevent
EBW among adults in the U S.132
Arterbum and colleagues used MEPS to compare the healthcare expenditures of
people who are morbidly obese with the healthcare expenditures of people of normal
weight.133 Body mass index (BMI) was used to classify people into 1 of 6 weight
categories.133 Adults who are morbidly obese had healthcare expenditures 81% higher
than adults of normal weight.133 This study found that total healthcare expenditures due
to excess body weight was $56 billion in the year 2000 and that morbidly obese adults
were responsible for $11 billion of the total .133 This study concluded that while morbidly
obese adults represent less than 3% of the US. population, they are responsible for more
than 20% of the healthcare expenditures due to excess body weight.133 The authors
propose that future research is needed to identify interventions that will reduce the
incidence and prevalence of morbid obesity.133
One study and one follow-up report were reviewed that used MEPS data to determine
the direct and indirect costs o f arthritis and other rheumatic conditions.141’142 Yelin et al.
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used MEPS to estimate the direct and indirect costs of arthritis and other rheumatic
conditions (AORC) for the United States in 1997.141 The study used ICD-9-CM codes
and divided persons with an AORC into the following categories: 1) persons with AORC
and no other chronic condition, 2) persons with AORC and non-AORC chronic
conditions, 3) persons with AORC and 1 non-AORC chronic condition, and 4) persons
with AORC and 2 or more chronic conditions.141 The total healthcare expenditures
specifically attributable to AORC were $51.1 billion.141 The indirect cost component
measured lost wages and found a total of $35.1 billion in lost wages specifically
attributable to AORC.141 The authors concluded that persons with AORC had a total of
$269.3 billion in direct and indirect costs for 1997 and that approximately one-third of
these costs ($86.2 billion) were due to their AORC. 141
Cistemas and colleagues reported on costs by state and found that total costs
attributable to AORC ranged by state from $163 million (Wyoming) to $11.3 billion
(California).142 A total of 38.4 million people in the United States (14.2%) have an
AORC.142 The report concluded that as the population in the United States continues to
age and more interventions become available, the treatment costs and overall costs of
AORC will rise. To reduce the costs of AORC, the authors suggest expanding AORC
self-management programs, maintaining healthy weight, and increasing physical
activity.142
Three MEPS studies focused on conditions of the respiratory system, with one
specifically focusing on asthma, one on rhinitis, and one on respiratory conditions in
general.135'137 Yelin and colleagues used MEPS to determine the direct costs associated
with respiratory conditions.135 The specific respiratory conditions were selected by ICD9-CM codes and included asthma, chronic bronchitis, emphysema, bronchiectasis,
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chronic obstructive disease, coal workers’ pneumoconiosis, and asbestosis.135 The study
used data from the 1996 MEPS and found that on average persons with respiratory
conditions spent $3,753 per year and that the national total for respiratory conditions in
the United States was $45.3 billion.135 Hospital stays represented forty-five percent of
costs associated with respiratory conditions, making it the largest component of direct
medical costs.135 This study also reported that individuals with the highest 5% of
expenditures accounted for 45% of the total expenditures for these conditions.135 The
authors concluded that interventions that reduce the use of costly asthma action plans and
improve self-management of asthma could greatly reduce the high direct costs of
•

respiratory conditions.

m e

Law and colleagues estimated the direct costs of allergic rhinitis using 1996 MEPS
data.137 This study estimated the direct costs of allergic rhinitis to be $3.4 billion
annually, with the majority attributable to outpatient visits and prescription
medications.137 This study found that 58% of patients with allergic rhinitis received at
least one prescription for its treatment .137 However, the direct costs of allergic rhinitis
increased dramatically since the introduction of second-generation antihistamines and
intranasal corticosteroids.137 Finally, this study found that individuals without insurance
coverage had higher out-of-pocket expenditures for prescription medications than
individuals with insurance coverage.137
Using 1996 MEPS data and the National Vital Statistics System, Wang et al. measured
the direct and indirect costs of asthma from a societal perspective.136 The total economic
impact of childhood asthma was $1.9 billion annually in 1996. This study compared
expenses for children with asthma to children without asthma and found that parents’ loss
of productivity from asthma-related school absence days was $719 million.136 To
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determine the value of lost wages, the authors used estimates from a previous study.143
Mortality costs were estimated using the National Vital Statistics System.136 A total of
211 school- aged children died of asthma, resulting in a loss of $264.7 million in lifetime
earnings.136 By using two data sources, Wang et al. were able to provide a comprehensive
estimate of cost of illness for childhood asthma.136
Yelin estimated the costs associated with musculoskeletal conditions in two studies
using MEPS data from 1996 and 1997.144,145 Both studies used ICD-9-CM codes for
musculoskeletal conditions and compared healthcare expenditures for people with and
without musculoskeletal conditions.144 In the 1996 study, Yelin used MEPS to estimate
all the direct medical expenditures for persons with musculoskeletal conditions and to
determine whether the existence of health insurance or managed care had an impact on
those medical expenditures.144 Yelin estimated an overall national total for
musculoskeletal conditions of $193 billion, with the largest component being hospital
admissions (37%).144 Among those with health insurance, a total of $3,249 in healthcare
expenditures per person was reported compared to $723 in persons without health
insurance.144 This study concluded that lack of insurance did have a significant effect
(/MX0001) among persons with a musculoskeletal condition.144
In 1997, Yelin again used MEPS to estimate the direct and indirect costs associated
with musculoskeletal conditions and for the subset of arthritis.145 The national total for
persons with musculoskeletal conditions was $239.6 billion; the largest components of
medical care expenditures were hospital-related costs (3 8%).145 Among persons with
musculoskeletal conditions, the average per capita expenditures were $4,251 compare to
$2,312 for persons who reported having no musculoskeletal conditions.145 This study
estimated the overall national total for arthritis conditions to be $186.9 billion, with the
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largest component being hospital-related costs (39%).145 Among persons with arthritis,
the average per capita expenditures were $4,865 and among persons without arthritis, the
average expenditures were $2,397.145
The indirect costs for musculoskeletal conditions were estimated in two stages. First,
the raw earnings gap due to lower employment rates of persons with a musculoskeletal
condition was compared to those without a musculoskeletal condition, and second,
earnings losses for persons with musculoskeletal conditions who were employed were
estimated.145 The raw earnings gap due to lower employment was $98.2 billion in 1997
and the estimated loss of earnings for those who were employed was $5.5 billion. The
net effect of the loss due to lower employment rate ($98.2 billion) and loss among those
who were employed ($5.5 billion) was $103.7 billion. The incremental aggregate net
earnings gap attributable to musculoskeletal conditions was $90.6 billion after controlling
for demographic characteristics, occupation, and industry.145
The indirect costs for arthritis were also estimated using the same two-stage process
for musculoskeletal conditions. The raw earning gap due to lower employment rates of
persons with arthritis compared to those without arthritis was $73.2 billion in 1997, and
the estimated loss of earnings for those who were employed was $9.2 billion. Yelin
reported that the net effect of the lower employment rate and loss of earnings to be $82.4
billion. Once demographic characteristics, occupation, and industry were controlled for,
the incremental aggregate net earnings gap attributable to arthritis was $65.2 billion.145
Druss used 1996 MEPS in two studies to compare direct and indirect costs between
various conditions.21,146 In the first study, Druss used MEPS data to examine the patterns
of economic burden among five chronic conditions: mood disorders, diabetes, heart
diseases, asthma, and hypertension.146 Druss found that hypertension had the highest
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total for direct health costs at $110.3 billion. Of the five conditions, heart disease had the
highest treatment cost total at $21.5 billion.146 Two conditions (mood disorders and
hypertension) had the highest total for indirect cost at an estimated work-loss cost of
$11.5 billion.146 Heart disease had the highest per capita costs for services directly
resulting from the condition.146 This study found that these high costs were associated
with elevated rates of hospitalization for heart disease compared to the other
conditions.146
Druss also used data from the 1996 MEPS to identify the 15 most expensive
conditions nationally.21 On a population level, the most expensive conditions were
ischemic heart disease ($21.5 billion annually) and motor vehicle accidents ($21.2 billion
annually).21 Per capita, the two most expensive conditions were respiratory malignancies
($5 billion annually) and ischemic heart disease.21 After ranking each of the conditions
by cost of treatment, Druss then ranked each condition by the amount the person was
disabled because of the condition21 Mood disorders, chronic obstructive pulmonary
disease, and arthropathies were the three conditions with the lowest treatment costs
relative to their disability level.21 Genitourinary cancers, motor vehicle accidents, and
cardiac dysrhythmias were the three conditions with the highest expenditures relative to
their disability level.21 Druss concluded that the most costly conditions are not
necessarily the most disabling conditions.21
Table 2-1 provides an overview of each of the cost studies discussed that used MEPS.
This table begins with the most recently published study using MEPS.
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Table 2-1. Overview of Cost of Illness Studies Using MBPS.
Author

Wang136

Arterbum133

Year

2005

2005

Newacheck138 2005

Yelin141

2004

Disease
Topic

Number in
Study
Unweighted
and Weighted
n = 248
(unweighted)

Direct and
indirect

n = 2,521,537
(weighted)
n = 9,812
(unweighted)

Estimate the direct and
indirect costs of childhood
asthma and compare to
children without asthma.

The cost of asthma on
children, families, and
society is high ($1.9
billion annually).

Direct
costs only

The economic burden of
morbid obesity in U.S.
adults is substantial
($1 lbillion annually).

Children
with
special
needs

n = 949
(unweighted)

Direct
costs only

Examine the impact of
morbid obesity on
healthcare expenditures
compared to persons who
are not morbidly obese.
Provide total healthcare
expenses and out-of-pocket
expenses for families with
special needs children.

Arthritis
and other
rheumatic
conditions
(AORC)

n = 4,776
(unweighted)

Asthma

Morbid
obesity

Costs
Measured

n = 11 million
(weighted)

n = 38.4 million
(weighted)

Direct and
indirect

Objective

Estimate the total medical
expenditures and earning
lost associated with AORC.

Conclusions

Families with special
needs children have
higher annual
expenditures ($2,099)
than families who do not
have a special needs child
($628).
Persons with AORC
earned less than those
without AORC. AORC
explained $1,500 of the
lost wages.

Table 2-1. (continued).
Author

Luo147

Year

Disease
Topic

2004 Back pain

Number in
Costs
Objective
Conclusions
Study
Measured
Unweighted
and Weighted ________________________________________________________
n = 25.9 million Direct
Estimate the total healthcare There is a wide variation
(weighted)
costs only expenditures of individuals
of costs among different
with back pain.
demographic and
socioeconomic groups.
Estimated overall cost of
back pain is $26.3 billion
annually.

Newacheck1,y 2004 Children
n = 963
with
(unweighted)
disabilities
n = 5 million
(weighted)

Direct
costs only

Examine healthcare
expenditure patterns for
children with disabilities.

Behavioral n = 3,955
disorders
(unweighted)
in children

Direct
costs only

Identify if children with
behavioral disorders have
similar healthcare
expenditures when
compared to children
without behavioral
disorders.

Guevara140

2003

There is an uneven
financial burden on
families with children
who have disabilities.
Low income families bore
a lot of out of pocket
expenses.
Children with emotional
disorders incurred higher
costs than children with
disruptive disorders.
Children with physical
conditions had similar
expenses as those children
with behavioral disorders.

Table 2-1. (continued).
Author

Year

Disease
Topic

Law137

2003

Allergic
rhinitis

Max33

2003

CDC14*

2003

Number in
Study
Unweighted
and Weighted
20.9 million
weighted

Costs
Measured

Objective

Direct
costs only

Update estimate of the
direct costs of allergic
rhinitis in the U.S.

Gynecologic n = 8,241
cancers
(unweighted)

Direct and
indirect
costs

Estimate the direct and
indirect costs of
gynecologic cancers in
California.

Arthritis and
other
rheumatic
Conditions,
(AORC)

Direct and
indirect
costs

Report a summary of cost
findings for AORC in the
1997 MEPS study of all
states.

Conclusions

Direct costs have
increased since the
introduction of secondgeneration antihistamines
and corticosteroids.
A cost-effective method
for screening is needed.
Early detection and
management could
reduce morbidity and
mortality costs.
Total costs were $116.3
billion in the U.S.
Treatments will grow
more costly and therefore
state and local health
officials should
implement programs to
reduce the costs of
AORC.

Table 2-1. (continued).
Year

Disease Topic

Max34

2002

Prostate
cancer

Number in Study
Unweighted and
Weighted
n = 9,043
(unweighted)

Yelin135

2002

Respiratory
conditions

n = 1,027
(unweighted)

Direct
costs only

Druss21

2002 Most
expensive
medical
conditions in
the U.S.

n = not reported

Direct and
indirect
costs

Wang132

2002

Cardiovascular n = 12.5 million
disease (CVD) (weighted)
due to excess
body weight
(EBW)

Direct
costs only

Author

Costs
Measured
Direct and
indirect
costs

Objective

Conclusions

Study the annual costs of Cost-effective
prostate cancer in
screening is critical in
California.
the efforts to reduce the
high costs of prostate
cancer.
Estimate the medical
Total medical
expenditures were
expenditures of persons
with respiratory
estimated to be $45.3
conditions.
billion in 1996.
Identify the most
The most expensive
expensive medical
conditions in the U.S.
conditions in the U.S.
have very little in
common except for
their high costs.
Estimate the direct costs
of CVD due to EBW.

EBW needs to be
prevented in order to
lower economic
burden.

Table 2-1. (continued).
Author

Year

Disease Topic

Yelin144 2001 Musculoskeletal
conditions

Druss146 2001

Yelin145

Number in Study
Unweighted and
Weighted
w = 4,161

Five most
chronic
conditions in
the U.S.

n = 5,176

1997 Musculoskeletal
conditions

n = 6,875
(unweighted)

Costs
Measured

Objective

Conclusions

Direct
costs only

Estimate the cost of
medical care for persons
with musculoskeletal
conditions.

Persons with
musculoskeletal
conditions had high
total medical
expenditures due to
their condition.
Each condition
represented a
substantial economic
burden. The
characteristics driving
these costs are unique
to each condition.
In 1997, persons with
musculoskeletal
conditions experienced
$239.6 billion in
medical expenditures.

Direct and Examine the patterns of
indirect the costs of the five most
costs chronic conditions in the
U.S.

Direct and
indirect
costs

Summarize the direct
and indirect costs of
persons with chronic
musculoskeletal
conditions.

Pooling Consecutive Years of MEPS Data
To enable researchers to generate reliable estimates and to facilitate the analysis of
low prevalence disease states, the method of pooling multiple years of the MEPS data is
used. Pooling data is done by dividing the annual person weight (PERWT) by the
number of years being analyzed. The PERWT is how many people a person in the MEPS
survey represents for a particular year. For example, one year a person may represent
1,000 people in the United States. The following year that same person represents 2,000
people in the United States. So if a researcher were analyzing two years of the MEPS
data, the PERWT for each person in the analysis file would be divided by two. For the
person in the example, their pooled PERWT would be: 1,000 (year 1 PERWT) +
2,000(year 2 PERWT) = 3,000 / 2 (number of years being pooled). By using pooled
years of data, standard errors of the estimate(s) are reduced, the types of statistical
analyses are extended, and any variations for expenditure estimates are reduced. Two
studies were reviewed that analyzed the MEPS data using the pooling methodology. The
first study was conducted to show the improvement in the precision of estimates that can
be obtained when the MEPS data are pooled.149 This study pooled data from four years
of the MEPS.149 It demonstrated how more specific statistical analyses could be done on
a subgroup of children.149 Specifically, the study wanted to provide detailed statistics on
healthcare expenditures for children who were Asian/Pacific Islander and under the age
of six years old.149 The single year files for the MEPS contained fewer than 100 children
who met these criteria.149 By using the pooling method, the researchers were able to
provide an accurate estimate of healthcare expenditures for this small subgroup.149
The second study pooled four years of the MEPS data to assess the relationship of
access to health care and the number of missed workdays for patients with migraine
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headaches.150 The study population was between the ages of 18 and 65 years old, and had
complete data in the MEPS on the number of missed worked days.150 A total of 1,628
patients in the four years of the MEPS data used in this study reported having migraine
headaches and of those, 703 met the criteria for inclusion.150 The study reported a
statistically significant relationship (P=.025) between missed work days and access to
care.150 This study concluded that high access to care is positively associated with the
probability to both miss work and to have a higher number of missed workdays.150

Pharmacoeconomic Studies and Parkinson’s Disease
While a national estimate of Parkinson’s disease in the United States does not exist,
seven studies have been conducted on the economical impact of Parkinson’s
disease.19’20’23’51’151'153 Four of the seven studies used patient interviews to examine
costs.19,23,151,152 One of the seven studies used national databases as the data source.20
Another study used a managed care database of a large healthcare plan in the Midwest
region of the United States.51 The other study used medical records of patients with
Parkinson’s disease and compared utilization of services with patients who did not have
Parkinson’s disease.
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Three of the four studies that used patient interviews measured the health status and
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The fourth study compared the costs of patients with Parkinson’s

disease who were on levodopa therapy with patients who were not on levodopa.152
In 2002, Parashos used medical records of 89 patients with Parkinson’s disease and 89
patients without Parkinson’s disease to determine differences among patients’ utilization
of medical services.153 Medical records from the Rochester Epidemiology Project in
Minnesota were reviewed from 1979 until 1988.153 Patients with Parkinson’s disease
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were found to have a statistically significantly higher median number of doctor visits per
year (7.9 compared to 5.9 in the non-Parkinson’s group; .P=.001).153 Overall, patients
with Parkinson’s disease used more outpatient and nursing homes services than patients
without Parkinson’s disease.153 Parashos also reported that education and clinical
characteristics influenced utilization of medical services and outcomes.
To establish a baseline cost of Parkinson’s disease in a healthcare plan, Littlefield, et
al. conducted a retrospective study of healthcare claims data.51 Covering approximately
1.8 million people in the Midwest, the healthcare plan database contained all claims for
medications, home health care, nursing home care, office-based visits, inpatient hospital
visits, and outpatient hospital visits.51 The study population consisted of 450 patients
with a diagnosis of Parkinson’s disease and enrollment in both medical and pharmacy
plans continuously from January 1, 1995 through June 30, 1998.51 The total healthcare
costs for the 3-year period were $6,575,450, with 60% of those costs were medication
costs ($3,945,270).51 The authors concluded that there is a need for healthcare plans to
establish guidelines for the cost-effective use of pharmaceuticals and that case
management strategies need to be developed to deliver optimal care to Parkinson’s
patients.51
Two studies measured the health and economic burdens of Parkinson’s disease.23,151
The first study used a cross-sectional survey of patients from the Neurology Clinic at the
University of Iowa Hospitals and Clinic (UIHC) and Iowa Methodist Hospital (IMH).151
The sample included both men and women with a diagnosis of idiopathic Parkinson’s
disease.151 The patients were also required to have stable Parkinson’s disease and be able
to be observed during a period without symptoms.151 Exclusion criteria were secondary
Parkinsonism resulting from drugs, metabolic disorders, or exposure to toxins and
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surgery in the last 90 days.151 Multiple survey instruments were used in this study to
assess both health and economic impact of Parkinson’s.151 To assess the health impact the
following instruments were used: the UPDRS, the Medical Outcome Study Short Form
(SF-36), the Visual Analog Scale (VAS), the Mini-Mental State Exam (MMSE), and
Center for Epidemiology Studies Depression Scale (CESD); general physical function
was assessed by 12 questions about activities of daily living and instrumental activities of
daily living.151 The direct economic burden of Parkinson’s disease was measured by the
use of primary, ancillary, and community services.151 In addition, patients were asked if
they had to make modifications to a home or automobile because of their condition.151 To
calculate the indirect economic burden of Parkinson’s disease, patients were asked about
the number of days that illness or injury kept them in bed or restricted their normal
activities.151 In addition, patients were asked about their inability to do certain kinds or
amounts of work because of health problems.151 Finally, patients were asked if they
retired early or became unemployed due to Parkinson’s disease.151
The results of the study found that as Parkinson’s disease advances, so does the use of
health-related resources.151 The use of physician services was not related to disease stage;
however, the Parkinson’s disease stage was related to hospitalization, emergency room
use, and the need for special equipment.151 Ancillary community services and home or
car modifications were also associated with Parkinson’s disease stage.151 When compared
with the general population, patients with Parkinson’s disease had lower scores in most
health related quality of life (HRQL) dimensions on the SF-36. Patients with Parkinson’s
disease in this study reported that as their disease progressed, there was a substantial
increase in physical limitations that led to decreased work productivity.151 This study did
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not report the actual dollar amounts for the direct and indirect costs of Parkinson’s
disease.151
The second study measured the health and economic burden of Parkinson’s disease
using in-home interviews in Central North Carolina.23 This cross-sectional study used
109 patients with Parkinson’s disease to examine the burden of Parkinson’s disease on
the individual, the family, and society.23 The Duke survey was the primary survey
instrument used in this study.23 Information on health status (activities of daily living and
instrumental activities of daily living), informal care, medical care, and alterations to
home and automobiles was gathered. 23
The study found that direct health costs were not the largest component of family
burden.23 The largest component of family burden was the burden of providing informal
care-giving and loss of earnings.23 Informal care cost was calculated for people who
received both formal and informal care, and for people who only received informal
care.23 If the person received both formal and informal care, the cost for the informal care
was calculated the using the price the survey respondent reported paying for formal
care.23 An average hourly wage of $12.95 from the Panel Study of Income Dynamics
(PSID) was used to calculate care-giving costs for those who only received informal
care.23 The average dollar amount for informal care-giving was $5,386 and the average
dollar amount for lost earnings was $12,082.
The average societal burden per individual with Parkinson’s disease was
approximately $6,000 annually.23 Compensation for earnings loss was the highest single
element and was highest for those less than age 65.23 The highest healthcare costs were
for physician visits, with an average of $1,324 annually.23 The overall average cost for
study participants was estimated to be $25,001 annually.23
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Regarding the individual burden of Parkinson’s disease, study participants were found
to spend an average of 326 hours on housework per year and 23 hours on yard work per
year.23 A previous study of high functioning older individuals provided the average of
739 hours for housework per year and 210 hours for yard per year.23 The same study
found in low functioning older individuals an average of 512 hours for housework per
year and 86 hours for yard per year.23 The large burden of Parkinson’s disease is not
related to financial burden, but rather the majority appears to fall into the category of
personal burden.
Following the previous study, a 3-year longitudinal evaluation of Parkinson’s disease
was conducted by the same authors between 1997-2000.19 The study data were collected
through an in-home interview and utilized surveys regarding health status, disease
symptoms, and functional status. In addition, data were collected on direct and indirect
costs.19 Health status was categorized as either good health or poor health.19 Persons who
rated their health as excellent, good, or very good were placed in the “good health”
group, and those who rated their health as fair or poor were placed in the “poor health”
group.19
The functional losses, co-morbid illnesses and disease symptoms were greater among
those in the poor health group than those in the good health group.19 Functional losses
included activities of daily living, instrumental activities of daily living, and whether or
not the person had to use walking aids.19 Nearly half (48.5%) of the poor health group
reported using a walking aid, compared to 19.4% in the good health group. The most
frequently reported co-morbid illness was arthritis (37%), followed by heart disease
(28%).19 Among the poor health group, 23% reported having a stroke, while only 2.7% of
the good health group reported having a stroke.19 Disease symptom variables included
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fatigue, pain, psychosocial issues, and cognitive impairment. Patients in the poor health
category reported having experienced depression almost twice as frequently (59.4%) as
those in the good health category (30.6%).
The direct costs captured by this study included expenditures for nursing homes,
hospitals, physicians, other health professionals, prescription drugs, formal care, and
other expenditures.19 In year one of the study, the good health group reported an average
of $5,146 in expenses for direct costs.19 The year three average for the good health group
was $6,362 in expenses for direct costs.19 The poor health group reported an average of
$4,949 in expenses for direct costs in year one and an average of $9,591 in year three.19
The indirect costs captured included costs for informal care and lost wages.19 The
largest difference between the two groups in costs was found in indirect costs.19 In year
one, the good health group reported an average of $2,664 for informal care expenditures,
compared to $6,340 among those in poor health group.19 The poor health group reported
an average of $15,508 in lost wages, compared to $5,261 for the good health group.19
The impact of Parkinson’s disease on health status, health expenditures, and
productivity were estimated by Rubenstein, et al. using the 1987 National Medical
Expenditure Survey (NMES).20 The author had established, in a previous study of the
burdens of Parkinson’s disease, a significant association between the stage of Parkinson’s
disease and the use of most health resources that persisted even after controlling for comorbid conditions.151 The purpose of this 1987 study was to determine if NMES was
useful in providing estimates on health status, health expenditures, and productivity.20
The estimates for Parkinson’s disease patients were then compared with patients with
other chronic medical conditions but not Parkinson’s disease.20 A total of 43 patients in
NMES were identified as having Parkinson’s disease.20 Each of these patients were
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matched according to race, gender, age group, presence of specific target conditions, and
urban-rural status with three patients without Parkinson’s disease (controls).20
The health status portion of this study found that 81.4% of patients with Parkinson’s
disease perceived their health as fair or poor, compared with 46% of the controls.20 In the
Parkinson’s group, 53.5% of patients could perform all ADL tasks without difficulty or
help, compared with 85% of controls.20 Only 46% of the Parkinson’s patients were able
to perform all 6 IADL tasks, compared with 79% of controls.20 In the control group, 88%
reported no use of aids for ADL tasks, compared with 39.4% of patients with Parkinson’s
disease.20 A total of 46.5% of patients with Parkinson’s disease, compared with 17.1% of
controls, reported difficulty using cars or buses to get around, making it the most
frequently reported IADL task for both cases and controls.20
For the category of healthcare resource use and expenditures, patients with
Parkinson’s disease had significantly more home healthcare visits and physician visits
than the control group.20 While there was no significant difference in the proportion of
Parkinson’s and control patients reporting at least one hospital visit, patients with
Parkinson’s disease had a higher average length of stay than the non-Parkinson’s patients
(controls).20 Patients with Parkinson’s disease received significantly more prescription
medications than controls, 26.5 compared to 16.4 respectively.20 Prescription medication
costs for patients with Parkinson’s disease were on average more than $400 higher than
patients without Parkinson’s disease.20 The total average expenditures for patients with
Parkinson’s disease (10,168) were significantly greater than total average expenditures
for the control group ($4,743).20
Patients with Parkinson’s disease were 5 times more likely to report that their health
had prevented them from working or carrying out normal activities.20 Significantly more
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bed days were reported by patients with Parkinson’s disease (44.2%) compared with
controls (31.8%).20 The authors did not report comparisons for work-loss days because
the number of people reporting work-loss days were too small for analysis.20
The authors concluded that patients with Parkinson’s disease have serious health and
economic burdens as a result of their disease.20 The authors further concluded that the
data from the NMES provided a description of the areas in which these burdens occur .20
The authors concluded that patients in the NMES sample did not adequately represent
patients in the early and the late stages of Parkinson’s disease. Therefore, estimates of
expenditures and resource use are probably more applicable to patients in the middle
stages of Parkinson’s disease.20 The reason the authors speculated that this population did
not represent patients in the early stages of Parkinson’s disease was because those
patients in the earliest stages often do not receive medications that are identifiable as
Parkinson’s medications. The authors further speculated that patients in the later stages
of Parkinson’s disease would be in nursing homes and therefore not captured by the
NMES.
In 1973, Singer measured the social costs of Parkinson’s in 169 patients from 23
specialty clinics.152 The study found a decrease in the percentage of patients who
remained employed compared with the general population.

Eighty-one percent of men

between the ages of 55-64 in the general population reported participation in the labor
force, compared to 51.2% in the Parkinson’s sample.152 Men over the age of 65 in the
general population reported a 25.8% participation in the labor force, while men over the
age of 65 with Parkinson’s disease reported only a 7.1% participation in the labor
force.152 A reduction in median income was also found among patients with Parkinson’s
disease compared to patients without Parkinson’s disease.152 The median annual income
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for married couples over the age of 65 who reported not having Parkinson’s disease was
$4,835, while the median annual income for married couples reporting Parkinson’s
disease was $4,632.152 Patients with Parkinson’s disease were also found to miss more
days of work compared to people without the disease.
Finally, Singer reported that persons with Parkinson’s disease reported a reduction in
the ability to participate in housework and leisure activities.152 Specifically, 75% of
persons under 65 with Parkinson’s disease reported spending some portion of their day
either napping or idle.152 When compared to the oldest general population group (over
80), only 73% reported spending some portion of their day either napping or idle.152 This
study concluded that the consequences of Parkinson’s disease are not equal across all
areas; however, the younger Parkinson’s patients incurred greatest social costs.152
Table 2-2 provides an overview of previous Parkinson’s disease cost studies done in
the United States.

Treatment Costs

Medication Treatment Costs

Cost Utility Analysis. In 1998, Hoerger et al. conducted a cost utility analysis of
pramipexole in two settings. In the first setting the authors compared pramipexole
without levodopa therapy in the early stages of Parkinson’s disease. In the second
setting, the authors compared pramipexole plus levodopa in advanced Parkinson’s
disease. To distinguish early stage from late stage Parkinson’s disease, the patient’s
score on the United Parkinson’s Disease Rating Scale (UPDRS) was used. To predict
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Table 2-2. Overview of Previous Parkinson’s Disease Cost of Illness Studies Done in
the United States.
Author
Parashos

Year
2002

N
89

Littlefield51

2002

912

Schenkmaniy

2001

70

Chrischilles151

1998

193

WhettenGoldstien23

1997

109

Rubenstein20

1997

43

Singer15*2

1973

169

Objective
Investigate outcomes and
utilization of medical services of
Parkinson’s patients to determine
predictors of utilization.
Establish baseline costs of
Parkinson’s disease in a midwestern healthcare plan.
Use Parkinson’s disease state
status, disease symptoms, and
functional status to explain
financial costs.
Provide a description of the patient
report HRQOL and economics of
Parkinson’s disease stage.

Examine the economic burden of
Parkinson’s disease on society,
family, and the individual.
Match patients with and without
Parkinson’s disease to estimate
additional resources used by
Parkinson’s patients.
Compare social costs of patients
using levodopa (n = 149) to
patients not using levodopa (n =
20).
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Data Source
Rochester
Epidemiology
Project
Health plan
database
Survey of
patients in
North Carolina
Survey of
patients in 2
Iowa
neurology
hospitals
Survey of
patients in
North Carolina
National
Medical
Expenditure
Survey
23 treatment
centers in all
regions of the
United States,
except the
South

hospital visits and working status, the authors used probit models. Logarithmic
regression was used for costs, and linear regression for utilities.
For both groups, incremental cost utility-ratio (ICUR) was below $35,000 per qualityadjusted life year (QALY). The study concluded that the use of pramipexole alone is cost
effective in early-stage Parkinson’s disease. In late stage Parkinson’s disease, the authors
concluded that pramipexole in combination with levodopa is also cost effective. In 2001,
Shimbo et al. compared the use of the dopamine agonists bromocriptine and pergolide
with levodopa mono-therapy among Japanese patients.154 The study used a 10- year
Markov model that consisted of 6 Markov stages based on the Hoehn-Yahr stages 15 and death.154 The results of this study concluded that both of the dopamine agonists
(bromocriptine and pergolide) are cost effective in Hoehn-Yahr stages 3-5 of
Parkinson’sdisease when compared to levodopa mono-therapy.154 There are limitations to
this study; first, the model used did not incorporate drug dosage, and second, it is not
generalizable to other countries because of the variation in therapy costs.
A Markov model was developed by Tomaszewski and Holloway to determine the
lifetime incremental cost-effectiveness between Deep Brain Stimulation (DBS) in late
stage Parkinson’s disease compared with the best medical treatment.155 In the model, if
DBS was chosen, the patient risked one of four outcomes: 1) death during the operation,
2) permanent complications from the operation, 3) temporary complications from the
operation, or 4) no complications.155 Baseline utility estimates were obtained from a
previous study that reported utilities from a visual analog scale where 0 was equal to
death and 100 was equal to best possible health.151 In that study, 20% of patients were in
the advanced stages of Parkinson’s disease and reported health-related quality of life
between 53.5 and 60.1.151 Therefore, the authors assumed the quality of life (QOL) for
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patients entering the model to be 0.55 on a 0-to-l scale.155 The results of the study found
that DBS cost $45,200 per patient and best medical management cost $41,700 per
patient.155 The number of quality adjusted life years (QALY’s) for DBS was 7.80
compared to 7.08 for best medical management.155 The DBS cost $35,000 more than best
medical management and provided an additional .72 QALY’s.155 The preliminary
conclusion of this study was that DBS is a more effective treatment for patients in the late
stages of Parkinson’s disease when compared to best medical management.155 The
authors suggest that further testing and refinement are necessary to determine if the initial
result of increased QALY’s when DBS is used instead of best medical treatment occurs
under more rigorous experiments.155

Cost-Effectiveness Analysis. In 2001, Davey et al. developed a decision-analytic
model to assess the cost-effectiveness of pergolide compared to bromocriptine in the
treatment of Parkinson’s disease. The authors used a Markov model that ran for 2cycles
of 6 months duration to examine cost-effectiveness. The model assessed patient progress
through the 6 stages—the same Hoehn-Yahr stages 1-5 and death stage that Shimbo
utilized. Over the ten year period, the total healthcare cost per patient in the pregolide
treatment arm was $46,323 and $47,351 in the bromocriptine arm. Patients receiving the
pergolide treatment also spent longer time in Hoehn-Yahr stages 1, 2, and 3. The authors
concluded that because pergolide was cost saving and more efficacious than
bromocriptine, it was cost effective.
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Surgical Treatment Costs
A retrospective study by Charles, et al. found that Deep Brain Stimulation of the
subthalamic nucleus (DBS-B-STN) reduces the medication costs for patients with
Parkinson’s disease.156 Sixteen patients (10 men and 6 women) with advanced,
idiopathic Parkinson’s disease who were not responding to optimal medication therapy
and who had been implanted with deep brain stimulators were included in the study.156
Following the surgery, the average daily cost of antiparkinsonian medications (APMED)
was $13.25 per patient, compared to an average daily cost prior to the operation of $19.53
per patient.156 Overall, medication costs decreased for 12 patients, remained the same for
two, and increased slightly for two.156 The authors concluded that the 32% reduction in
medication costs two years following surgery warranted further research to confirm long
term (APMED) savings after DBS-B-STN.156
Using data from the Nationwide Inpatient Sample, Eskandar, et al. conducted a
retrospective cohort study of surgery for Parkinson’s disease in the United States between
the years 1996 and 2000.157 The purpose of the study was to investigate surgery practice
patterns and short-term outcomes following surgery.157 A total of 1,761 patients in 71
hospitals underwent surgical treatment during the study period.157 The study found a
change in the surgical procedures being chosen between 1996 and 2000. In 1996,
approximately 93% of surgeries were pallidotomies and 7% were thalamotomies.157 By
the year 2000, the percentage of surgical procedures for Parkinson’s disease were
dramatically different, with 88% DBS, 7% pallidotomies, and 5% thalamotomies.157
During the overall study period of 1996-2000, 6% percent had thalamotomies, 33% had
DBS and 60% had pallidotomies.157 At the time of this study, there were no randomized
controlled trials comparing pallidotomy and DBS.157 Pallidotomy involves creating a
62

permanent lesion that may cause permanent complications, while DBS uses highfrequency stimulations to create a reversible lesion effect.

157

Short-term outcomes for Parkinson’s surgery were measured by mortality and
morbidity immediately following surgery.157 Hospitals were categorized based on the
number of Parkinson’s disease surgeries performed annually.157 Hospitals with high
volume of Parkinson’s disease surgeries (>54 surgeries annually) had better short-term
outcomes for both mortality and morbidity than hospitals with low volume (<17 surgeries
annually).157 Of the four deaths that occurred, three were at hospitals with a low volume
of Parkinson’s disease surgeries.157 Discharges to short-term or long-term care facilities
occurred in 11.4% of operations at low volume hospitals and in 3.4% of high volume
hospitals.157
The authors stated that for other neurosurgical procedures, better outcomes are
reported for patients treated at high volume facilities.157 The authors concluded that the
results of their study reinforce previously reported mortality and morbidity rates for other
neurological procedures.

The authors pointed out that these differences may be due to

the presence of more experienced staff (neurologists, physical, and occupational
therapists) that have a higher comfort level with discharging patients straight home after
Parkinson’s disease surgery.

Finally, the authors suggested that future studies should

focus on comparing long-term functional end points and cost-benefit of Parkinson’s
disease surgery.157
In order to obtain an assessment of pallidotomy for Parkinson’s disease, Alkhani et al.
conducted a review of published literature in 2001.158 In the 85 articles reviewed, 1,959
patients with Parkinson’s disease had pallidotomies at 40 centers located in 12
countries.158 The average length of time with Parkinson’s disease symptoms in these
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patients was 12.3 years, with a standard deviation of 1.9 years, and the average age of
patients was 61.4, with a standard deviation of 3.6 years.158 The majority of the
pallidotomies were unilateral (88.6%) compared with bilateral (11.4%).158 In 501 of the
cases (25.6%), outcomes were reported using the Unified Parkinson’s Disease Rating
Scale (UPDRS) at 6 months, in 218 (11.1%) of the cases at 1 year, and 59 cases (3%) at
24 months.158
A total of 142 patients were accessible six months after the surgery, and 34.2%
reported an improvement in UPDRS sections 2 and 3 (ADL assessment and motor
examination) during their first “off’ period.158 Ninety-nine patients were accessible 12
months after surgery and 35.7% reported an improvement in UPDRS sections 2 and 3.158
When section 3 (motor examination) of the UPDRS was reported alone, a total of 256
patients were accessible six months after surgery and the improvement was 40.6%. Of
the 161 accessible patients that were accessible 12 months after surgery, 45.3% reported
an improvement in UPDRS section 3.158 The authors concluded that pallidotomy is safe
and effective for treatment of patients with advanced Parkinson’s disease.

Pallidotomy

improved motor performance and ADL during “off’ periods as well as during druginduced dyskinesias.158 Finally, the authors concluded that there is a lack of long-term
results after pallidotomy and that there is a need for prospective studies to compare
pallidotomy with best medical treatment and also with other surgical options.158
This chapter provided a review of literature relevant to the cost of illness,
retrospective data analyses and Parkinson’s disease. Chapter three will provide the
detailed methodology that was used to estimate the cost of illness for Parkinson’s disease
in the United States.
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CHAPTER IIL METHODOLOGY

Purpose
The purpose of this study was to provide a prevalence-based retrospective national
estimate of the cost of illness (direct and indirect costs) of Parkinson’s disease in the
United States for the year 2003. The methodology to estimate the cost of illness for
Parkinson’s disease in the United States is detailed in this chapter.

Research Design
The research method employed to measure the cost of illness for Parkinson’s disease
was a multi-year retrospective database analysis. The estimation of the cost of illness
was accomplished by using the data from the Medical Expenditures Panel Survey
(MEPS), the Bureau of Labor Statistics (BLS), and the National Vital Statistics Survey
(NVSS), which provided the direct and indirect costs for Parkinson’s disease.
Direct costs include both direct medical and direct non-medical costs. Direct medical
costs are related to medical care and include costs for hospitalization, rehabilitation,
nursing home care, prescription medications and treatment by a medical professional.26
Direct non-medical costs are those costs, borne by the patient, that do not involve
treatment but are required to access the healthcare system, such as transportation,
childcare, and household expenses.26
Indirect costs are those that are related to a loss in productivity by the individual or
family members who may care for the individual.26 The two components of indirect
costs are morbidity and mortality costs. Morbidity costs are those costs associated with a
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loss in productivity due to a person’s inability to work in the labor market or at home.
Mortality costs are due to premature death and are an estimate of future earnings lost.

Data Overview
The data sources for this study were 1) the 1999-2003 Medical Expenditures Panel
Survey Household Component (MEPS-HC), 2) the 1996 Medical Expenditures Panel
Surveys Nursing Home Component (MEPS-NHC), 3) the 1999-2003 National Vital
Statistics System (NVSS), and 4) the 1999-2003 Bureau of Labor Statistics (BLS). The
purpose of MEPS is to provide nationally representative estimates of healthcare
utilization, expenditures, sources of payments, and insurance coverage for the United
States civilian non-institutionalized population.131 The civilian non-institutionalized
population includes anyone who is not on active duty in the United States Armed Forces
and who is not institutionalized.159 Institutionalized persons are those under supervised
care in long-term care facilities other than nursing homes.159
The Agency for Healthcare Research and Quality (AHRQ), in collaboration with the
National Center for Health Statistics (NCHS), began collecting data for the MEPS in
1996.131 The MEPS survey is a longitudinal study utilizing an overlapping panel design
to collect healthcare expenditure and utilization data at the person and household
levels.131 The four components of the MEPS survey include the household component
(HC), the insurance component (IC), the nursing home component (NHC), and the
medical provider component (MPC).

i o i

To calculate the direct and indirect costs of

Parkinson’s disease, the household component (HC) and the nursing home component
(NHC) were used. The most recent set of complete data for the MEPS-HC (2003) was
used in this study along with the 2003 NVSS and 2003 BLS to make a 1-year estimate of
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the direct and indirect costs of Parkinson’s disease. However, it was necessary to use all
5 years (1999-2003) of MEPS-HC data in order to have a large enough sample to conduct
statistical analysis. The MEPS-NHC was last collected in 1996; therefore, nursing home
costs were calculated using 1996 data and then adjusted to 1999-2003 dollars. The base
year for the consumer price index for nursing home costs was 1996. To adjust Nursing
Home Costs from 1996 dollars to 2003 dollars, the following formula was used:
(1996) X 2003 CPI for NHC) / 1996 CPI for NHC = $ amount for the year 2003160,161
Where: CPI = Consumer Price Index and NHC = Nursing Home Costs
Mortality data are not collected by the MEPS survey; therefore, mortality was
estimated using data from the 1999-2003 National Vital Statistics Survey (NVSS) and the
1999-2003 Bureau of Labor Statistics (BLS). The NVSS provides the number of deaths
due to Parkinson’s disease in the United States according to the demographic
characteristics of age, gender, and race.162 The BLS collects data on labor force
participation rates and wages according to the same demographic characteristics (age,
gender, and race) as the NVSS.

Survey Design
The MEPS-HC collects data through five in-person interviews conducted over a 2year calendar period.131 The data collected during the in-person interviews are then linked
with the information collected from the respondent’s employer, medical provider, and
insurance provider.131 Figure 3-1 shows a diagram of the panel design. By using this
design, longitudinal and point-in-time estimates of healthcare expenditures can be made
for individuals and households. To gather data for the calendar year 2003, data from
panels 7 and 8 were used. Panel 7, round 1, started in January of 2002 and concluded in
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Figure 3-1. MEPS Overlapping Panels: 2003 Annual File. See Appendix.
Source: Used with permission from the Agency for Healthcare Research and Quality.
Agency for Healthcare Research and Quality. Medical Expenditures Panel Survey. 2005
http://www.meps.ahrq.gov. Accessed 9-25-2005.
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December 2003 with round 5. Data for Panel 8, rounds 1, 2, and 3 were collected
beginning in January 2003 and concluded in December of 2003. The two panels overlap
for the entire year of 2003, with Panel 7 participants being in rounds 3, 4, and 5 of the
survey and Panel 8 participants being in rounds 1, 2, and 3.
The MEPS survey process includes direct contact by a trained interviewer with the
respondent. The MEPS interviewer specifically documents the medical conditions and
procedures reported by the respondent.131 The data are then re-coded by professional
coders into specified ICD-9-CM codes.131 This data collection process is repeated every
year using a new sample of households and overlapping panels of survey data.
The core interview content of the MEPS-HC includes patient demographics, health
status, utilization of health care, employment, health insurance, and charges and
payments.131 The utilization portion of the MEPS-HC collects event-level data on
hospital stays, office-based physician care, home health care, prescribed medications,
medical equipment, and medical supplies.131 The event portion of MEPS-HC collects
data on the types of provider (physician, specialists, allied health workers, etc.) seen by
the respondent, the amount of time spent with the provider, and the type of care
received.131 The event file also collects data on the condition for which the respondent
was seen and the charges and payments made for each event.131

Pooling the MEPS-HC
To generate reliable estimates and to facilitate the analysis of low prevalence disease
states, the method of pooling multiple years of the MEPS data was used. By using
pooled years of data, the standard errors of the estimate(s) are reduced, the types of
statistical analyses are extended, and any fluctuations for cost estimates are reduced. The
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MEPS-HC file HC-036 contains the variables necessary to put data from multiple years
into a shared structure and to form the standard error estimates for pooling MEPS. Two
variables, STRA9603 and the PSU9603, were used in place of the assigned Stratum
(STRATA) and Population Sampling Unit (PSU) to account for the complex survey
design when conducting the analyses of data that are pooled. These variables were
matched to each DUPERSID (unique person identification number) used in the MEPS
between 1996 and 2003 and are found in the HC-036 file.

MEPS-NHC
The MEPS-NHC was a survey of nursing homes and persons residing in or admitted
to nursing homes at any time during calendar year 1996. The MEPS-NHC collects
information on demographic characteristics, residence history, health and functional
status, use of services, use of prescription medications, and healthcare expenditures of
nursing home residents. The NHC sample was selected by using a two-stage probability
design. The first stage was used to select facilities; the second stage was used to sample
facility residents. The sample frame for the facilities portion is derived from the National
Health Provider Inventory. The sample of facility residents was selected from persons
both in the nursing home residence on January 1, 1996, and those admitted between
January 1 and December 31, 1996. The survey captures approximately 800 nursing home
facilities and 3,100 patients that were residents as of January 1, 1996, and an additional
2,200 eligible patients admitted after January 1, 1996.
The MEPS-NHC is only accessible through the Center for Financing, Access, and
Cost Trends (CFACT) located in Rockville, Maryland. In order to obtain data on nursing
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home costs, application was made to the CFACT Data Center to request access to the
data.

NVSS and BLS
Mortality data from the 1999-2003 NVSS and wage data from the 1999-2003 BLS
were used to calculate lost wages due to death from Parkinson’s disease.35,38 The NVSS
data are collected and disseminated by the National Center for Health Statistics
(NCHS).38 The NCHS collects data on all births, deaths (mortality), marriages, divorces,
and fetal deaths for the nation, which includes 50 states, 2 cities (Washington DC, and
New York City), and 5 territories (Puerto Rico, the Virgin Islands, Guam, American
Samoa, and the Commonwealth of the Northern Mariana Islands).38 The mortality data
available from the NVSS includes age (broken into 5 year age groups), race (white,
black, and other) and gender.38 The NVSS also provides data on the probability of
survivorship by age, race, and gender.
The BLS provides information on labor force participation, wages, earnings and
benefits for workers in the United States by using the Current Population Survey (CPS).35
The CPS is a survey conducted by the Bureau of Census for the BLS and provides data
on the United States labor force, employment, unemployment and persons not in the
labor force.35 The CPS data includes demographic data for age (broken into 5-year age
groups), race (white and black), and gender.35 The probability of being in the labor force
was calculated using demographic categories and labor force participation information.35
Wage information for the years 1999-2003 was available from BLS and provided the
average wage earned for the same demographic categories used in the CPS.
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Study Setting
This study was completed at the University of Tennessee Health Science Center,
Memphis, TN.

Sampling Plan
Using a nationally representative sample, the sampling plan for this prevalence-based
cost of illness study used data from the complete 1999-2003 MEPS-HC data files and the
1996 MEPS-NHC file. From these data, all patients with a diagnosis of Parkinson’s
disease were selected for inclusion. The ICD-9 code 332 was used in MEPS to identify
patients with Parkinson’s disease. The source of costs from each file provided all the
direct medical, direct non-medical, and morbidity costs for persons with Parkinson’s
disease. The 1999-2003 NVSS Mortality Data and 1999-2003 BLS data were used to
estimate the remaining portion of indirect costs (mortality costs) for Parkinson’s disease.

MEPS Sampling Frame
The MEPS sample was derived from participants in the previous year’s National
Health Interview Survey (NHIS) with an over-sampling of persons who are African
American and Hispanic.131 Because this was a nationally representative sample,
respondents are weighted based on demographic factors to allow for extrapolation to the
United States population as a whole. A person-level weight was developed to allow
extrapolation. A person-level weight was developed for each person during round 1 as a
base weight and then adjusted for non-response in rounds 2 and 3. In order to be
assigned a person-level weight, the person had to be considered an “in-scope, key
person.” If the person was a member of the civilian non-institutionalized portion of the
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population, the person was defined as “in-scope.” In order to be defined as a “key”
person, the person had to be a member of a household in the NHIS. A person-level
weight was designated for each “in-scope, key person” who responded to MEPS for the
full 2003 time period. Using five demographic variables (census region, metropolitan
statistical area, race/ethnicity, gender, and age), post-stratification estimates were
obtained by controlling to the Current Population Survey (CPS) population estimates.
Each year (1999-2003) a composite weight was formed by multiplying each panel
weight by 0.5. Specifically, each person represents a certain number of people in the
United States population and his/her person weight indicates how many people in the
United States that one person represents.

Protection of Human Subjects
This study was a secondary data analysis of the MEPS database. Prior to obtaining any
data from MEPS, approval from the University of Tennessee Health Science Center
Institutional Review Board (IRB) was obtained (see Appendix B).

Study Procedures
This study estimated the direct and indirect costs of Parkinson’s disease in the United
States. The ICD-9 codes for Parkinson’s disease include 332.0-332.9. MEPS-HC
collapses the diagnosis codes for various diseases, including Parkinson’s, to the threedigit code categories. Therefore, the code 332 was the only ICD-9 code necessary for
this study. All patients in the 2003 MEPS-HC and the 1996 MEPS-NHC databases with
a diagnosis of Parkinson’s disease were used to estimate the cost of illness of Parkinson’s
disease. All persons whose cause of death was reported as Parkinson’s disease in the
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2003 NVSS were used to estimate mortality costs. The costs of Parkinson’s disease
presented are prevalence-based, estimating the direct and indirect costs incurred in 2003
as a result of Parkinson’s disease.
MEPS-HC data are provided in both an event-level and person-level format and are
made available to the public in SAS format. Seven event-level files (inpatient hospital,
emergency room, outpatient hospital, office-based visits, home-health care, other medical
expenses, and prescription drugs) and three person-level files (full year population
characteristics, jobs file, and medical conditions) from the MEPS-HC were used in the
study. Event-level files provide information on the utilization and costs of medical
services. The person-level file for population characteristics reports the demographics of
the MEPS-HC participant, while the medical conditions file reports medical conditions
experienced by the participant.
Nursing home data from the MEPS-NHC are available in person-level and facilitylevel files at the CFACT Data Center in Rockville, Maryland. Data from the MEPSNHC were merged to create an event-level file.
Figure 3-2 details the cost of illness framework used. The figure includes the
components to be measured and the corresponding MEPS event-level and person-level
files.
The following event-level files from the 1999-2003 MEPS-HC were used to conduct
this cost of illness study: prescription mediations (HC-033A, HC-051A, HC-059A, HC067A, and HC-077A), other medical expenses (HC-033C, HC-051C, HC-059C, HC067C, and HC-077C), hospital inpatient stays (HC-033D, HC-051D, HC-059D, HC067D, and HC-77D), emergency room visits (HC-033E, HC-051E, HC-059E, HC-067E,
and HC-077E), outpatient visits (HC-033F, HC-051F, HC-059F, HC-067F, and
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Figure 3-2. Expanded Cost of Illness Model. Author’s visual representation of the
components outlined by Rice28 and the MEPS, NVSS, and BLS databases and variables
being used to measure direct costs and indirect costs of Parkinson’s disease.
Source: Rice DP. Estimating the Cost of Illness. 6, 3-19. 1966. Washington, DC,
U.S.Department of Health, Education and Welfare. Health Economics Series.
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HC-077F), office-based medical provider visits (HC-033G, HC-051G, HC-059G, HC067G, and HC-077G), and home health visits (HC-033H, HC-051H, HC-059H, HC067H, and HC-077H). The following person-level data files from the 1999-2003 MEPSHC were used to conduct this cost of illness study: full year population characteristics
(HC-038, HC-050, HC-060, HC-070, and HC-073), jobs file (HC-032, HC-040, HC-056,
HC-063, and HC-074), and medical conditions (HC-037, HC-052, HC-061, HC-069, and
HC-078). Variables selected from each of the event-level and person-level files were
based on their usefulness in this particular cost of illness study. Appendix C contains a
complete listing of the variables selected for this study. The variable name, a description
of the variable, and the MEPS file from which the variable came are included in
Appendix C. Appendix C also contains a listing of the variables which contain cost data
and what category of cost (direct medical, direct non-medical or indirect) each variable
represents.
Event-level cost data are available in MEPS for seven types of healthcare services:
Inpatient hospital visits, emergency room visits, outpatient visits, prescription
medications, office-based medical visits, other medical expenses, and home health visits.
Costs of prescription medications (HC-033A, HC-051A, HC-059A, HC-067A, and HC077A), other medical expenses (HC-033C, HC-051C, HC-059C, HC-067C, and HC77C), inpatient hospital stays (HC-033D, HC-051D, HC-059D, HC-067D, and HC077D), emergency room visits (HC-033E, HC-051E, HC-059E, HC-067E, and HC077E), outpatient visits (HC-033F, HC-051F, HC-059F, HC-067F and HC-077F), officebased provider visits (HC-033G, HC-051G, HC-059G, HC-067G ,and HC-077G), and
home healthcare visits (HC-033H, HC-051H, HC-059H, HC-067H, and HC-077H) were
estimated using expenditures reported for persons with Parkinson’s disease in the 1999-
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2003 MEPS databases. Each medical condition reported by a respondent is linked to a
medical event code in MEPS. Medical care expenses incurred in the treatment of
Parkinson’s disease can therefore be determined from Parkinson’s disease medical events
that are linked by the specific medical condition code, ICD-9-CM 332. For each of these
services, MEPS provides sample estimates that can be extrapolated to the entire United
States population, allowing the costs for each of these services to be estimated as a
weighted sum and as a weighted average cost.

MEPS Data Files
The following are the MEPS data files used in this study and a brief description
of each file:

Inpatient Hospital Visits. An event-level data file containing characteristics
associated with the hospital inpatient stay. Information in this file includes date of the
hospital inpatient stay, reason for the stay, types of services received, condition(s) and
procedure(s) associated with the hospital inpatient stay, whether or not medicines were
prescribed, and imputed expenditure data.

Emergency Room Visits. An event-level data file that contains characteristics
associated with the emergency room visit. Information in this file includes the date of the
visit, types of care and services received, types of medicine prescribed during the visit,
condition codes, expenditures, sources of payment associated with the visit, and imputed
expenditure variables.
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Prescription Medications. An event-level file that represents a unique prescribed
medicine event. A prescribed medicine that was reported as being purchased or
otherwise obtained by the household respondent includes the following: an identifier for
each unique prescribed medicine; detailed characteristics associated with the event (e g.,
national drug code [NDC], medicine name, etc.); conditions, if any, associated with the
medicine; the date on which the person first used the medicine; total expenditure and
sources of payments; and types of pharmacies that filled the household’s prescriptions.

Outpatient Visits. An event-level file that contains characteristics associated with the
outpatient visit including the date of the visit, whether or not a doctor was seen, type of
care received, type of services provided, expenditures, sources of payment, and imputed
sources of payment.

Office-Based Medical Provider Visits. An event-level file that contains
characteristics associated with the office-based visit, such as date of the visit, time spent
with the provider, type of provider seen by the patient, types of treatment and services
received, types of medicine prescribed, condition codes, expenditures, source of payment
associated with the visit, and imputed expenditure variables.

Home Health Visits. An event-level file that contains information on expenditures for
home health visits, including the type of provider, type of services received, length of the
visit, reason for the visit, expenditures, and sources of payment.
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Other Medical Expenses. An event-level and person-level file that provides
information on the purchase of and expenditures for medical equipment, supplies,
glasses, and other medical items. This file also provides information on expenses, such
as transportation to the healthcare providers’ office, lodging, childcare, and any other
household expenses not reported in a previous section.

Nursing Home Component This component of MEPS contains two types of files:
person-level and facility-level. In the person-level file, variables include demographics,
health status, insurance coverage, and medical conditions as reported by facility sources.
The facility-level file contains variables pertaining to characteristics of the facilities
including detailed information on the facility’s structure. The variables include number
of beds by licensing and certification categories, ownership, number of residents, special
care units by type and size, and staffing. Both the facility-level file and the person-level
file contain expenditure information.

Jobs File This person-level file includes variables pertaining to household-reported
jobs; including wages, hours, industry, and occupation.

Medical Conditions. This file provides information on the household-reported
medical conditions.

Full Year Consolidated This person-level file consolidates all of the final personlevel variables into one file. This file contains the following variables: survey
administration, demographics, employment, health status, quality of care, patient
80

satisfaction and health insurance. The file also includes additional variables: parent
identifiers, access to care and days of disability variables, language of interview variable,
income variables, additional health insurance variables (including summary indicators),
and use and expenditure variables.

NVSS Data
The NVSS data used in this study are the Death: Final Data Reports. These reports
detail the national annual mortality statistics and provide data on deaths and death rates
by demographic characteristics such as age, gender, and race.

BLS Data
The following are the BLS data used in this study and a brief description of each file:

Labor Force Statistics. This file provides information on employment and
unemployment rates by age, race, and gender.

Waees and Earnings Statistics. Information on wages are available by occupation for
the nation, region, and state, age, race, and gender.

Data Analysis File Creation
The complex design of MEPS-HC requires that sample data be weighted to obtain
unbiased national estimates for the U.S. non-institutionalized civilian population. The
sample weights used to obtain unbiased estimates were necessary because of the
disproportionate sampling used

in NHIS to over-sample minority populations. The
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sample weights also account for non-response of eligible sampling units, partial
responses by survey participants, and post-stratification.37 The weights were used to
estimate population values and vary among individuals in the sample to correct for
variance in response rates by age, gender, race/ethnicity, region of the country, and
poverty status. All utilization and cost estimates used in this study were weighted to
reflect national population estimates. Thus, for each person included in the MEPS
survey, his/her responses were weighted according to the demographic group (age,
gender, race/ethnicity, region of the country, and poverty status) he/she represents.
National census data were used to determine the weights used for each demographic
group.
In order to perform the final data analysis, it was necessary to merge all of the 19992003 MEPS data files into one file and then generate a pooled weight for each person.
This final analysis file was created in five steps. The first step linked the Medical
Conditions File with the Consolidated Full Year File and identified persons with
Parkinson’s disease. In this step, if the person reported having Parkinson’s disease (ICD9-CM code 332) in the Medical Conditions File, then the person’s unique identifier
(DUPERSID) was used to link with the Consolidated Full Year File. This resulted in the
creation of a single file that contained only persons with Parkinson’s disease. The second
step of merging linked the resulting first step file of persons with Parkinson’s disease to
each of the Medical Event Files. This resulted in the creation of a single file that
contained only persons with Parkinson’s disease and the medical events reported by that
person that were related to Parkinson’s disease. By creating this file, it was possible to
aggregate costs by person and by category of medical event. An overall total sum of
costs could also be calculated from this file. Figure
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3-3 visually depicts how the 2003

Figure 3-3. MEPS-HC Data Files Linking Diagram. Construction of file for
estimated direct and indirect costs for Parkinson’s disease in the United States from
2003 MEPS data files. Figure design used with permission from Dr. Norm Carroll,
Virginia Commonwealth University.163 See Appendix A.
Source: Carroll NV, Slattum PW, Cox FM. The cost of falls among the community
dwelling elderly. J M anag Care Pharm 2005; 11(4):307-316.
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MEPS-HC data files were linked together to create one data file for analysis. The third
step was to repeat steps one and two for the other four years (1999-2002). The fourth
step of merging merged all years of MEPS-HC data (1999-2003) into one file for a fiveyear analysis. It is possible that a person could be in multiple years of the MEPS-HC.
Each year the person received a new person weight (PERWT), stratum (STRATA), and
population sampling unit (PSU). Once all data were in file, the person weight (PERWT)
variable for each person and each year was divided by five (the number of years of the
MEPS data used) to obtain the pooled weight. The process of dividing each person
weight (PERWT) variable resulted in the creation of a new variable that was named
POOLWT and represented one-fifth the value of each person weight (PERWT). Also, for
the process of pooling the MEPS-HC files, the two variables, stratum (STRA9603) and
population sampling unit (PSU9603), were used in place of the assigned stratum
(STRATA) and population sampling unit (PSU). These variables were matched to each
unique identifier (DUPERSED) in the merged file containing the MEPS-HC for 1999
through 2003.
In order to get cost variables from 1999-2002 to the 2003 dollar amount, the cost
variables were multiplied by each year’s CPI. For example, the total dollar amount
associated with the MEPS-HC for 1999 was multiplied to the CPI for 2003 and so on.
The following formula represents how CPI was calculated for the year 1999 to 2003
dollars.
Year Cost Total 1999 * (CPI 2003/CPI 1999) = Amount in 2003 dollars
For example: If MEPS-HC costs in 1999 were found equal to $3 billion dollars, the
amount in 2003 dollars would be calculated as follows:
$3,000,000,000 X (184/166.6) = $3,313,325,330
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Where:
$3,000,000,000= Hypothetical 1999 MEPS-HC Costs
184 = actual 2003 Medical Care CPI
166.6= actual 1999 Medical Care CPI
$3,313,325,330 = Hypothetical 2003 MEPS-HC Costs

This formula was repeated for each year and the product for each year was then added
together and the final total represented the pooled CPI total for cost of illness for
Parkinson’s disease in 2003 (minus nursing home costs and mortality costs). Figure 3-4
visually depicts how all five years of MEPS-HC data were merged into one single file for
pooled analysis.
Figure 3-5 visually depicts how the Nursing Home Component (NHC) data files were
merged together to create one file for data analysis. The person-level files (NHC001P,
NHC-002, and NHC-007) were merged using the person identification number
(OR.IGPERSID), resulting in the creation of one person-level file. The Facility-level files
(NHC-001F and NHC-003) were merged using the facility identification number (SFID),
which resulted in one facility-level file. The SFID appeared in NHC-002 of the personlevel files and was used as the common variable to merge the single person-level file and
facility-level files that were created into one final merged file.
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Figure 3-4. Merge of Five Years of MEPS-HC Data Files for a One-Year Pooled Estimate of Direct and Indirect Cost of
Parkinson’s Disease in the United States MEPS Data Files.

Figure 3-5. Nursing Home Component Data File Creation. Construction of file for estimated costs for Parkinson’s disease
in the United States from 1996 MEPS Nursine Home data files. Figure design used with permission from Dr. Norm
Carroll, Virginia Commonwealth University. 3 See Appendix A.
Source: Carroll NV, Slattum PW, Cox FM. The cost of falls among the community-dwelling elderly. J Manag Care
Pharm 2005; 11(4):307-316.

Costs

Determination o f Direct Medical Costs
Data were used from seven event-level files to estimate direct medical costs of
Parkinson’s disease in 2003: Prescription medications (HC-077A), other medical
expenses (HC-077C), hospital inpatient stays (HC-077D), emergency room visits (HC077E), outpatient visits (HC-077F), office-based medical provider visits (HC-077G), and
home health visits (HC-077H). Nursing home data were also used from the patient-level
file (NHC-007) and the facility-level file (NHC-003) to estimate direct medical costs.
The following steps were necessary to determine the overall cost for each of the
MEPS files:
1. The first step was to sort patients by their identification number (DUPERSID) and
add together the cost associated with each Parkinson’s-related event reported. For
example: Patient 1001 reported the condition Parkinson’s disease and stated that
he/she had three prescriptions filled for treatment of Parkinson’s; the total cost for
one prescription was captured by the variable RXXP03X. This patient’s
DUPERSID appears in the prescription medications file three times and the
RXXP03X variable also appears. Each of the dollar amounts were added together
to get a total sum of

prescription medications for this patient. Hypothetically, if

the three RXXP03X variables were $217, $75, and $65 for patient 1001 for
prescription medications, these were totaled together. A new variable was then
created and labeled RXXP03XUWPT (prescription medication unweighted
patient total).
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2. The next step was to take this unweighted patient total and multiply it by the
patient’s person-level pooled weight (POOLWT) value. A new variable was
created to represent the resulting product of multiplying POOLWT and
RXXP03XUWPT. This value was labeled RXXP03X WPT (prescription
medication weighted patient total). The POOLWT value was the same for the
patient throughout all MEPS files. (The POOLWT value varies for each patient
and the value was determined by using census data and demographic
characteristics.) In this example, the patient had a total unweighted cost of $357 in
prescription medication costs. The patients’ POOLWT value was 2,365, meaning
this patient represented 2,365 people in the United States. The $357 spent by the
patient actually represents $844,305 spent for medications to treat Parkinson’s
disease.
POOLWT x RXXP03 XUWPT = RXXP03XWPT
2,365 x $357 = $844,305
3. The next step was to repeat steps 1 and 2 for all patients with Parkinson’s disease
in the MEPS database. All of the RXXP03X WPT values for each person were
then added together to get an overall total for prescription medication costs. This
process required creating a new variable RXXP03XWOT (representing the
weighted overall total of prescription medications).
(RXXP03XWPT i + RXXP03XWPT2....+ RXXP03XWPT54) = RXXP03XWOT
This procedure was repeated for each of the MEPS files to arrive at weighted overall
totals for other medical expenses (HC-077C), hospital inpatient stays (HC-077D),
emergency room visits (HC-077E), outpatient visits (HC-077F), office-based medical
provider visits (HC-077G), and home health visits (HC-077H). The specific direct
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medical cost variables used from the various event files appear in Table 3-1. Figure 3-6
visually depicts the prescription medication (HC-077A) example. Appendix D contains
each of the formulas for each individual event files (other medical expenses, HC-077C,
hospital inpatient stays, HC-077D, emergency room visits, HC-077E, outpatient visits,
HC-077F, office-based medical provider visits, HC-077G, home health visits, HC-077H,
and nursing home stays (NHC-003, and NHC-007).

Direct Medical Costs-Nursing Home
Nursing home costs were estimated using the 1996 Nursing Home Component (NHC)
of MEPS, which is the most recent set of data available. The NHC is divided into
person-level files (NHC-001P, NHC-002, and NHC-007) and facility-level files (NHC001F, NHC-003). To adjust Nursing Home Costs from 1996 dollars to 2003 dollars, the
following formula was used:
(1996) X 2003 CPI for NHC / 1996 CPI for NHC = $ amount for the year 2003.160
Where:
CPI = Consumer Price Index
NHC = Nursing Home Costs
*Base Year = 1996
For example: If nursing home costs in 1996 were found equal to $2 billion dollars, the
amount in 2003 dollars would be calculated as follows.
$2,000,000,000 X 135.2/100 = $2,704,000,000
Where:
$2,000,000,000= Hypothetical 1996 Nursing Home Costs
135.2 = actual 2003 Nursing Home CPI
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Table 3-1. Variables Used to Calculate Direct Medical Expenses.
MEPS File

Variable Name

Description

RXXP03X

Sum of payments for each Prescription
Medications
prescribed medicine
(HC-077A)
Sum of facility payments Hospital
Inpatient Stays
for inpatient stays
(HC-077D)
Hospital
Sum of doctor payments
Inpatient Stays
for inpatient stays
(HC-077D)
Other Medical
Sum of all 12 sources of
Expenses
payments
(HC-077C)
Facility sum of payments Emergency
Room Visits
for emergency room
(HC-077E)
Emergency
Doctor sum of payments
Room Visits
for emergency room
(HC-077E)
Outpatient Visits
Sum of doctor payments
(HC-077F)
for outpatient visits

IPEXP03X

IPDXP03X

OMXP03X

ERFXP03X

ERDXP03X

OPDXP03

OPFXP03

Sum of facility payments
for outpatient visits

Outpatient Visits
(HC-077F)

OBXP03X

Sum of payments for
office based provider
visits

HHXP03X

Sum of payments for
home health visits

Office-Based
Medical Provider
Visits
(HC-077G)
Home Health
Visits
(HC-077H)

TOTPEXP

Total patient expenses

Nursing Home
Component
(person level)
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Cost
Component
Measured
Direct Medical
Medications
Direct Medical
Hospital Visits
Direct Medical
Hospital Visits
Direct Medical
Other Medical
Expenses
Direct Medical
Emergency
Room Visits
Direct Medical
Emergency
Room Visits
Direct Medical
Outpatient
Visits
Direct Medical
Outpatient
Visits
Direct Medical
Treatment by
Medical
Professionals
Direct Medical
Treatment by
Medical
Professionals
Direct Medical
Nursing Home
Care

Table 3-1. Continued.
Variable Name

Description

MEPS File

POOLWT

The final person-level
weight divided by 5 that
was previously adjusted to
match census population
estimates on the following
demographic
characteristics: sex, age,
race/ethnicity, and
geographic area
Person identifier that
remains the same for
duration of survey
participation

Contained in
all MEPS files

DUPERSID
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Contained in
all MEPS files

Cost
Component
Measured
Weighting
Variable
All

Patient Identifier
All

Step One: Add together all reported medication events for the prescription medication
event file.

RXXP03X
($217)

+

RXXP03X
($75)

RXXP03X
($65)

=

RXXP03 XUWPT
($357)

Step Two: Multiply unweighted cost variable total by PERWT01F (patient weighted
value) to get amount that 2,365 Parkinson’s patients would spend on medications.

RXXP03 XUWPT
($357)

X

POOLWT
(2,365)

RXXP03XWPT
($844,305)

Step Three: Add together all weighted totals for Prescription Medications to arrive at a
national estimate for 2003.

£ (RXXP03XWPT)

=

RXXP03XWOT

Figure 3-6. Example of the Calculation of Medication Costs. Visual example of how
overall costs for prescription medications were calculated.
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100= actual 1996 Nursing Home CPI
$2,704,000,000= Hypothetical 2003 Nursing Home Costs
This formula was calculated for each year of data included in the study (1999-2003)
and the base year will always be 1996 because that is the only year of data available for
Nursing Home Costs.

Direct Non-Medical Costs
Direct non-medical costs were identified from the MEPS database based on
information on the health status of family members and condition-specific limitations.
Variables from the Other Medical Expenses (HC077C) database were used to calculate
cost information on direct non-medical costs. If a patient reported that they had a direct
non-medical expense (OMOTHOS), then the events for this specific person were
reviewed to see if the event (EVNTEDX) was related to Parkinson’s disease. The total for
direct non-medical expenses (OMOTHOS) that were related to Parkinson’s disease were
then multiplied the individuals person weight (POOLWT) to arrive at direct non-medical
expenses for each individual. The specific direct non-medical cost variables used from
the various event files appear in Table 3-2.

Indirect Costs
Indirect costs of Parkinson’s disease were determined by using the human capital
method. The human capital method quantifies indirect costs by calculating non-medical
costs associated with a particular disease state. The human capital method calculates the
value of lost productivity due to absences from work (labor market work force and
housework), disability (morbidity costs), or death (mortality costs).
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Table 3-2. Variables Used to Calculate Direct Non-Medical Expenses.
Variable
Name

Description

MEPS file

OMOTHOS

Captures expenses for
transportation, lodging, child
care, and home modifications

Other Medical
Expenses
(HC-077C)

EVNTIDX

Identifies that the expense was
due to Parkinson’s disease

POOLWT

The final person-level weight
divided by five and was
previously adjusted to match
Census population estimates on
the following demographic
characteristics: sex, age,
race/ethnicity, and geographic
area

Other Medical
Expenses
(HC-077C)
Contained in
all MEPS files
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Cost
Component
Measured
Direct NonMedical
Transportation
Child care
Household
Expenses
Event
Identifier
All
Weighting
Variable
All

The MEPS databases provide the number of persons who missed work due to
Parkinson’s disease, the average earnings per hour of each person, the average
number of hours the person worked per day, and the number of days of lost work for each
person who reported missing work due to Parkinson’s disease. Morbidity costs were
estimated from the number of patients with Parkinson’s disease reporting either a loss of
paid employment or inability to perform non-paid housekeeping duties. The variables
that were used to measure morbidity costs came from the jobs file (HC-063)
database, the full year consolidated data file, and the medical conditions file (HC-078)
database. The specific morbidity cost variables used from the three files appear in Table
3-3.
The number of days of missed work and the daily wage rate are available in the Jobs
File (HC-074). If the person had bed days, this was reported as a Yes or No response in
the Jobs File (HC-074), and the total number of bed days are in the Full Year
Consolidated File (HC-073). A bed day is defined as staying in bed for fifty percent (or
more) of the day due to a specific condition.164 The value of lost housekeeping services
and bed days are based on the human capital methodology.165 If a person reported that
they had bed days, but were not employed, then the number of bed days was multiplied
times the value of a bed day. The value of a bed day (for individuals not in the labor
force) is estimated as the value of lost housekeeping services. The human capital
methodology estimates the present value of lifetime earnings based on the assumption
that earnings reflect the contribution workers make to the value of goods and services.165
Housekeeping and bed days are valued as a loss of goods and services that the individual
would have contributed to the household in the absence of illness.165 The morbidity
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Table 3-3. Variables Used to Calculate Indirect Cost (Morbidity).

Variable Name
DW

Description
Persons daily wage rate

File
Jobs File

VBD

Value of a bed day

BLS

MISSWORK

Jobs File and
Medical
Conditions
File
Person reports being in bed V2 Full Year
day or more due to reported
Consolidated
condition
File
Number of bed days reported Full Year
in specific panel and round
Consolidated
File
Number of bed days reported Full Year
in specific panel and round
Consolidated
File
Number of bed days reported Full Year
in specific panel and round
Consolidated
File
Number of days of missed
Full Year
work reported in specific
Consolidated
panel and round
File
Number of days of missed
Full Year
work reported in specific
Consolidated
panel and round
File
Number of days of missed
Full Year
work reported in specific
Consolidated
panel and round
File
The five year pooled person- Medical
level weight
Condition
File

INBEDFLG
(BED DAY)
DDBDYS31

DDBDYS42

DDBDYS53

DDNWRK31

DDNWRK42

DDNWRK53

POOLWT

Missed work days
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Purpose
Calculation of
Indirect Costs
(Morbidity)
Calculation of
Indirect Costs
(Morbidity)
Calculation of
Indirect Costs
(Morbidity)
Calculation of
Indirect Costs
(Morbidity)
Calculation of
Indirect Costs
(Morbidity)
Calculation of
Indirect Costs
(Morbidity)
Calculation of
Indirect Costs
(Morbidity)
Calculation of
Indirect Costs
(Morbidity)
Calculation of
Indirect Costs
(Morbidity)
Calculation of
Indirect Costs
(Morbidity)
Calculation of
Indirect Costs
(Morbidity)

estimate for this study was calculated from a sample of people with Parkinson’s disease,
and it was necessary to apply patient weights (POOLWT) to the estimate in order to
accurately reflect the morbidity costs for the U.S. population.
The following steps were necessary to reach an overall cost of morbidity:
1. The first step in reaching an overall cost of morbidity for Parkinson’s disease was
to determine if a person reported having missed work and/or had bed days due to
Parkinson’s disease.
2. Next, the number of days of missed work and bed days had to be calculated. A
person reports the number of missed work days and bed days in each round of the
survey panel. There are three rounds of interviewing in a year; therefore, there are
three separate variables to be totaled to get the actual yearly total of missed work
days (DDNWRK31, DDNWRK42, and DDNWRK53) and bed days
(DDBDYS31, DDBDYS42, and DDBDYS53). A separate variable was created
to represent the total number of missed work days (DDNWRKTOT) and bed days
(BDOT).
3. The number of missed work days (DDNWRKTOT) was then multiplied by the
person’s daily wage rate (DW), which came from BLS. The number of bed days
(BDOT) was then multiplied by the value of a bed day (VBD).
4. In order to account for Parkinson’s patients that didn’t work, but had lost
productivity due to bed days, it was necessary to create a separate variable to
value their lost productivity. The variable “value of a bed day” (VBD) is not
contained in MEPS, so it was necessary to use wage data from the BLS to
calculate the value of a bed day based on the age and gender of those who
reported bed

days. The if/then function in SAS was used to calculate the
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appropriate value of a bed day (VBD) by race, age, and gender. For example, if
the person reporting bed days was a white female age 55 and the value of a bed
day for a white female age 55 is $40, then VBD for this person would be $40.
5. As with the previous MEPS data files, it was necessary to calculate a total for
each individual patient and to then multiply that total by the individual patient
weight (POOLWT). The variable that was created was titled MORBTWPT
(individual patient weighted total for morbidity), and all MORBTWPT variables
were summed to calculate a grand total that was called MORBWOT (overall
weighted total for morbidity).
The formula used to calculate morbidity costs was:
X [NMWDT x DW] + (BDOT x VBD)] POOLWT = Morbidity Costs
Where:
NMWDT = overall total number of missed work days;
DW = daily wage rate;
BDOT = overall total number of bed days;
VBD = value of bed day;
POOLWT = five year pooled person-level weight.
Mortality costs are not specifically gathered by the MEPS database. For the purposes
of this study, the 1999-2003 NVSS and the 1999-2003 BLS variables were used to
calculate the mortality costs portion of this cost of illness estimate that appear in Table 34.
The NVSS contains the number of deaths due to Parkinson’s disease by gender, race,
and age (broken into five-year age groups). The formula following Table 3-4 was used to
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Table 3-4. Variables Used to Calculate Indirect Cost (Mortality).
Variable
Age

Description
Age of person at time o f death

Data Source
NVSS/BLS

Gender

Male or female

NVSS/BLS

Race

Race (black, white, or other)

NVSS/BLS

Employment

Labor force participation rates

BLS

Wage

Average wage by demographic
characteristics

BLS

Life Expectancy

Average life expectancy of a
person, based on race and gender

NVSS

Life Tables for
Probability of
Survival

Probability that a person will
survive to a certain age, based on
gender and race

NVSS

NVSS = National Vital Statistics Survey
BLS = Bureau of Labor Statistics
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Purpose
Calculation o f
Indirect Costs
(Mortality)
Calculation of
Indirect Costs
(Mortality)
Calculation of
Indirect Costs
(Mortality)
Calculation of
Indirect Costs
(Mortality)
Calculation of
Indirect Costs
(Mortality)
Calculation of
Indirect Costs
(Mortality)
Calculation of
Indirect Costs
(Mortality)

calculate mortality costs, for each race, age, and gender combination (black males, black
females, white males, and white females):
85+

S WnLnSn = WXnS„
W,LnS„ WnL„Sn
n =a (l+r)"'a
(l+r)° + (1+r)1 + (1+r)2 +....
Where:
W„= wage amount at particular age (BLS)
L„ = probability of still being in the labor force at a given age (BLS)
Sn = probability of surviving to a given age (NVSS)
r = discount rate
a = age at death (NVSS)
n = life expectancy (NVSS)
Discounting future earnings is necessary to determine their net present value.31 The
discounting process uses a discount rate to convert a stream of future earnings to its
present value 31 The discount rate is generally between 2 and 4% 31 If a higher discount
rate is selected, the present value of a given stream of future earnings will be lower.31
Conversely, if a lower discount rate is selected, the present value of future
earnings will be higher.31 For purposes of this study, future earnings were discounted
using a 3% discount rate.31 By using an average 3% discount rate, the risk of
underestimating or overestimating the actual value of future earnings was reduced.166
The NVSS is not a sample of the US. population because it collects information on all
deaths nationally; therefore it is not necessary to apply any weights to the mortality
estimate.38 The total amount of indirect costs was calculated by adding the total from the
morbidity estimate to the total from the mortality estimate:
Morbidity Costs + Mortality Costs = Indirect Costs
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Objectives and Hypotheses
Following is a list of the objectives and hypotheses for this research. Objectives 1 and
2 were descriptive in nature and do not have corresponding hypotheses. Objective 8 also
has no corresponding hypothesis. Objectives 3 through 8 do have hypotheses and they are
listed below.
1. Objective 1: To use a national database to determine the direct and indirect costs
(cost of illness) for persons with Parkinson’s disease in the United States.
2. Objective 2: To describe healthcare utilization for persons with Parkinson’s
disease in the United States.
3. Objective 3: To determine if there is a statistical difference between gender and
cost of illness for Parkinson’s disease in the United States.
Null Hypothesis: There is no difference between the average costs of
Parkinson’s disease for males compared to females.
4. Objective 4: To determine if there is a statistically significant relationship
between education level and cost of illness for Parkinson’s disease in the United
States.
Null Hypothesis: There are no differences between the average costs of
Parkinson’s disease when comparing levels of education.
5. Objective 5: To determine if there is a statistically significant relationship
between age groups and cost of illness for Parkinson’s disease.
Null Hypothesis: There are no differences between the average costs of
Parkinson’s disease when comparing age groups.
6. Objective 6: To determine if there is a statistically significant relationship
between income level and cost of illness for Parkinson’s disease.
102

Null Hypothesis: There are no differences between the average costs of
Parkinson’s disease when comparing income levels.
7. Objective 7: To determine if there is a statistically significant relationship
between marital status and cost of illness for Parkinson’s disease.
Null Hypothesis: There are no differences between the average costs of
Parkinson’s disease when comparing marital status.
8. Objective 8: To determine if there is a statistically significant relationship
between region of residence and cost of illness for Parkinson’s disease.
Null Hypothesis: There are no differences between the average costs of
Parkinson’s disease when comparing region of residence.
10. Objective 9: To determine the relative influence of each demographic variable
(gender, education level, age, income level, marital status and region of residence)
when controlling for the influence of other variables.

Data Analysis-Total Cost of Illness
Calculating the total cost of illness of Parkinson’s disease for a single year was the
primary purpose of this study. Therefore, the fundamental analysis was conducted using
all of the components of cost of illness (direct medical costs + direct non-medical costs +
indirect morbidity costs + indirect mortality costs). The overall total cost of illness for
Parkinson’s disease was calculated by adding direct medical, direct non-medical costs,
and indirect morbidity costs obtained from the MEPS-HC, the MEPS-NHC, and BLS
with indirect mortality costs obtained from the NVSS and BLS. As discussed previously,
the MEPS-NHC was only conducted in 1996, so the estimate for nursing home costs was
inflated to represent 2003 dollars. For each year of data (1999-2003), a total overall cost
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of Parkinson’s disease was calculated. Figure 3-7 shows the formula for the overall cost
of illness for Parkinson’s disease.
For each of the demographic variables (age, gender, education level, marital status,
and income) descriptive statistics were used to describe the cost of Parkinson’s
disease. In addition, results for objectives 1 and 2, the total number of events were
reported that occurred in each of the individual event-level files (prescribed medicines,
hospital inpatient stays, emergency room visits, outpatient visits, office-based medical
visits, home health visits, other medical expenses, missed worked days, bed days, and
deaths).
For objectives 3 and 4, a t-test was used to test for a difference between costs for
males and females. For objectives 5 through 8 a series of one-way ANOVA
analyses were used with each of the demographic variables (age, marital status, income
and region of residence) serving as the independent variable and the cost of Parkinson’s
disease (minus costs from MEPS-NHC and mortality) as the dependent variable. For
objective 9, each of the demographic variables (age, gender, education level, marital
status, income and region of residence) was considered concurrently to determine
multivariate significance. Post-hoc contrasts were performed to determine multivariate
significance. Post-hoc contrasts were performed to determine where the statistically
significant differences occurred between demographic groups. In this research study, a Pvalue of 0.05 (or less) was considered statistically significant. In order to reduce the risk
of type 1 error, Bonferroni Adjustments were applied to the P-values. The Bonferroni
Adjustment was done by dividing the accepted P-value of 0.05 by the number of
comparisons being made between the demographic groups. For example, the
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Overall Total
Cost for
Prescription
Medications
(Direct Medical
Cost)

Overall Total Cost for
Home Health Visits
(Direct Medical Cost)

Overall Total
Cost for Inpatient
Visits
(Direct Medical
Cost)

Overall Total Cost
for Outpatient Visits
(Direct Medical
Cost)

Overall Total
Cost for Other
Medical Expenses
(Direct Medical,
and Direct NonMedical Cost)

Overall Total Cost
for Office Based
Visits
(Direct Medical
Cost)

Overall Total Cost
for Nursing Home
(Direct Medical
Cost)

Overall Total
Cost for
Mortality
(Indirect Cost)

Overall Total Cost
for Morbidity
(Indirect Cost)

Overall Total Direct
and Indirect Cost for
Parkinson’s disease

+

Overall Total
Cost for
Emergency
Room Visits
(Direct Medical
Cost)

Figure 3-7. Formula Used to Determine the Overall Direct and Indirect Cost of
Parkinson’s Disease for One Year.
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+

+

+

demographic marital status had three groups (single, married, widowed) and therefore in
order to be statistically significant, the P-value would have to be less than 0.016.

SAS
SAS version 9.13 was used for all statistical analyses in this study. For objective 3
and 4, the SAS procedure PROC TTEST (t-test) was used to compare total costs (minus
nursing home costs and mortality costs) between gender (males and females) and
between education levels (less than high school and greater than high school). For
objectives 5 through 8 the SAS procedures Proc Surveymeans and Proc Surveyreg and
were used. Proc Surveyreg provided the one-way ANOVA tests for objectives 5-8. This
SAS procedure was done for each of the selected demographics in objectives 5-8. For
objective 9, the Proc Surveyreg procedure was done while holding the selected
demographics constant using the Estimate step in the Proc Surveyreg procedure. Once
SAS produced the P-value for each of the selected demographics, Bonferroni
Adjustments were applied to each of the selected demographic categories to determine if
the P-value was significant.
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CHAPTER IV. RESULTS

Introduction
The results of this study of cost of illness in Parkinson’s disease are presented in three
sections. The first section describes the demographic data from the MEPS-HC and the
MEPS-NHC. The first section also describes the direct and indirect costs (cost of illness)
as well as total costs for persons with Parkinson’s disease in the United States,
corresponding with objective 1. The second section describes healthcare resource
utilization for persons with Parkinson’s disease and corresponds with objective 2. The
third section provides statistical analysis of the direct and indirect costs obtained from the
MEPS-HC and corresponds with study objectives 3 through 9.

Demographic Data
Table 4-1 provides an overview of each year of MEPS-HC data used in this study.
When all 5 years were combined, an unweighted total o f242 patients were in the MEPSHC sample. Of the 242 patients with Parkinson’s disease in the MEPS-HC sample, 9 had
non-positive patient weights and were excluded from the study, making the final sample
total 233 patients. The average age of the 116 females in the MEPS-HC with Parkinson’s
disease was 68.9 and the average age of the 117 males was 67.8. These 233 patients
represented a weighted total of 2.6 million people with Parkinson’s disease over a 5 year
period. Using the MEPS-HC assigned patient weights, 1.18 million (45%) of the noninstitutionalized patients with Parkinson’s disease were female and 1.43 million (55%)
were male.

107

Table 4-1. Overview Demographic Data for Gender and Patients with Parkinson’s
Disease from MEPS-HC 1999-2003.
Year Unweighted
Number
1999
37
2000
43
2001
52
2002
60
2003
50

Females
15
26
36
27
21

Males Weighted
Number
22
512,265
17
483,273
16
560,014
33
585,287
29
484,929

Females

Males

210,574
278,812
369,704
179,637
149,956

301,691
204,461
190,310
405,650
334,973

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey, Household Component 1999-2003.

Table 4-2 provides a breakdown of the selected demographics of the 233 MEPS-HC
patients with Parkinson’s disease. This table shows the values of the “poolwt” variable
that represents the persons’ weight for the five year period of the study. The majority of
patients (67%) in the weighted sample were between 65-84 years of age and 52.8% were
widowed. Males made up 54.7% of the weighted sample and 70% had a high school
education or greater. The majority (66.8%) of patients with Parkinson’s disease in the
sample reported an income of less than $20,000 annually. The largest percentage
(37.4%) of patients with Parkinson’s disease in the sample lived in the South.
Table 4-3 provides a breakdown of the nursing home patients with Parkinson’s disease
from the MEPS-NHC used for this study. In 1996, there were a total of 5,899 patients in
the MEPS-NHC survey; 208 of these patients had a diagnosis of Parkinson’s disease.
Using the patient weights assigned, these 208 patients represented 99,989 Parkinson’s
patients in nursing home facilities in the United States (65,928 females and 34,061 males).
Table 4-3 provides the selected demographics for the 1996 Nursing Home data. The
majority of nursing home patients with Parkinson’s disease were white (94.23%) and
over the age of 80 (60.58%). Almost half (48%) were widowed and 29% were married.
The remaining 23% of patients with Parkinson’s disease were single, divorced or
separated.

Direct, Indirect, and Total Cost of Illness
Table 4-4 provides the weighted overall annual cost of Parkinson’s disease broken
down by direct medical costs, direct non-medical and indirect costs. The cost of
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Table 4-2. Breakdown of All Selected Demographics Data for Patients with Parkinson’s
Disease from MEPS-HC 1999-2003 Combined.
Demographic
Gender
Male
Female
Age
Under 65
65-84
>85
Education
< High School
> High School
Marital Status
Married
Widowed
Single
Income
< $20,000
$20,000-$29,999
>$30,000
Region
Northeast
Mid-West
South
West

Unweighted
Number

Unweighted
Percent

117
116

50.3%
49.7%

287,417
237,737

54.7%
45.3%

43
156
34

18.5%
70.0%
14.5%

75,507
352,233
97,414

14.3%
67.0%
18.7%

90
143

38.6%
61.4%

157,324
367,830

30.0%
70.0%

41
115
77

17.6%
49.3%
33.1%

74,830
277,495
172,829

14.2%
52.8%
33.0%

164
28
41

70.3%
12.0%
17.7%

350,861
71,494
102,799

66.8%
13.6%
19.6%

37
51
93
52

15.9%
21.9%
39.9%
22.3%

95,170
118,132
196,153
116,699

18.1%
22.5%
37.4%
22.0%

Poolwt
Number

Poolwt
Percent

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey, Household Component 1999-2003.
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Table 4-3. Selected Nursing Home Demographics Weighted and Unweighted for Patients
with Parkinson’s Disease from the MEPS-NHC, 1996.
Demographic
Gender
-Males
-Females

Unweighted Number

Weighted Number

74
134

34,061
65,928

___________ Age_____________________________________
-Under 80
-Over 80
Marital Status
-Single
-Married
-Widowed
-Unknown
Education Level
-Less than High
School
-High School
-College
-Don’t Know
Overall

82
126

33,149
66,570

47
60
100
1

22,166
29,115
48184
524

84

35,233

31
35
58
208

12,923
28,286
23,547
99,989

Source: Center for Financing Access and Cost Trends, Agency for Healthcare Research
and Quality; Medical Expenditures Panel Survey, Nursing Home Component, 1996.

I l l

Table 4-4. Overall Annual Cost of Illness for Parkinson’s Disease from MEPS-HC 1999-2003, MEPS-NHC 1996, BLS 19992003 and National Vital Statistics System 1999-2003.
Component
Direct
Medical
Direct NonMedical
Indirect
Total

1999
$4,266,866,331

2000
$4,670,693,881

2001
$5,820,637,444

2002
$5,629,814,316

2003
$5,298,491,603

Total
$25,686,503,575

$306,203,804

$2,195,358

$5,260,885

$3,704,973

$10,683,797

$328,048,817

$1,537,093,738
$6,110,163,873

$1,971,778,359
$6,644,667,598

$3,070,872,134
$8,896,770,463

$3,287,857,779
$8,921,377,068

$1,003,268,392
$6,312,443,792

$10,870,870,402
$36,885,422,794
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Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel Survey Household Component
1999-2003, Center for Financing Access and Cost Trends, Agency for Healthcare Research and Quality; Medical
Expenditures Panel Survey, Nursing Home Component, 1996, Bureau of Labor Statistics, Wage and Labor Statistics,
United States Department of Labor, 1999-2003 and National Vital Statistics System, 1999-2003 Mortality Tables, National
Center for Health Statistics.

illness for Parkinson’s disease from 1999-2003 was $36.8 billion dollars. The majority
(69.6%) of costs for Parkinson’s disease were direct medical costs, and
29.5% were indirect costs. Direct non-medical costs comprised less than 1% of total costs
due to Parkinson’s disease.
Table 4-5 further breaks down direct medical costs into those from MEPS-HC and
those from MEPS-NHC. The majority (53.5%) of direct medical costs were due to
nursing home care (MEPS-NHC). The largest percentage (88.5%) of indirect costs was
morbidity due to bed days.

Healthcare Resource Utilization and Costs
The following section presents the utilization of healthcare resources and is reported for
each of the MEPS-HC components. These components are: prescription medication
costs, office-based visits, emergency room visits, inpatient hospital stays, outpatient
visits, home health visits, and other medical expenses. For each component, the year, the
unweighted and weighted total number of times a resource was utilized, and the
unweighted and weighted cost for the resource, are reported.
Direct medical costs are provided in Tables 4-6 through 4-12. Tables 4-6 through 411 provide a break down of the weighted and unweighted utilization and costs for each of
the MEPS-HC components for 1999-2003. Table 4-12 provides the cost of nursing home
care using the 1996 MEPS-NHC. Table 4-13 provides direct non-medical costs, while
indirect costs are presented in Tables 4-14 through 4-17.
Table 4-6 provides an overall breakdown of prescription medication utilization and
costs for 1999-2003. The second largest direct medical cost reported by patients with
Parkinson’s disease was for prescription medications. The greatest percentage
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(25.9%)

Table 4-5. Overall Annual Costs by Category from MEPS-HC 1999-2003, MEPS-NHC 1996, BLS 1999-2003 and NVSS
1999-2003.
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V a r ia b le

1999

2000

2001

2002

2003

C a te g o r y T o ta l

D ire c t M e d ic a l
M E P S -H C

$ 6 7 3 ,7 0 8 ,4 4 6

$ 9 0 3 ,6 7 3 ,5 1 8

$ 1 ,8 9 9 ,0 7 2 ,6 5 6

$ 1 ,5 1 1 ,8 4 9 ,3 2 1

$ 9 4 5 ,4 9 0 ,2 9 4

$ 5 ,9 3 3 ,7 9 4 ,2 3 5

D ire c t M e d ic a l
M E P S -N H C

$ 3 ,5 9 3 ,1 5 7 ,8 8 5

$ 3 ,7 6 7 ,0 2 0 ,3 6 3

$ 3 ,9 2 1 ,5 6 4 ,7 8 8

$ 4 ,1 1 7 ,9 6 4 ,9 9 5

$ 4 ,3 5 3 ,0 0 1 ,3 0 9

$ 1 9 ,7 5 2 ,7 0 9 ,3 4 0

D ire c t N o n M e d ic a l
M E P S -H C

$ 3 0 6 ,2 0 3 ,8 0 4

$ 2 ,1 9 5 ,3 5 8

$ 5 ,2 6 0 ,8 8 5

$ 3 ,7 0 4 ,9 7 3

$ 1 0 ,6 8 3 ,7 9 7

$ 3 2 8 ,0 4 8 ,8 1 7

In d ire c t
M o rb id ity
M E P S -H C
(M is s e d W o rk )

$ 1 8 7 ,7 8 5 ,7 1 2

$ 1 3 0 ,2 9 4 ,4 4 6

$0

$ 7 0 ,0 1 6 ,0 7 0

$ 1 ,6 3 9 ,7 7 0

$ 3 8 9 ,7 3 5 ,9 9 8

In d ire c t
M o rb id ity
M E P S -H C
(B e d D a y s)

$ 1 ,2 2 2 ,1 1 9 ,4 4 9

$ 1 ,6 9 0 ,3 1 7 ,6 7 0

$ 2 ,8 9 6 ,2 9 5 ,0 1 4

$ 3 ,0 1 8 ,9 9 1 ,1 1 8

$ 7 9 1 ,8 8 0 ,2 8 3

$ 9 ,6 1 9 ,6 0 3 ,5 3 4

In d ire c t
M o rta lity
NVSS

$ 1 2 7 ,1 8 8 ,5 7 7

$ 1 5 1 ,1 6 6 ,2 4 3

$ 1 7 4 ,5 7 7 ,1 2 0

$ 1 9 8 ,8 5 0 ,5 9 1

$ 2 0 9 ,7 4 8 ,3 3 9

$ 8 6 1 ,5 3 0 ,8 7 0

A n n u a l T o ta l
A n n u a l T o ta l in
2003 D o lla rs

$ 6 ,1 1 0 ,1 6 3 ,8 7 3
$ 7 ,1 3 2 ,8 8 7 ,8 7 4

$ 6 ,6 4 4 ,6 6 7 ,5 9 8
$ 7 ,4 2 7 ,8 3 9 ,2 3 7

$ 8 ,8 9 6 ,7 7 0 ,4 6 3
$ 9 ,5 2 2 ,0 4 6 ,1 6 6

$ 8 ,9 2 1 ,3 7 7 ,0 6 8

$ 6 ,3 1 2 ,4 4 3 ,7 9 2
$ 6 ,3 1 2 ,4 4 3 ,7 9 2

$ 3 6 ,8 8 5 ,4 2 2 ,7 9 4

$ 9 ,2 6 5 ,8 8 5 ,2 5 2

$ 3 9 ,6 6 1 ,1 0 2 ,3 2 1

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel Survey Household Component 19992003, Center for Financing Access and Cost Trends, Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey, Nursing Home Component, 1996, Bureau of Labor Statistics, Wage and Labor Statistics, United States Department of
Labor, 1999-2003 and National Vital Statistics System, 1999-2003 Mortality Tables, National Center for Health Statistics.

Table 4-6. Unweighted and Weighted Number and Cost of Prescription Medication from
the MEPS-HC 1999-2003 for Patients with Parkinson’s Disease.
Year
1999
2000
2001
2002
2003
Overall
Total

Unweighted
Number
330
473
613
514
432
2,362

Weighted
Number
5,092,013
4,917,244
5,301,378
4,980,544
4,764,877
25,056,056

Unweighted Cost

Weighted Cost

$28,087
$37,121
$49,015
$37,912
$36,377
$188,512

$420,603,519
$377,857,783
$398,453,297
$361,345,738
$422,955,793
$1,981,216,130

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.

Table 4-7. Unweighted and Weighted Number and Cost of Office-Based Visits from the
MEPS-HC 1999-2003 for Patients with Parkinson’s Disease.
Year
1999
2000
2001
2002
2003
Overall
Total

Unweighted
Number
61
66
202
165
148
642

Weighted
Number
961,463
654,821
1,922,768
1,716,046
1,559,291
6,814,389

Unweighted Cost

Weighted Cost

$6,378
$7,108
$23,218
$15,063
$12,201
$63,968

$94,378,654
$71,916,205
$243,053,730
$141,817,647
$ 117,064,110
$668,230,346

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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Table 4-8. Unweighted and Weighted Number and Cost of Emergency Room Visits from
the MEPS-HC 1999-2003 for Patients with Parkinson’s Disease.
Year
1999
2000
2001
2002
2003
Overall
Total

Unweighted
Number
0
1
4
1
3
9

Weighted
Number
0
16,933
38,898
13,813
29,551
99,195

Unweighted Cost

Weighted Cost

$0
$279
$1957
$518
$703
$3,459

$0
$ 4,725,475
$18,270,344
$7,166,445
$ 9,347,535
$39,509,801

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.

Table 4-9. Unweighted and Weighted Number and Cost of Inpatient Hospitals Stays from
the MEPS-HC 1999-2003 for Patients with Parkinson’s Disease.
Year
1999
2000
2001
2002
2003
Overall
Total

Unweighted
Number
0
1
2
2
3
8

Weighted Unweighted Cost
Number
0
$0
9,943
$16,656
32,588
$21,322
29,118
$7,926
19,567
$42,407
91,216
$88,311

Weighted Cost
$0
$165,632,204
$397,575,101
$333,957,291
$194,340,095
$1,091,504,691

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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Table 4-10. Unweighted and Weighted Number and Cost of Outpatient Visits from the
MEPS-HC 1999-2003 for Patients with Parkinson’s Disease.
Year
1999
2000
2001
2002
2003
Overall
Total

Unweighted
Number
23
8
3
13
27
74

Weighted Unweighted Cost
Number
201,333
$3,709
80,603
$ 594
39,913
$6,170
186,100
$7,456
299,232
$3,272
807,181
$21,201

Weighted Cost
$28,505,556
$ 5,968,446
$77,255,493
$88,032,415
$30,108,823
$229,870,733

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.

Table 4-11. Unweighted and Weighted Number and Cost of Home Health Visits ffom the
MEPS-HC 1999-2003 for Patients with Parkinson’s Disease.
Year
1999
2000
2001
2002
2003
Overall
Total

Unweighted
Number
49
38
99
62
47
295

Weighted
Number
665,495
369,242
1,653,407
965,950
335,115
3,989,209

Unweighted Cost

Weighted Cost

$ 8,382
$ 25,890
$ 59,839
$36,519
$ 50,423
$181,053

$ 130,220,717
$ 277,573,403
$ 764,464,690
$ 579,529,784
$ 171,673,936
$1,923,462,530

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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Table 4-12. Nursing Home Costs from the MEPS-NHC, 1996 Using CPI for Nursing
Home Care for the Years 1999-2003.
1996 Nursing
Home Costs
$3,219,675,524
$3,219,675,524
$3,219,675,524
$3,219,675,524
$3,219,675,524

CPI (Year)
X
X
X
X
X

Adjusted Cost

111.6(1999)
117.0(2000)
121.8(2001)
127.9 (2002)
135.2 (2003)

=

=
=
=
=

$3,593,157,885
$3,767,020,363
$3,921,564,788
$4,117,964,995
$4,353,001,309

‘Consumer Price Index for Nursing Homes (1996 base year)

Table 4-13. Unweighted and Weighted Number and Cost of Direct Non-Medical
Expenses from the MEPS-HC 1999-2003 for Patients with Parkinson’s Disease.
Year
1999
2000
2001
2002
2003
Overall
Total

Unweighted
Number
2
4
6
4
11
27

Weighted
Number
17,462
37,264
56,006
48,015
155,318
314,065

Unweighted Cost

Weighted Cost

$35,070
$233
$574
$435
$765
$37,077

$306,203,804
$2,195,357
$5,260,885
$3,704,972
$10,683,797
$328,048,815

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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Table 4-14. Morbidity: Missed Work Days Weighted and Unweighted from the MEPS-HC 1999-2003 for Patients with
Parkinson’s Disease.
Year
1999
115
Total # Days
of Missed
Work
(Unweighted)
115
-Males
0
-Females
1,362,669
Total # Days
of Missed
Work
Weighted
1,362,669
-Males
0
-Females
Cost
$15,510
Unweighted
$15,510
-Males
$0
-Females
Cost $187,785,712
Weighted
-Males $187,785,712
-Females
$0

2000
109

2001
0

2002
145

2003
1

Total
370

0
109
1,728,723

0
0
0

0
145
673,231

0
1
13,224

115
255
3,777,847

0
1,728,723
$10,205

0
0
$0

0
673,231
$15,080

0
13,224
$124

1,362,669
2,415,178
$40,919

$0
$10,205
$130,294,446

$0
$0
$0

$0
$15,080
$70,016,070

$0
$15,510
$124
$25,409
$1,639,770 $389,735,998

$0
$130,294,446

$0
$0

$0
$70,016,070

$0 $187,785,712
$1,639,770 $201,950,286

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel Survey Household Component 1999-2003
and Bureau of Labor Statistics, Wage and Labor Statistics, United States Department of Labor, 1999-2003.

Table 4.15. Morbidity: Bed Days Weighted and Unweighted from the MEPS-HC 1999-2003 for Patients with Parkinson’s
Disease.
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Year
Total # bed
days
(Unweighted)
-Males
-Females
Total # bed
days
Weighted
-Males
-Females
Cost
Unweighted
-Males
-Females
Cost
Weighted
-Males
-Females

1999
1228

2000
1423

2001
1812

2002
2029

2003
964

Total
7456

1227
1
12,916,485

1012
411
17,492,721

786
1026
30,329,004

1314
715
30,132,834

538
426
6,976,979

4877
2579
97,848,022

12,899,666
16,819
$127,743

6,626,179
10,866,542
$145,466

12,561,305
17,767,699
$174,282

24,655,415
5,477,419
$196,071

3,056,579
3,920,400
$116,632

59,799,144
38,048,879
$760,194

$127,669
$74
$1,222,119,449

$114,756
$30,710
$1,690,317,670

$91,176
$83,106
$2,896,295,014

$136,726
$80,923
$35,709
$59,345
$3,018,991,118 $791,880,283

$551,250
$208,944
$9,619,603,533

$1,220,874,852
$1,244,596

$1,194,018,178
$496,299,492

$1,457,111,337
$1,439,183,677

$2,564,365,346 $460,270,577
$454,625,772 $331,609,706

$6,896,640,290
$2,722,963,243

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel Survey Household Component 1999-2003
and Bureau of Labor Statistics, Wage and Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-16. Mortality due to Parkinson’s Disease from the 1999-2003 NVSS.
Year

1999

2000

2001

2002

2003

Total

Total # of
deaths
Total # Males

14,593

15,682

16,544

16,959

18,002

81,780

8,262

8,804

9,405

9,593

10,183

46,247

-Black Males
-White Males
-Other Males

270
7,880
112

308
8367
129

294
8982
129

313
9130
150

352
9632
199

1537
43,991
719

Total #
Females
-Black
Females
-White
Females
-Other
Females
Deaths prior to
life expectancy

6,331

6,878

7,139

7,366

7,819

35,533

237

226

257

244

278

1242

6006

6575

6775

7005

7416

33777

88

77

107

117

125

514

5,190

3,616

7,014

3,774

8,275

27,869

Source: National Vital Statistics System, 1999-2003 Mortality Tables, National Center for Health Statistics.

Table 4-17. Mortality Costs due to Parkinson’s Disease from the 1999-2003 NVSS.
Total
Mortality
Costs by
year, gender
and race
Males
White
Black
Females
White
Black
Average
Mortality
Costs
Males
White
Black
Females
White
Black
Total
Mortality
Costs

1999

2000

2001

2002

$92,163,647
$90,666,767
$1,496,880
$35,024,928
$32,718,630
$2,306,297

$104,530,444
$100,932,467
$3,597,977
$46,635,798
$44,817,877
$1,817,920

$130,760,828
$122,942,250
$7,818,578
$43,816,291
$41,469,299
$2,346,991

$138,443,536
$135,254,453
$3,189,083
$60,407,054
$57,921,266
$2,485,787

$27,651
$27,811
$20,505
$18,861
$18,106
$46,125

$70,390
$69,608
$102,799
$21,884
$21,851
$22,724

$36,322
$13,687
$26,593
$10,915
$6,120
$9,132

$127,188,577

$151,166,243

$174,577,120

$81,822
$84,534
$34,663
$29,013
$28,448
$54,038
$198,850,591

2003

$131,584,795
$127,833,039
$3,751,756
$78,163,542
$73,971,395
$4,192,147

Total

$597,483,250
$577,628,976
$19,854,274
$264,047,613
$250,898,467
$13,149,142

$33,657
$33,516
$38,677
$17,910
$17,417
$35,830

$249,842
$229,156
$223,237
$98,583
$91,942
$167,849

$209,748,339

$861,530,870

Source: National Vital Statistics System, 1999-2003 Mortality Tables, National Center for Health Statistics

of weighted and unweighted prescription medications were reported in 2001 by patients
with Parkinson’s disease. Unweighted medication costs were highest in 2001, however
weighted prescription medication costs were the highest in 2003.
Table 4-7 provides the overall breakdown of office based utilization and costs for
1999-2003. Office based visits was the second most frequently occurring MEPS-HC
component reported by patients with Parkinson’s disease. Approximately seven million
weighted visits were reported from 1999-2003. The year 2001 had the most (28.2%)
weighted visits and the most (31.4%) unweighted visits. The year 2001 also had the
highest weighted costs (36.2%) and unweighted costs (36.3 %) for office-based visits.
Table 4-8 provides an overall breakdown of the number and cost of emergency room
visits for patients with Parkinson’s disease from 1999-2003. Emergency room visits had
the second lowest occurrence of the MEPS-HC components and had the lowest cost of all
the MEPS-HC direct cost components. In 1999, no one reported visiting an emergency
room due to Parkinson’s disease in the MEPS-HC sample. The largest percentage
(39.2%) occurred in 2001 and represented almost half of the five year total costs for
emergency room visits.
Table 4-9 provides the overall breakdown of the number and cost of inpatient visits
for patients with Parkinson’s disease. Inpatient hospital stays had the lowest occurring
frequency of visits reported, but represented the fourth highest weighted direct medical
costs. In 1999, no one with Parkinson’s disease in the MEPS-HC sample reported an
inpatient hospital stay.
Table 4-10 provides an overall breakdown of the outpatient utilization and costs for
patients with Parkinson’s disease. The highest number of outpatient visits occurred in
2003. The largest percentage (38.2%) of the outpatient visit costs occurred in 2002. The
123

fewest outpatient visits occurred in 2001; however, the second highest percentage
(33.6%) of outpatient visit costs occurred in 2001.
Table 4-11 depicts an overall breakdown of the number and cost of home health visits
for patients with Parkinson’s disease between 1999 and 2003. Home health visits for
patients with Parkinson’s disease represented the third highest direct medical costs.
Between 1999 and 2003 a total of just over $1.9 billion was spent on home health visits
for patients with Parkinson’s disease. The largest percentage (33.3%) of home health
visits and costs for home health visits occurred in 2001.

Nursing Home Cost
Table 4-12 provides nursing home costs for patients with Parkinson’s disease using
the Nursing Home Consumer Price Index for 1999-2003. The weighted total for nursing
home costs for patients with Parkinson’s disease in 1996 was $3.2 billion. The weighted
total nursing home expenses for males in 1996 was $1.14 billion and for females the
weighted total was $2.08 billion. Using the Nursing Home Consumer Price Index for
2003, nursing home costs in 2003 dollars would be approximately $4.4 billion. Nursing
Home costs were estimated for each of the corresponding years for which MEPS-HC data
were analyzed. Between 1999 and 2003, the total Nursing Home costs were
$19,752,709,342, and the annual average was $3,950,541,868. Table 4-13 presents an
overall breakdown of direct non-medical expenses for patients with Parkinson’s disease
in the MEPS-HC for the years 1999-2003. These other medical expenses include
modifications to the home, such as handrails in the shower and raised toilet seats. Other
medical expenses were the third lowest cost component of MEPS-HC. The fewest other
medical expenses occurred in 1999, however this was also the highest year for

124

costs due

to other medical expenses. Over ninety-three percent of the costs for other medical
expenses occurred in 1999. The smallest amount for other medical expenses was
reported the following year in 2000.

Morbidity Costs: Missed Work and Bed Days
Tables 4-14 and 4-15 provide a breakdown of the morbidity costs (weighted and
unweighted) associated with Parkinson’s disease for 1999-2003. The total cost of missed
work days was $389,735,998 for the five year period. Table 4-14 provides a full
breakdown of missed work days by gender. In 2001, no one in the MEPS-HC sample
reported having missed work due to Parkinson’s disease. The largest number of work
days missed were reported in 1999. Also, in 1999, the highest cost for missed work days
was reported by patients with Parkinson’s disease. The majority of work days missed
(68.9%) were reported by females at a cost of $201,950,286. Table 4-15 provides a break
down of the number of bed days reported by patients with Parkinson’s disease. At a five
year total cost of $9,619,603,533 bed days represented the largest portion (96%) of
morbidity costs for patients with Parkinson’s disease. The largest percentage (65.4%) of
bed days were reported by men with Parkinson’s disease.

Mortality Costs
The previous Tables provided an overview of the number of deaths (Table 4-16) and
mortality costs (Table 4-17) for people with Parkinson’s disease between the 1999 and
2003. Table 4-16 provides a brief overview of the number of people who died from
Parkinson’s disease by gender. The number of deaths due to Parkinson’s disease
increased every year from 1999-2003. Of the 81,870 deaths due to Parkinson’s disease
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between the years 1999-2003, males accounted for 56.5% of the total. Based on race and
gender, a total of 34% (27,869) of deaths due to Parkinson’s disease occurred prior to life
expectancy. The largest number of deaths prior to life expectancy due to Parkinson’s
disease occurred in 2003.
Table 4-17 expands the mortality data further by gender and race. In addition, Table
4-17 provides the average mortality cost for Parkinson’s disease and the overall cost of
mortality by gender and race. The overall mortality cost due to Parkinson’s disease was
$861,530,870. Approximately one-fourth (24.3%) of mortality costs due to Parkinson’s
disease occurred in 2003. From 1999-2003, mortality costs due to Parkinson’s disease
increased steadily. Overall, from 1999-2003 mortality costs due to Parkinson’s disease
were highest for white males at $577,628,976 followed by white females at $250,898,467.
Black females represented the lowest mortality costs ($13,149,142) due to Parkinson’s
disease.

Statistical Analysis of Direct and Indirect Costs
The following section provides the statistical analysis of the direct and indirect costs
obtained from the MEPS-HC for study objectives 3-9.
Table 4-18 provides the overall mean for total cost of Parkinson’s disease (minus
mortality costs and nursing home costs) for the patients in the combined or “pooled”
sample. The unweighted total number of people in the MEPS-HC was 233. In order to
have these patients in a single file representing one year, the assigned patient weights for
each person were divided by 5 (the number of years of MEPS-HC data used) and the cost
totals for each year were multiplied by the CPI for the year 2003 (the last year of data
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Table 4-18. Mean Overall Total Costs (Minus Nursing Home and Mortality Costs) from
the Combined MEPS-HC for Patients with Parkinson’s Disease.
Weighted Mean
Number
(unweighted
number)
525,154 (233) $5,365

Standard
Error

Overall Total
Pooled Cost

95% Confidence
Limits

$819

$2,817,451,210

$3,712-$7,019

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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used in this study). These 233 patients with Parkinson’s disease represented 525,154
United States citizens and accounted for a total cost (minus mortality costs and nursing
home costs) of $2,817,451,210. The mean overall cost for Parkinson’s disease per home
patient was $5,365 per year.
For objective 3, a t-test was used to determine if there was a statistically significant
difference in the mean cost of illness between men and women. Table 4-19 provides the
results of the t-test between the mean cost of illness (excluding nursing home and
mortality costs) for men and women with Parkinson’s disease. The mean cost of illness
for males with Parkinson’s disease was $6,256 and the mean cost of illness for females
with Parkinson’s disease was $4,287. Based on the results of the t-test, a statistically
significant difference does not exist between males and females and the mean cost of
illness in Parkinson’s disease.
Table 4-20 provides the mean, standard error and 95% confidence limits for cost of
illness in Parkinson’s disease (minus nursing home and mortality costs) based on age
groups. The 233 patients with a positive weight values were divided into three age
categories: 1) under age 65, 2) age 65 to 84 and 3) age 85 and older. Those under the age
of 65 reported the highest mean average for overall expenses related to Parkinson’s
disease. The lowest mean average for overall expenses related to Parkinson’s disease
was reported by those over the age of 85.
Table 4-21 provides the results of the One-Way ANOVA that was used to test for a
significant mean difference in the cost of illness (minus nursing home and mortality costs)
for patients with Parkinson’s disease among age groups. Age group did not have a
statistically significant impact on the mean overall cost of Parkinson’s disease.
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Table 4-19. T-Test Between Males and Females for Overall Total Costs (Minus Nursing
Home and Mortality Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Mean

Weighted Cost

S.E.

Male

Weighted
Number
(unweighted
number)
287,417(117)

$6,257

$1,798,343,627

$1,261

1.16

.2483

Female

237,737(116)

$4,287

$1,019,136,621

$1,121

1.16

.2483

Gender

t- Probability
VaJue
oft

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-20. Mean Overall Total Costs (Minus Nursing Home and Mortality Costs) for
Age Categories from the MEPS-HC for Patients with Parkinson’s Disease.
Age

N

Mean

Standard Error

Under 65
65-84
85 and
Over

75,507 (43)
352,233 (156)
97,414(34)

$5,691
$5,420
$4,912

$1,635
$1,156
$1,881

95% Confidence
Limits
$2,440-$8,942
$3,102-$7,739
$l,174-$8,649

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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Table 4-21. ANOVA Results for Age Categories for Overall Total Costs (Minus Nursing
Home and Mortality Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Demographic
Age

Degrees of
Freedom
2

F Value

Probability of F

0.04

0.956

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

130

Table 4-22 provides the results of the t-test for a significant difference in the cost of
illness (minus nursing home and mortality costs) for Parkinson’s disease among different
education levels. Education level and mean cost of illness for Parkinson’s disease was
not statistically significant at the 0.05 significance level.
Table 4-23 provides the mean, standard error and 95% confidence limits for cost of
illness in Parkinson’s disease for the variable income. Patients with incomes over
$30,000 a year had the highest mean for total overall costs.
Table 4-24 provides the results of the One-Way ANOVA that was used to test for
differences in overall total cost of illness between income categories. A significant
relationship was not found to exist between income level and overall cost of illness for
Parkinson’s disease.
Table 4-25 provides the mean, standard error and 95% confidence limits for the
overall cost of illness in Parkinson’s disease for the variable marital status. The largest
mean difference between marital status categories for patients with Parkinson’s disease
was found to exist between patients who were widowed and patients who were single.
Table 4-26 provides the results of the One-Way ANOVA that was used to test for
differences in overall total cost of illness and marital status. No significant difference was
found between marital status and the mean overall total cost of illness for patients with
Parkinson’s disease.
Table 4-27 provides the mean, standard error and 95% confidence limits for cost of
illness in Parkinson’s disease for the variable region. The largest mean cost of
Parkinson’s disease was found in the South. Thirty-seven percent of the weighted sample
and forty percent of the unweighted sample resided in the Southern region of the United
States. The largest difference in mean overall total costs for Parkinson’s disease among
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Table 4-22. T-Test Between Education Level and Mean for Overall Total Costs (Minus
Nursing Home and Mortality Costs) from the MEPS-HC for Patients with Parkinson’s
Disease.
Education
Level

Weighted
Mean
95%
t-Value Probability
Number
of t
Confidence
(unweighted
Limits
number)
Less than High
157,324 (90)
$7,119
$2,8781.75
0.0812
School
11,360
$4,615
High School or 367,830 (143)
$2,6891.75
0.0812
Higher
$6541

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-23. Mean Overall Total Costs (Minus Nursing Home and Mortality Costs) and
Income Level from the MEPS-HC for Patients with Parkinson’s Disease.
Income

Weighted
Number
(Unweighted
Number)
Less than 350,861 (164)
$19,999
$20,00071,494 (28)
$29,999
$30,000 and
102,798 (41)
over

Mean

Standard Error

95%
Confidence
Limits

$5,183

$1,051

$3,070-$7,296

$4,143

$1,474

$l,212-$7,073

$6,836

$2,040

$2,776-$10,896

Sources. Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

132

Table 4-24. ANOVA Results and Income Level for Overall Total Costs (Minus Nursing
Home and Mortality Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Demographic
Income

Degrees of
Freedom
2

F-Value Probability of
F
0.50
0.6095

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-25. Mean Overall Total Costs (Minus Nursing Home and Mortality Costs) and
Marital Status from the MEPS-HC for Patients with Parkinson’s Disease.
Marital
Status
Married
Widowed
Single

Weighted Number
(unweighted
number)
74,830(41)
277,494(115)
172,829 (77)

Mean

Standard
Error

95% Confidence
Limits

$5,330
$5,530
$5,116

$1,903
$1,304
$1,348

$1,548-$9,112
$2,925-$8,134
$2,430-$7,801

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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Table 4-26. ANOVA Results Between Marital Status Categories for Overall Total Costs
(Minus Nursing Home and Mortality Costs) from the MEPS-HC for Patients with
Parkinson’s Disease.
Demographic
Marital Status

Degrees of
Freedom
2

F Value
0.02

Probability of
F
0.9808

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-27. Mean Overall Total Costs (Minus Nursing Home and Mortality Costs) and
Region of Residence from the MEPS-HC for Patients with Parkinson’s Disease.
Region

Northeast
MidWest
South
West

Weighted
Number
(unweighted
number)
95,170 (37)
118,132(51)

Mean

Standard Error

95% Confidence
Limits

$2,828
$4,663

$638
$1,783

$1,560-$4,095
$l,121-$8,205

196,153 (93)
115,699(52)

$6,765
$5,796

$1,605
$1,712

$3,572-$9,958
$2,394-$9,198

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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regions in the United States was found between the Northeast and South. The smallest
difference between the means among regions was found between the South and West.
Table 4-28 provides the results of the One-Way ANOVA procedure that was used to
test for differences in overall total cost of illness by region of residence. A significant
relationship was not found to exist for region of residence and overall cost of illness for
Parkinson’s disease.
Table 4-29 provides the results of the multiple regression model for overall total cost
of illness for Parkinson’s disease (minus nursing home costs and mortality costs). When
selected demographics were held constant, no significant difference was found to exist
between any of the selected demographics and overall total cost of illness for Parkinson’s
disease.
Table 4-30 provides the coefficients for the linear regression model for overall total
cost of illness for Parkinson’s disease (minus nursing home costs and mortality costs). No
significant difference was found to exist between any of the selected demographics and
overall total cost of illness for Parkinson’s disease.
The following section provides the statistical analysis for direct medical costs of
Parkinson’s disease (minus nursing home costs) for the selected demographics.
Table 4-31 shows the overall mean and standard error for direct medical costs (minus
nursing home costs) for the 525,154 patients with Parkinson’s disease. The mean direct
medical cost of Parkinson’s disease was $1,755 per year.
Table 4-32 provides the results of the t-test for direct medical costs (minus nursing
home costs) between males and females. The difference between mean direct medical
costs for males and females was $571 annually. A significant difference between males
and females and the mean direct medical costs for was not found to exist.
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Table 4-28. ANOVA Results Between Region of Residence for Overall Total Costs
(Minus Nursing Home and Mortality Costs) from the MEPS-HC for Patients with
Parkinson’s Disease.
Demographic
Region of Residence

Degrees of
Freedom
3

F Value
1.84

Probability of
F
0.147

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-29. F Value and Degrees of Freedom for the Overall Regression Model Results
for Overall Total Costs (Minus Nursing Home and Mortality Costs) and Selected
Demographics from the MEPS-HC for Patients with Parkinson’s Disease.
Effect
Overall Model
Gender
Age
Education
Income
Marital Status
Region of Residence

Degrees of
Freedom
11
1
2
1
2
2
3

F Value

Probability of F

1.29
1.94
0.00
.99
.48
.12
1.69

.248
.168
.995
.323
.618
.888
.173

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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Table 4-30. Coefficients for Linear Regression for Overall Total Costs (Minus Nursing
Home and Mortality Costs) and Selected Demographics from the MEPS-HC for Patients
with Parkinson’s Disease.
Variable
Gender
Female
Education Level
Less than High School
Age
Under 65
65-84
Income
Less than $20,000
$20,000-$30,000
Marital Status
Married
Widowed
Region of Residence
Northeast
Mid-West
South

Estimate

Probability of t

-$2,652

0.1680
0.3232

$2,761
-$171
-$251

0.9611
0.9260

-$2,737
-$2,309

0.3373
0.3902

-$1,498
-$1,017

0.6765
0.6616

-$3,112
-$1,515
$725

0.1975
0.5931
0.7495

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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Table 4-31. Mean Direct Medical Costs (Minus Nursing Home Costs) from the MEPSHC 1999-2003 for Patients with Parkinson’s Disease.
Weighted
Number
(unweighted
number)
525,154(233)

Mean

Standard Error

95% Confidence Limits

$1,755

$140

$l,472-$2,039

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.

Table 4-32. T-Test Between Males and Females for Direct Medical Costs (Minus
Nursing Home Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Gender

Male
Female

Weighted
Number
(unweighted
number)
287,417(117)
237,737(116)

Mean

95% Confidence
Limits

t-Value

Probability
of t

$2,014
$1,443

$l,573-$2,455
$1,028-$1859

1.74
1.74

0.0858
0.0858

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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Table 4-33 presents the mean direct medical costs (minus nursing home costs) for
patients with Parkinson’s disease among age categories. Persons between the ages of 65
and 84 reported the lowest overall mean direct medical costs and comprised sixty-seven
percent of patients with Parkinson’s disease in this study. Patients with Parkinson’s
disease under the age of 65 reported the highest mean average for direct medical costs in
this study. The largest difference between mean direct medical costs for Parkinson’s
disease exists between patients under the age of 65 and those patients between 65 and 84
years old. The smallest difference between mean direct medical costs was found between
patients under the age of 65 and those over 85 years old.
Table 4-34 provides the results of the One-Way ANOVA that was used to test for a
significant mean difference in the direct medical costs (minus nursing home costs) for
patients with Parkinson’s disease among age groups. Age group did not have a
statistically significant impact on the mean direct medical costs of Parkinson’s disease.
Table 4-35 provides the results of the t-test and the mean direct medical costs (minus
nursing home costs) for Parkinson’s disease and education level. The difference between
the mean direct medical costs for Parkinson’s disease by education level was $25 and was
found not to be statistically significant.
Table 4-36 provides the mean, standard error and 95% confidence limits for direct
medical costs (minus nursing home costs) and income category. The largest mean direct
medical costs were found among patients who had an annual income over $30,000. The
majority (67%) of patients with Parkinson’s disease in this study reported having an
annual income of less that $19,999. The smallest mean direct medical costs were
reported by those patients whose income was between $20, 000 and $29,999. The largest
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Table 4-33. Mean Direct Medical Costs (Minus Nursing Home Costs) for Age Categories
from the MEPS-HC for Patients with Parkinson’s Disease.
Age

Under
65
65-84
85 and
Over

Weighted
Number
(unweighted
number)
75,507 (43)

Mean

Standard Error

95% Confidence Limits

$2,291

$438

$1,420-$3,162

352,233 (156)
97,414(34)

$1,497
$2,276

$271
$753

$953-$2,040
$780-$3,772

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.

Table 4-34. ANOVA Results for Age Categories for Direct Medical Costs (Minus
Nursing Home Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Demographic
Age

Degrees of
Freedom
2

F Value

Probability of F

0.98

0.379

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.

Table 4-35. T-Test Between Education Level and Mean for Direct Medical Costs (Minus
Nursing Home Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Education
Level
Less than
High School
High School
or Higher

Weighted Number Mean
(unweighted
number)
157,324 (90) $1,773

95%
Confidence
Limits
$909-$2,636

tValue

Probabilit
y of t

-0.04

0.9684

367,830 (143) $1,748

$1,270$2,227

-0.04

0.9684

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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Table 4-36. Mean Direct Medical Costs (Minus Nursing Home Costs) and Income Level
from the MEPS-HC for Patients with Parkinson’s Disease.
Income

Less than
$19,999
$20,000$29,999
$30,000 and
over

Weighted
Number
(unweighted
number)
350,861 (164)

Mean

Standard
Error

95%
Confidence
Limits

$1,758

$298

$l,159-$2,358

71,494 (28)

$1,190

$260

$672-$1708

102,798 (41)

$2,139

$617

$912-$3,367

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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difference between mean direct medical costs was between patients whose annual income
was between $20,000 and $29,999 and those patients whose income was over $30,000
annually. The smallest difference between the mean direct medical costs for patients
with Parkinson’s disease was between those who income was less than $19,999 and those
whose income was over $30,000 annually.
Table 4-37 provides the results of the One-Way ANOVA that was used to test for
differences in direct medical costs (minus nursing home costs) between income
categories. A significant relationship was not found to exist between income level and
overall cost of illness for Parkinson’s disease.
Table 4-38 provides the mean, standard error and 95% confidence limits for direct
medical costs of Parkinson’s disease among the various marital categories. The smallest
mean direct medical costs were reported by patients with Parkinson’s disease who were
married. Married patients reported mean direct medical costs that were more than 50%
less than patients who were single or widowed. The largest difference between mean
direct medical costs for Parkinson’s disease was reported between married and single
patients. The smallest difference in mean direct medical costs was reported between
single and widowed patients.
Table 4-39 provides the results of the One-Way ANOVA for marital groups for direct
medical costs (minus nursing home costs) for Parkinson’s disease. A significant
difference was found to exist between marital groups and the mean direct medical cost of
illness for patients with Parkinson’s disease at the 0.05 level.
Table 4-40 provides the mean, standard error and 95% confidence limits for direct
medical costs for patients with Parkinson’s disease by region of residence. The largest
mean direct medical costs for Parkinson’s disease were reported by patients living in the
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Table 4-37. ANOVA Results Between Income Categories for Direct Medical Costs
(Minus Nursing Home Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Demographic

Degrees of
Freedom
2

Income

F-Value

Probability of F

2.32

0.105

Source. Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.

Table 4-38. Mean Direct Medical Costs (Minus Nursing Home Costs) and Marital Status
from the MEPS-HC for Patients with Parkinson’s Disease.
Marital Status

Married
Widowed
Single

Weighted Mean
Number
(unweighted
number)
74,830 (41)
$897
277,494(115) $1,895
172,829 (77) $1,903

Standard Error

95% Confidence
Limits

$287
$347
$404

$327-$l,476
$l,203-$2,588
$l,097-$2,708

Source. Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.

Table 4-39. ANOVA Results Between Marital Status Categories for Direct Medical Costs
(Minus Nursing Home Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Demographic
Marital Status

Degrees of
Freedom
2

F Value
3.14

Probability of
F
0.049

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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Table 4-40. Mean Direct Medical Costs (Minus Nursing Home Costs) and Region of
Residence from the MEPS-HC for Patients with Parkinson’s Disease.
Region

Northeast
Mid-West
South
West

Weighted
Number
(unweighted
number)
95,170 (37)
118,132 (51)
196,153 (93)
115,699 (52)

Mean

Standard
Error

95% Confidence
Limits

$1,306
$1,645
$2,219
$1,452

$147
$349
$267
$264

$1,015-$l,597
$951-$2,338
$l,689-$2,750
$928-$ 1,976

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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South region of the United States, with a reported mean direct medical cost (minus
nursing home costs) of $2,219 per year. The second largest mean direct medical costs
were reported by patients in the Mid-West. The largest difference for mean direct
medical costs and region of residence existed between patients with Parkinson’s disease
living in the South and patients living in the Northeast. Patients living in the South
reported mean direct medical costs 42% higher than patients living in the Northeast.
«

Table 4-41 provides the results of the One-Way ANOVA that was used to test for
differences in direct medical costs (minus nursing home costs) and region of residence.
A significant relationship was found to exist at the 0.05 significance level for direct
medical costs for Parkinson’s disease and region of residence.
Table 4-42 provides the results of the overall regression model with selected
demographics as the independent variables and direct medical costs (minus nursing home
costs) as the dependent variable. Gender, marital status and region of residence were all
statistically significant at the 0.05 level when all other selected demographics were held
constant.
Gender did not have statistically significant differences in the mean direct medical
costs (minus nursing home costs) when the t-test procedure was used and other
demographic variables were not taken into consideration. Marital status and region of
residence were both statistically significant in the One-Way ANOVA and the overall
regression model results presented in Table 4-42.
Table 4-43 provides the coefficients for the linear regression model for direct medical
costs for Parkinson’s disease (minus nursing home costs). No significant differences were
found to exist between the selected demographics gender, marital status and region of
residence for direct medical costs for Parkinson’s disease.
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Table 4-41. ANOVA Results for Region of Residence for Direct Medical Costs (Minus
Nursing Home Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Demographic
Region of Residence

Degrees of
Freedom
3

F Value

Probability of F

2.71

0.050

Source. Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.

Table 4-42. F Value and Degrees of Freedom for the Overall Regression Model Results
for Direct Medical Costs (Minus Nursing Home Costs) and Selected Demographics from
the MEPS-HC for Patients with Parkinson’s Disease.
Effect
Overall Model
Gender
Age
Education
Income
Marital Status
Region of Residence

Degrees of
Freedom
11
1
2
1
2
2
3

F Value

Probability of F

2.57
6.73
2.84
0.00
0.75
3.14
4.24

0.0078*
0.0113*
0.0646
0.9495
0.4746
0.0491*
0.0079*

Source. Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
* Statistically significant at the 0.05 level
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Table 4-43. Coefficients for Linear Regression for Direct Medical Costs (Minus
Nursing Home Costs) and Selected Demographics from the MEPS-HC for
Patients with Parkinson’s Disease.
Estimate

Probability of t

-$1,069

0.0113

i00

Variable
Gender
Female
Education Level
Less than High School
Age
Under 65
65-84
Income
Less than $20,000
$20,000-$30,000
Marital Status
Married
Widowed
Region of Residence
Northeast
Mid-West
South

0.9495

-$3.69
-$1,095

0.9971
0.2651

-$303
-$593

0.8001
0.4123

-$1,598
-$587

0.0254
0.4017

-$147
$328
$1,058

0.7191
0.5487
0.0113

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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Tables 4-44 and 4-45 provide the results of the post-hoc contrasts that were performed
to determine which mean direct medical costs (minus nursing home costs) were
significantly different between the selected demographic groups. Contrasts were run only
on those demographic characteristics that were found to be statistically significant at the
0.05 level to determine between which groups the difference occurred.
To reduce the likelihood of type I error, a Bonferroni Adjustment was performed on
the data. The Bonferroni Adjustment involved dividing the significance level of 0.05 by
the number of comparisons being made in each of the selected demographic categories.
For gender, the significance level would be 0.025 or less (0.05/2=0.25) and for region of
residence the significance level would be 0.0083 (0.05/6=0.0083). After adjustment, both
gender and region of residence were still statistically significant for direct medical costs.
For the category marital status, 3 comparisons were made. The resulting P-value must
be lower than 0.016 (0.05 / 3=0.016), in order for the reported p-value to be significant
for marital status. Marital status was not statistically significant after the Bonferroni
Adjustment was made. Post-hoc contrasts were conducted on the two selected
demographic characteristics (gender and region of residence) and direct medical costs
(minus nursing home costs) that were found to be statistically significant after Bonferroni
Adjustment. The results of those post-hoc contrasts appear in Tables 4-44 and 4-45.
Table 4-44 provides the results of the contrast between mean direct medical costs
(minus nursing home costs) for males and females when all other selected demographics
were held constant. The mean direct medical costs for males with Parkinson’s disease
were $571 higher than the mean direct medical costs for females with Parkinson’s disease.
Table 4-45 provides the results of the contrast between region of residence and direct
medical costs (minus nursing home costs) for patients with Parkinson’s disease. Patients
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Table 4-44. Contrast Results for Gender for Direct Medical Costs (Minus Nursing Home
Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Gender
Male vs. Female

Difference Between
the means
$571

T-Value

Probability of t

-2.59

0.0113*

Source. Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
*Statistically significant after Bonferroni Adjustment

Table 4-45. Contrast Results for Region of Residence Between Categories for Direct
Medical Costs (Minus Nursing Home Costs) from the MEPS-HC for Patients with
Parkinson’s Disease.
Region
Northeast vs. Mid-West
Northeast vs. South
Northeast vs. West
Mid-West vs. South
Mid-West vs. West
South vs. West

Difference Between
the means
$339
$913
$146
$574
$193
$767

Probability of t
0.3943
0.0013*
0.7191
0.1902
0.5487
0.0113

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
* Statistically significant after Bonferroni Adjustment
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with Parkinson’s disease who live in the South have mean direct medical costs (minus
nursing home costs) that are $913 higher than patients with Parkinson’s disease who live
in the Northeast. After Bonferroni Adjustment (0.05/6=0.0083), the only p-value for
patients living in the South compared to patients living in the Northeast was found to be
statistically significant. The mean direct medical costs difference between patients living
in the South compared to patients living in the West were statistically significant at the
0.05 level, however after Bonferroni Adjustment were not found to be statistically
significant. In order to be statistically significant, the probability of t would need to be
less than or equal to 0.0083.
The following section provides the statistical analysis for direct non-medical costs of
Parkinson’s disease for the selected demographics.
Table 4-46 provides the mean direct non-medical costs of illness reported by patients
with Parkinson’s disease. A mean of $1,401 for direct non-medical costs were reported
by patients with Parkinson’s disease.
Direct Non-Medical Costs due to Parkinson’s disease were reported only reported by
9% (21) of the patients in the sample. Because of this low sample size, ANOVA and
regression models were not run on direct non-medical costs for Parkinson’s disease.
Descriptive information is provided in Tables 4-46 and 4-47 for direct non-medical costs.
Table 4-47 provides the mean, standard error and 95% confidence limits for direct
non-medical costs of patients with Parkinson’s disease when broken down by various
demographic variables. Due to one female patient reporting a large amount of home
repairs ($35,000), the mean direct non-medical costs for females was much higher than
the mean direct non-medical costs for males.

150

Table 4-46. Mean Direct Non-Medical Costs (Minus Nursing Home Costs) from the
MEPS-HC for Patients with Parkinson’s Disease.
Demographic

Direct NonMedical Costs
(Overall)

Weighted
Number
(unweighted
number)
51,607(21)

Mean

95% Confidence Limits

$1,401

$1,251-51,552

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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Table 4-47. Means for Selected Demographics for Direct Non-Medical Costs from the
MEPS-HC for Patients with Parkinson’s Disease.
Selected
Demographic
Gender
Male
Female
Age
Under 65
65-84
85 and Over
Education
Less than
High School
High School
or Higher
Income Level
Less than
$19,999
$20,000$29,999
$30,000 and
over
Marital Status
Married
Widowed
Single
Region
Northeast
Mid-West
South
West

Weighted Number
(unweighted number)

Mean

95% Confidence
Limits

39,011 (13)
12,596 (8)

$95
$5,547

$95-$95
$4,892-$6,002

4,400 (2)
39,048 (17)
8,159 (2)

$15,639
$75
$72

$15,639-$15,639
$58-$91
$72-$72

11,900 (8)

$123

$83-$162

39,707(13)

$1,784

$1,784

24,320 (12)

$84

$82-$86

8,735 (3)

$84

$30-$138

3,748 (6)

$3,748

$3,748-$3,748

8,439 (4)
32,597 (12)
10,571 (5)

$8,234
$62
$77

$8,234-$8,234
$62-$62
$27-$126

8,125(4)
7,129(3)
24,638 (9)
11,715(5)

$8,398
$214
$80
$51

$8,398-$8,398
$214-$214
$58-$101
$51-$51

Source: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003.
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The majority of patients (81%) reporting direct non-medical costs were between 65
and 84 years of age. The majority of patients (62%) reporting direct non-medical costs
had a high school education or greater. Patients whose income was less than $20,000
annually had reported the largest number of direct non-medical costs. Patients who were
widowed reported the largest percentage (57%) of direct non-medical costs for
Parkinson’s disease. The majority (43%) of patients reporting direct non-medical costs
for Parkinson’s disease reside in the South.
The following section provides the statistical analysis for indirect costs of Parkinson’s
disease (minus mortality costs) for the selected demographics.
Table 4-48 provides the mean indirect costs (minus mortality costs) for patients with
Parkinson’s disease. Patients with Parkinson’s disease reported a mean indirect cost of
$15,035 annually. Approximately 22% (52) of the unweighted total patient sample (233)
reported having missed work or bed days due to Parkinson’s disease.
Table 4-49 provides the results of the t-test between means for males and females for
indirect costs (minus mortality costs) due to Parkinson’s disease. Males reported their
annual mean indirect costs due to Parkinson’s disease to be $2,229 higher than females.
No significant difference for male and female patients with Parkinson’s disease existed
between the mean indirect costs.
Table 4-50 provides the mean, standard error and 95% confidence limits for indirect
cost (minus mortality costs) of Parkinson’s disease by age category. Only four people
over the age of 85 reported having indirect costs due to Parkinson’s disease. Patients
under the age of 65 reported having the lowest mean indirect costs due to Parkinson’s
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Table 4-48. Mean Indirect Costs (Minus Mortality Costs) from the MEPS-HC for
Patients with Parkinson’s Disease.
Weighted Number
(unweighted number)
121,278 (52)

Mean

Standard Error

$15,036

$1,046

95% Confidence
Limits
$12,669-$ 17,402

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-49. T-Test Between Males and Females for Indirect Costs (Minus Mortality
Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Gender

Weighted Number Mean
(unweighted
number)
76,698 (29) $15,855
Male
Female
44,580(23) $13,626

95% Confidence
Limits

tValue

Probabilit
y of t

$14,374-$17,335
$8,300-$18,952

.52
.52

0.6070
0.6070

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-50. Mean Indirect Costs (Minus Mortality Costs) for Age Categories from the
MEPS-HC for Patients with Parkinson’s Disease.
Age

Under 65
65-84
85 and Over

Weighted Number
(unweighted
number)
17,595(10)
92,459 (38)
11,224(4)

Mean

Standard
Error

95% Confidence
Limits

$10,686
$14,918
$22,825

$2,521
$1,299
$1,851

$5,537-$15,835
$12,164-$ 17,671
$19,064-$26,587

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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disease. The largest percentage (74%) of patients reporting indirect costs for Parkinson’s
disease were between 65 and 84 years of age.
Table 4-51 provides the results of the One-Way ANOVA procedure to test
fordifferences in indirect costs (minus mortality costs) and the selected demographic
category age. A significant relationship was found to exist at the 0.05 significance level
for indirect costs for Parkinson’s disease and age.
Table 4-52 provides the results of the t-test for the selected demographic variable
education and indirect costs (minus mortality costs) for Parkinson’s disease. A
significant difference between education level and mean indirect costs was not found to
exist at the 0.05 level. Indirect costs were higher for patients without a high school
education.
Table 4-53 provides the mean, standard error and 95% confidence limits for mean
indirect costs (minus mortality costs) and income levels for patients with Parkinson’s
disease. Patients with incomes less than $20,000 annually reported the highest mean for
indirect costs due to Parkinson’s disease. Patients with income levels between $20,000
and $29,999 reported the lowest mean for indirect costs due to Parkinson’s disease.
Seventy-one percent of patients reporting indirect costs had incomes of less than $20,000
annually.
Table 4-54 provides the results of the One-Way ANOVA with indirect costs (minus
mortality costs) as the dependent variable and income level as the independent
demographic. A significant relationship was not found to exist between indirect costs
and income levels.
Table 4-55 provides the mean, standard error and 95% confidence limits for marital
status and indirect costs (minus mortality costs) o f Parkinson’s disease. The largest
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Table 4-51. ANOVA Results and Age Categories for Indirect Costs (Minus Mortality
Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Demographic
Age

Degrees of
Freedom
2

F Value

Probability of F

3.36

0.048

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-52. T-Test Between Education Level and Mean for Indirect Costs (Minus
Mortality Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Education
Level

Less than
High School
High School
or Higher

Weighted
Number
(unweighted
number)
44,250 (27)

Mean

95%
Confidence
Limits

tValue

Probability
of t

$18,975

-1.37

0.1797

77,028 (25)

$12,773

$16,737$21,212
$9,228$16,318

-1.37

0.1797

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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Table 4-53. Mean Indirect Costs (Minus Mortality Costs) and Income Level from the
MEPS-HC for Patients with Parkinson’s Disease.
Income

Less than
$19,999
$20,000$29,999
$30,000 and
over

Weighted Number
(unweighted
number)
71,532 (36)

Mean

Standard Error

$16,772

$1,297

19,032(6)

$11,054

$2,893

30,715(10)

$13,460

$632

95%
Confidence
Limits
$14,046$19,497
$5,162$16,946
$12,166$14,753

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-54. ANOVA Results Between Income Categories for Indirect Costs (Minus
Mortality Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Demographic
Income

Degrees of
Freedom
2

F-Value Probability of
F
0.88
0.426

Sources. Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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Table 4-55. Mean Indirect Costs (Minus Mortality Costs) and Marital Status from the
MEPS-HC for Patients with Parkinson’s Disease.
Marital
Status
Married
Widowed
Single

Weighted Number
(unweighted
number)
13,531 (8)
68,520 (23)
39,227(21)

Mean

Standard
Error

95% Confidence
Limits

$19,388
$14,690
$14,137

$1,525
$928
$3,004

$16,281-$22,495
$12,760-$16,621
$7,951-$20,324

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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percentage (44%) of patients reporting indirect costs for Parkinson’s disease were
widowed. Patients who are married represented the smallest percentage (11%) of patients
with Parkinson’s disease reporting indirect costs. Married patients also reported the
highest mean for indirect costs among patients with Parkinson’s disease.
Table 4-56 provides the results of the One-Way ANOVA for marital groups for the
indirect costs (minus mortality costs) of Parkinson’s disease. A significant difference was
not found to exist between marital groups and the mean indirect medical (Minus
Mortality Costs) for patients with Parkinson’s disease at the 0.05 level.
Table 4-57 provides the mean, standard error and 95% confidence limits for the
indirect cost (minus mortality costs) of Parkinson’s disease and the region of residence.
Patients living in the Northeast region of the United States reported the lowest mean total
for indirect costs. The largest number of patients reporting indirect costs lived in the
South. Patients living in the West reported the highest amount of indirect costs due to
Parkinson’s disease.
Table 4-58 provides the results of the One-Way ANOVA used to determine if the
mean indirect cost (minus mortality costs) of Parkinson’s disease was statistically
different depending on region of residence. A significant difference was not found to
exist between region of residence and the mean indirect cost (Minus Mortality Costs) for
patients with Parkinson’s disease at the 0.05 level.
Table 4-59 provides the results of the multiple regression model with selected
demographics as the independent variables and indirect costs (minus mortality costs) as
the dependent variable. When selected demographics were held constant, no significant
difference was found to exist between any of the selected demographics and indirect cost
for Parkinson’s disease. However, the overall model was significant.
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Table 4-56. ANOVA Results Between Marital Status Categories for Indirect Costs
(Minus Mortality Costs) from the MEPS-HC for Patients with Parkinson’s Disease.
Demographic
Marital Status

Degrees of
Freedom
2

F Value
0.58

Probability
ofF
0.568

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-57. Mean Indirect Costs (Minus Mortality Costs) and Region of Residence from
the MEPS-HC for Patients with Parkinson’s Disease.
Region

Weighted
Number
(unweighted
number)
Northeast
11,461 (3)
Mid-West
20,364 (6)
South
64,340 (31)
West
25,114(12)

Mean

Standard Error

95% Confidence
Limits

$6,684
$17,441
$13,828
$19,989

$0
$1,140
$1,122
$2,944

$6,684-$6,684
$15,121-$19,761
$l,689-$2,750
$928-$ 1,976

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.

Table 4-58. ANOVA Results for Region of Residence Between Categories for Indirect
Costs (Minus Mortality Costs) from the MEPS-HC for Patients with Parkinson’s Disease
Demographic
Region of Residence

Degrees of
Freedom
3

F Value

Probability of F

2.33

0.094

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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Table 4-59. F Value and Degrees of Freedom for the Overall Regression Model Results
for Indirect Costs (Minus Mortality Costs) and Selected Demographics from the MEPSHC for Patients with Parkinson’s Disease.
Effect
Overall Model
Sex
Age
Education
Income
Marital Status
Region of Residence

Degrees of
Freedom
11
1
2
1
2
2
3

F Value

Probability of F

3.82
1.27
1.11
1.75
0.68
0.52
2.09

0.0019
0.2685
0.3422
0.1966
0.5151
0.6001
0.1233

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics, United States Department of Labor, 1999-2003.
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Table 4-60 provides the coefficients for the linear regression model for indirect costs
for Parkinson’s disease (minus nursing home costs and mortality costs). No significant
difference was found to exist between any of the selected demographics and indirect
costs for Parkinson’s disease.
Chapter 5 will provide discussion and conclusions of the findings from this chapter,
limitations of this study, implications of the study, and recommendations for future
research.
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Table 4-60. Coefficients for Linear Regression for Indirect Medical Costs (Minus
Mortality Costs) and Selected Demographics from the MEPS-HC for Patients with
Parkinson’s Disease.
Variable
Gender
Female
Education Level
Less than High School
Age
Under 65
65-84
Income
Less than $20,000
$20,000-$30,000
Marital Status
Married
Widowed
Region of Residence
Northeast
Mid-West
South

Estimate

Probability of t

-$7,965

0.2685

$6,430

0.1966

-$10,389
-$1,805

0.1711
0.7471

$4,484
$394

0.3145
0.9469

$4,913
$1,466

0.4258
0.8692

-$16,989
-$2,811
-$10,862

0.0591
0.7478
0.0845

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003 and Bureau of Labor Statistics, Wage and
Labor Statistics United States Department of Labor, 1999-2003.
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CHAPTER V. DISCUSSION
The final chapter will review the purpose and objectives of the study, discuss the
results of the study, present limitations of the study, provide implications of the study,
and recommend future research opportunities. The discussion portion of this chapter
includes the following sections. 1) overall cost of illness for Parkinson’s disease, 2) direct
medical costs, 3) direct non-medical costs, 4) indirect morbidity costs, and 5) indirect
mortality costs. The limitations of this study focus on two main areas: data sources and
study methodology. The implications section of this chapter covers the following four
areas: 1) implications for patients with Parkinson’s disease and for caregivers of patients
with Parkinson’s disease, 2) implications for healthcare policy, 3) implications for
healthcare providers and insurers, and 4) implications for healthcare administrators.
Despite continued advances in the medical treatment of Parkinson’s disease, little
research has been done with regard to the economic consequences associated with
medical costs and lost productivity costs due to Parkinson’s disease. Limitations of
previous economic studies of the impact of Parkinson’s disease include 1) incomplete
measures, 2) small sample sizes, and 3) nongeneralizable results to the United States as a
whole.
The purpose of this study was to determine the cost of illness for Parkinson’s disease
in the United States. The first two objectives of the study were to determine the direct
and indirect cost of illness for Parkinson’s disease and to describe healthcare resource
utilization for patients with Parkinson’s disease. Other objectives were to determine if,
when considered individually, any of the selected demographic variables (gender,
education level, age, income, marital status, and region of residence) were statistically
164

significant with respect to the overall cost of illness for Parkinson’s disease. The study
also sought to determine if the selected demographic characteristics, when considered
individually, were statistically significant with respect to direct medical costs, direct non
medical costs and indirect costs of Parkinson’s disease. The final objective of this study
was to determine if any statistically significant relationship existed when adjusting for
selected demographic characteristics jointly for overall total costs. This was also done
for direct medical costs, direct non-medical costs and indirect costs.
This study estimated the number, gender and age of patients with Parkinson’s disease
to be similar to previously reported national estimates of patients with Parkinson’s
disease. This study found a weighted total of 525,154 non-institutionalized patients
(MEPS-HC) with Parkinson’s disease and a weighted total of 99,989 institutionalized
patients (MEPS-NHC) with Parkinson’s disease for a total of 625,143. Previous
estimates have estimated between 500,000 to 1.5 million people have Parkinson’s disease
in the United States, which would contain this estimate.4-6 This study estimated the
percentage of the non-institutionalized (MEPS-HC) patient population with Parkinson’s
disease to be 54.7% male and 45.3% female. This estimate is similar to previous
estimates of gender differences in patients with Parkinson’s disease.22’55,56 The smallest
percentage of patients in this study were in the youngest age group (under 65) and the
majority of patients in this study were between 65-84 years of age. When compared to
previous estimates these data demonstrate similar age and incidence trends of Parkinson’s
disease.11,52
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Overall Cost of Parkinson’s Disease
The estimate presented in this study has followed the cost of illness methodology as
originally outlined by Rice.28 This study estimated the total cost of illness from 19992003 to be $39,661,102,321 in 2003 dollars for Parkinson’s disease. This estimate was
based on data from the 1999-2003 MEPS-HC, 1999-2003 BLS wage tables, 1999-2003
NVSS and the 1996 MEPS-NHC. In 2003, this study estimated the cost of illness for
Parkinson’s disease to be $6,312,443,792. This estimate of overall cost of illness for
Parkinson’s disease is in the lower range of previous estimates between $5.6 billion and
$25 billion annually.7,8 Compared to the $2.5 billion annual estimate of the cost of illness
for Multiple Sclerosis, a disease with similar prevalence as Parkinson’s disease,
Parkinson’s disease is a more costly disease state.10 However, compared to Alzheimer’s
disease, a similar neurological disease state, Parkinson’s disease is a less costly disease.
Alzheimer’s has been estimated to cost between $5.6 billion and $88 billion annually.167
However, the prevalence of Alzheimer’s disease is estimated to be between 4.2 million
and 15.4 million compared to 500,000 to 1.5 million for Parkinson’s disease.168
Table 5-1 provides a breakdown of the cost of illness for one year for patients with
Parkinson’s disease, the average cost of each economic component and an overall
average cost of illness per patient. To determine an overall average cost for patients with
Parkinson’s disease for one year, the direct medical costs, direct non-medical costs and
indirect costs for 2003 were totaled. The total number of patients with Parkinson’s
disease was 625,143 and was calculated using the population from the MEPS-HC
(525,154) and the population for the MEPS-NHC (99,989). The average direct medical
costs for patients with Parkinson’s disease were $8,476 annually. The average cost for
patients reporting direct non-medical costs were $17 per patient with Parkinson’s disease.
166

Table 5-1. Overall Costs and Averages for 2003 for Patients with Parkinson’s Disease
Using MEPS-HC, MEPS-NHC, BLS and NVSS.
Cost Component
Direct Medical
Direct Non-Medical
Indirect
All Components

Overall 2003 Cost of
Component
$5,298,491,603
$10,683,797
$1,003,268,392
$6,312,443,792

Overall Average of
Component
$8,476
$17
$1605
$10,098

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003, Center for Financing Access and Cost Trends,
Agency for Healthcare Research and Quality; Medical Expenditures Panel Survey,
Nursing Home Component, 1996, Bureau of Labor Statistics, Wage and Labor Statistics,
United States Department of Labor, 1999-2003 and National Vital Statistics System,
1999-2003 Mortality Tables, National Center for Health Statistics.
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Indirect costs had averaged $1,605 annually for patients with Parkinson’s disease. The
overall annual average cost was $10,098 per patient with Parkinson’s disease.

Direct Medical Costs
Direct medical costs included in this study were: prescription medications, officebased visits, emergency room visits, inpatient hospital stays, outpatient visits, home
health visits and nursing home stays. The majority (76%) of the direct medical costs
included in this study for Parkinson’s disease were for nursing home costs. This is in
contrast to one study that measured only the direct medical costs of Parkinson’s disease
and reported nursing home costs to be lower than most other direct medical costs.51 The
study used data from an insurance company that served patients in the Midwest. The
patient population of the Midwest study was younger on average and therefore tended to
use less nursing home care.
The second largest portion of direct medical costs for patients with Parkinson’s
disease was for prescription medications, at 7.7%. This finding is similar to other studies
that have measured direct medical costs.19,51 Schenkman, et al. found that the
prescription medication costs made up a large percentage (26%-37%) of direct medical
costs for patients with Parkinson’s disease, regardless of whether their health rating was
good or poor.19 Littlefield, et al. reported that prescription medication costs increased
dramatically between the first and third year after diagnosis of Parkinson’s disease.51
Prescription medication costs accounted for 60% of total costs for treatment of patients
with Parkinson’s disease who reported having Parkinson’s disease longer than three
years.51
Another healthcare resource service that was frequently used and carried a large five
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year cumulative cost was home health visits. Over a five year period, home health visits
cost over $1.9 billion. Home health visits were the third largest cost category of the
direct medical costs measured in this study. In addition to being one of the highest direct
medical cost categories, home health visits were also one of the most utilized direct
medical services. Approximately 4 billion home health visits were reported for
Parkinson’s disease during the five year period between 1999 and 2003.
Inpatient hospital stays carried a direct medical expenses burden. Costs of inpatient
stays totaled approximately $1.1 billion over the five year period. This is similar to a
previous 2002 study in which Littlefield, et al. reported that inpatient stays for
Parkinson’s disease were the second largest direct medical cost after prescription
medication costs.51
One health care resource frequently used by patients with Parkinson’s disease in this
study was office-based visits. A weighted total of 6.8 million office visits were reported
by patients in this study. Despite being frequently used, the cost for office-based visits
was low ($668,230,346) compared to the cost and frequency of use of the other patient
services in this study. Previous studies of direct medical costs found similar findings as
those found in this research.19,51
In estimating the cost of illness due to Parkinson’s disease, questions were raised
regarding the proper methodology for measuring and estimating the cost of illness.
Specific to direct medical costs, current national data for nursing homes are lacking. The
estimate in the current study used existing MEPS-NHC data. However, it is very likely
that present day nursing home costs for patients with Parkinson’s disease are much higher
than reported here. The estimate presented here for nursing home costs in patients with
Parkinson’s disease cannot take into account a variety o f events that may alter the
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estimate if the estimate were from more current data. Life expectancy has continued to
rise for both males and females across all racial and ethnic groups, making it possible that
more people are in nursing homes today than were in 1996.
Table 5-2 provides a listing of 1999-2003 totals for direct medical costs that were
included in this study. The largest percentage of direct medical costs for Parkinson’s
disease was for nursing home stays, followed by prescription medications. Emergency
room visits and outpatient visits comprised the smallest percentage of direct medical
costs for Parkinson’s disease.

Direct Non-Medical Costs
The direct non-medical costs reported by patients with Parkinson’s disease in this
study were primarily for home modifications. The items reported in this study included
modifications such as raised toilet seats and handrails in the shower. The MEPS-HC
other medical expenses category allows patients to write in items that did not fit into the
specified. Due to the small unweighted number of patients reporting direct non-medical
costs, inferential statistical analyses were not possible. However, this study did provide
insight into the direct non-medical items reported by patients with Parkinson’s disease.
Two previous studies on the burden of Parkinson’s disease have reported on direct
non-medical items that patients require for their Parkinson’s disease.23,151 Chrischilles et
al. reported in a study of 193 patients with Parkinson’s disease, 40% had installed
handrails in the bathtub and 20% installed shower seats.23 Whetten-Goldstein et al.
reported an annual average of $242 for direct non-medical costs.23 The cost of the direct
non-medical costs were not provided in the Chrischilles study and the number of patients
with Parkinson’s disease who reported direct non-medical costs was not provided in the
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Table 5-2. Overall Total and Percentage of Overall Total of Each Component of Direct
Medical Costs for 1999-2003 for Patients with Parkinson’s Disease.
Direct Medical Cost
Component
Prescription Medication
Office-Based Visits
Emergency Room Visits
Inpatient Visits
Outpatient Visits
Home Health Visits
Nursing Home Stays
Overall Total

Overall Direct Cost
Amount
$1,981,216,130
$668,230,346
$39,509,801
$1,091,504,691
$229,870,733
$1,923,462,530
$19,752,709,340
$25,686,503,575

Percentage of Direct
Medical Costs
7.7
2.6
.15
4.2
.89
7.5
76.96
100%

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003, and Center for Financing Access and Cost
Trends, Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey, Nursing Home Component, 1996.
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Whetten-Goldstein study. 23,151

Indirect Costs

Morbidity
Indirect costs for Parkinson’s disease due to morbidity were divided into two
categories: bed days and missed work days. Of the 233 patients in this study, 52 (22%)
reported either having bed days or missing work due to their Parkinson’s disease. Bed
days made up the largest percentage (96%) of morbidity costs for patients with
Parkinson’s disease. Of the 52 patients reporting morbidity costs due to Parkinson’s
disease, the majority (86%) were reporting morbidity costs due to bed days. Patients
experiencing bed days averaged 166 bed days per year. The average number of missed
work days for patients with Parkinson’s disease was 45 days. Because the average age of
Parkinson’s disease diagnosis is 55 years of age and Parkinson’s disease medications are
effective at alleviating symptoms during the first 10 years after diagnosis, the majority of
the Parkinson’s disease population are likely to be retired when their Parkinson’s disease
symptoms become debilitating.12’18 Thus, this may account for the low number of missed
work days and the high number of bed days.

Mortality
The number of deaths due to Parkinson’s disease increased every year from 19992003. The number of deaths prior to life expectancy fluctuated each year, with the
greatest number of deaths prior to life expectancy occurring in 2003. There are at least
two reasons why the mortality costs due to Parkinson’s disease may have been
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underestimated in this study. First, only mortality costs for people who died prior to their
respective life expectancy due to Parkinson’s disease were estimated. Around one-third
(34%) of patients with Parkinson’s disease died prior to life expectancy. Because this
study did not include or place a value on the loss of life after life expectancy it is likely
that mortality costs due to Parkinson’s disease were underestimated. Second, because the
source of the mortality data in this study came from death certificates, it is possible that
the number of deaths due to Parkinson’s disease was underestimated. The accuracy of
death certificate data is reliant upon the knowledge of the person filling out the death
certificate information. It is possible that some individuals who died of Parkinson’s
disease were inadvertently missed due to lack of knowledge regarding the deceased’s
health status.
Table 5-3 provides a breakdown of 1999-2003 indirect costs included in this study.
The largest percentage (88.5%) of the indirect cost components for Parkinson’s disease
was due to morbidity due to bed days. The smallest percentage of indirect costs for
Parkinson’s disease was due to missed work days.

Results of Statistical Tests
This study looked for statistically significant cost differences for overall total cost,
direct medical costs, direct non-medical costs, and indirect costs of Parkinson’s disease
for gender, education level, age, income, marital status and region of residence. Previous
studies for other disease states have typically studied differences in the cost of illness for
patients with a particular disease when compared to patients without a particular disease.
While these studies are useful in comparing costs and utilization between diseased versus
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Table 5-3. Indirect Cost Components, Overall Amount and Percentage for 1999-2003 for
Patients with Parkinson’s Disease.
Indirect Cost Component
Morbidity (Missed Work)
Morbidity (Bed Days)
Mortality
Overall Total

Overall Indirect Cost
Amount
$389,735,998
$9,619,603,534
$861,530,870
$10,870,870,402

Percentage of Indirect
Costs
3.6
88.5
7.9
100%

Sources: Agency for Healthcare Research and Quality; Medical Expenditures Panel
Survey Household Component 1999-2003, Bureau of Labor Statistics, Wage and Labor
Statistics, United States Department of Labor, 1999-2003 and National Vital Statistics
System, 1999-2003 Mortality Tables, National Center for Health Statistics.
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non-diseased populations, they do not provide insight into cost differences for patients
within a disease population.
For overall total cost of illness for Parkinson’s disease, none of the mean differences
in costs for selected demographic characteristics were statistically significant. Also, no
statistically significant differences existed between the mean indirect costs for selected
demographics for Parkinson’s disease. With the exception of direct medical costs for
males compared to females, and those patients residing in the South compared to patients
residing in the Northeast, the differences between direct medical costs of Parkinson’s
disease and the selected demographics presented in this study were not found to be
statistically significant.
One of the possible reasons why direct medical costs were found to be statistically
significant for males compared to females is that males do not access healthcare as
frequently as females with Parkinson’s disease. Therefore males require more expensive
services (i.e., home health visits) and treatments (i.e., prescription medications) when
they do access healthcare. If females with Parkinson’s disease are less likely to delay
accessing care they may require fewer healthcare services than males. Another possible
reason for gender differences in direct medical costs may be associated with treatment
patterns of physicians. Previous studies have established that physicians are less likely to
prescribe pain medications and are less aggressive in their prescribing patterns for female
patients compared to male patients.169’170 Physicians may prescribe a more aggressive
and costly treatment plan for males compared to females with Parkinson’s disease,
therefore explaining the additional direct medical costs that males experience.
There are four possible reasons why patients with Parkinson’s disease who live in the
South experience higher direct medical costs compared to patients who live in the
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Northeast. First a difference may exist in treatment patterns of physicians in the South
compared to physicians in the Northeast. Previous research has demonstrated different
patterns of treatment for the same disease state by physicians depending on geographic
location.171 Second, patients in the South and Northeast may differ in when and how
frequently they access healthcare services related to direct medical costs. It is possible
that patients living in the South do not access healthcare until later in the disease process
when more expensive and costly treatments will be necessary. Previous studies have
established that patients living in rural areas are more likely to rank poorly on health
indicators such as health behaviors, mortality and morbidity.172 Third, geographic
distribution of the elderly may also play a role in the increased cost for patients with
Parkinson’s disease who live in the South. Between 1990 and 2000, the greatest
proportion of increases in the elderly population was reported in the South and West .173
Specific to the South, the increases in the elderly population were seen in the South
Atlantic states.173 The South and West regions of the United States have also
experienced the greatest increases in the oldest of the old population, which are those
people age 85 and older.173 Finally, Parkinson’s disease differences may exist between
the two regions that are not known. For example, Parkinson’s disease is thought to be
caused by exposure to environmental toxins. ’ ’

Patients living in the South may be

experiencing more severe symptoms due to more environmental exposure to these toxins
and therefore they require more healthcare services than patients with Parkinson’s disease
residing in the Northeast.
There are three possible reasons why so few statistically significant differences were
found in this study. First, it is possible that statistically significant cost differences do

exist within each of the components (direct medical costs, direct non-medical costs and
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indirect costs) of cost of illness when they are further broken down. For example, mean
direct medical costs were not statistically significant between various age groups,
however prescription medication costs may be significantly higher for people in the under
65 age group. Second, other variables outside of the selected demographics for this study
may be predictors of cost of illness for Parkinson’s disease. Finally, no other variables
may exist that are predictive of costs for Parkinson’s disease.

Implications of the Study

Implications fo r Patients and Caregivers
Patients with Parkinson’s disease primarily will find this study useful in financial
planning. When institutionalized (MEPS-NHC) and non-institutionalized (MEPS-HC)
costs were considered together, the majority of direct medical costs were due to nursing
home costs and prescription medication costs. One implication of the prescription
medication costs for patients with Parkinson’s disease is the introduction of Medicare
Part D. This is important specifically because Medicare Part D limits the uptake of new
medications that Parkinson’s disease patients sometimes require. In addition to financial
planning, patients will find it useful to know that the most frequently utilized healthcare
services related to Parkinson’s disease are office based visits and home health visits.
Direct non-medical costs due to Parkinson’s disease in this study were primarily for
home modifications. The direct non-medical costs most commonly reported in this study
were bathroom aides such as handrails for the shower and raised toilet seats. Patients will
find it useful to know that the direct non-medical items in this study were generally
inexpensive and related to mobility in the home.
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The majority (88%) of indirect costs were due to bed-days (morbidity). Patients will
find it useful to know that approximately 20% of patients in this study reported having
bed-days due to Parkinson’s disease. This is important information because patients
restricted to the bed due to their Parkinson’s disease will require the assistance of either a
formal or an informal caregiver. Informal care giving has previously been established as
the largest financial burden on family members of patients with Parkinson’s disease.23

Implications fo r Healthcare Policy
Although the prevalence of Parkinson’s disease is low compared to other chronic
disease states, the cost of Parkinson’s disease in the United States was found to be
substantial. Previous to this study, the clinical impact of Parkinson’s disease was known
to be overwhelming; however, little was known regarding the economic impact. It has
been hypothesized that new medications for Parkinson’s disease that slow the progression
of the disease potentially improve not only the Health Related Quality of Life (HRQL)
but also reduce the use of healthcare resources.151 Healthcare policy makers can use
these findings to plan for future resource allocation to efforts geared at reducing the
effects of or potentially searching for cures for Parkinson’s disease. One final policy
implication from this study would be that nursing home data needs to be collected on a
more regular basis in order to track trends in nursing home admissions.

Implications fo r Healthcare Providers and Insurers
The greatest portion of costs for patients with Parkinson’s disease came from nursing
home care. As the number of people with Parkinson’s disease rises due to increased life
expectancy, the need for healthcare providers in nursing homes may also increase. This
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study found that the high utilization of a healthcare service was not always associated
with high costs and low utilization of a particular healthcare service was not always
associated with low costs.
For the non-institutionalized population (MEPS-HC) healthcare services for direct
medical costs that had the highest costs were prescription medications and home health
visits. The weighted number of prescription medications was six times higher than the
weighted number of home health visits however, the cost of home health visits were only
slightly lower than the cost of prescription medications. Healthcare insurers may find
this information useful if a prescription medication reduces the need for or the frequency
of home health visits.
For direct medical costs, one healthcare service with high costs, but low utilization
was inpatient stays. Hospital stays are the most expensive component of healthcare.175,176
Healthcare providers and insurers may need to find out why the cost of inpatient stays are
so expensive for so few patients with Parkinson’s disease and see what, if any, preventive
measures could have been instituted. For example, if the inpatient stays were related to
falls, healthcare insurers may want to cover the cost of inexpensive items such as
handrails in the shower that would reduce the risk of a fall. Another source of the high
cost of inpatient stays in this study was the length of stay for the patients with
Parkinson’s disease. Healthcare providers and insurers may want to look at other costeffective alternatives that shorten the length of a patient’s stay in the hospital.
Two of the largest components of direct medical costs that were found as a result of
this study were nursing home costs and prescription medications. This trend will
continue for two reasons. First, as life expectancy increases, so does the likelihood o f
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developing Parkinson’s disease. It is very likely that the number of people entering
nursing homes with Parkinson’s disease will increase over the next several years.
Second, as new and more costly treatments are developed, medication costs for
Parkinson’s disease will remain high or increase. New medications used for treating
Parkinson’s disease have been approved by the Food and Drug Administration (FDA)
since 2003. The utilization of these new medications will initially increase the direct
medical cost of Parkinson’s disease. Eventually, however, the number of people entering
nursing homes may be reduced, or at least delayed, due to the use of new medications.
This may reduce the direct medical costs for nursing home care.
Since 2003, four new medications have been approved by the FDA for treatment of
Parkinson’s disease. While these medications were not included in the medication cost
estimates for this study, they do have important implications for the cost of Parkinson’s
disease, especially to healthcare providers and insurers. The first medication that was
approved by the FDA for patients with Parkinson’s disease is apomorphine hydrochloride
(Apokyn®). This medication was approved for use in the treatment of Parkinson’s
disease in 2004 and is indicated to treat the approximately 10 percent of patients who are
unresponsive to existing Parkinson’s disease medications.120 This medication is also used
in patients with Parkinson’s disease who have reached stage 4 of Parkinson’s disease and
are experiencing severe on/off motor fluctuations.120 Apomorphine hydrochloride
(Apokyn®) has received “orphan” drug status due to the low number of patients it is
targeted to treat. Orphan drug status means that this medication will have an extended
patent life, making the manufacturer the exclusive marketer of this medication for several
years.
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Health insurers, such as Medicare, that insure the elderly, (the primary age group with
Parkinson’s disease) will find new medications of particular interest. The implications
for healthcare providers and insurers of this new medication are two-fold. First, the initial
expense of the medication to patients and healthcare insurers will be higher than previous
medications used to treat Parkinson’s disease. However, the patients using this
medication should eventually require fewer healthcare services. Healthcare insurers
should therefore, begin to see reduced healthcare expenses for these patients, but only in
the small percentage of patients with Parkinson’s disease who require apomorphine
hydrochloride (Apokyn®). A final implication of this medication is that since the
medication is under an extended patent, a less-expensive generic version will not be
available for awhile. This means that if a healthcare insurer has a patient requiring
apomorphine hydrochloride (Apokyn®), there will not be a viable cheaper option for at
least seven years.
Additional new medications approved by the FDA since 2003 include Stalevo®,
Parcopa®, and Azilect®. Stalevo® and Parcopa® were both approved in 2004 while
Azilect® was approved in 2006 for the treatment of Parkinson’s disease. Since these
medications will treat more patients with Parkinson’s disease than Apokyn®, there are
some additional implications to healthcare providers and insurers.
Stalevo® is a combination of levodopa, carbidopa and entacapone.121 Stalevo®
allows some patients with Parkinson’s disease to take only one pill per day instead of
two.

Stalevo® is also less expensive than taking the same medications (carbidopa,

levodopa, and entacapone) separately. Healthcare insurers may find Stalevo® a viable
option for reducing medication costs for their patients with Parkinson’s disease.
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However, this is not a new therapeutic modality, so all previous limitations and side
effects still apply.
Parcopa® is another medication that was approved by the FDA since 2003 for the
treatment of Parkinson’s disease. Parcopa® is a combination of carbidopa and levodopa
that dissolves on the tongue and can be taken without water.122 Since being released in
2004, some doctors have reported that Parcopa® may be beneficial to patients with
gastrointestinal issues.123 There have also been reports that Parcopa® may be of practical
use when patients with Parkinson’s disease are having swallowing problems or patients
that are undergoing procedures that do not allow anything to be taken by mouth.123
Currently there are no published studies of Parcopa® and it is more expensive than the
existing generic and brand name combinations of carbidopa and levodopa. Healthcare
providers may find this new medication an option for a patient experiencing
gastrointestinal issues or swallowing issues.
Azilect® is a mono-therapy that was approved in May 2006 by the FDA for the
treatment of Parkinson’s disease.124 Because this medication was recently approved by
FDA, there are no published studies on the cost-effectiveness of Azilect®. However,
Azilect® has been shown to significantly improve Unified Parkinson’s Disease Rating
Scale (UPDRS) total score in clinical trials.125 Healthcare providers may find the single
therapy (mono-therapy) useful to patients that are having difficulty with other
Parkinson’s disease medications. Healthcare insurers may find it useful to know that
UPDRS total scores improved in clinical trials. The improved UPDRS total scores may
correlate with decrease patient needs for medications patients require and visits with
medical professionals (i.e., doctors, physical therapists etc.).
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Implications for Health Care Administrators
This cost of illness study has provided the first initial insight into the cost of illness
and pattern of expenditures for Parkinson’s disease on a national level. In addition, this
study has provided insight into utilization patterns of healthcare services by patients with
Parkinson’s disease. Using this study as a baseline, future cost of illness studies on
Parkinson’s disease will be able to track the patterns of expenditures and utilization of
patient services. The cost of illness study presented here may provide health care
administrators with insight into the categories of spending that may be modified so that
total expenditures are decreased. Finally, this research will be useful to health care
administrators when applying for grants because the National Institutes of Health (NIH)
use cost of illness studies such as this one when making decisions on the allocation of
research funding.177

Limitations of the Study
The primary limitation of this study was that multiple data sources were used to make
an estimate of the cost of Parkinson’s disease. Because of this, the population used to
make the cost of illness estimate was not from one sample of people. Therefore, data
analyses beyond descriptive statistics were limited to within population samples from the
same source. Another limitation of this study is due to the source of the nursing home
data. While the primary data source for this research was the 1999-2003 MEPS-HC data,
the estimate for the nursing home portion came from the 1996 MEPS-NHC data. Despite
using the CPI for nursing home costs, it is likely that the estimate presented in this study
is low. The number of patients reporting Parkinson’s disease increased each year in the
MEPS-HC. The CPI for nursing home was multiplied by the cost for the number of
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patients who reported having Parkinson’s disease in 1996, assuming no volume increase.
The estimate for nursing home costs presented here is lower than the actual cost for
nursing home cost for patients with Parkinson’s disease.
Another limitation is that this study did not take into account any new prescription
medications for Parkinson’s disease that have come onto the market since 2003. The
introduction of new medications may initially increase the medication cost component for
Parkinson’s disease. However, later gains may be realized due to improved health.
Therefore the cost of illness for Parkinson’s disease may start to decline.
Two additional limitations are related to the estimate of direct non-medical costs for
patients with Parkinson’s disease. The first limitation was due to the methodology
utilized for calculating direct non-medical costs. Items selected for inclusion in this
category had to be classified as either a home modification, a bathroom aid, or a specified
other. The cost specified “other” had to be clarified further by the patient as an item that
would be necessary due to Parkinson’s disease (i.e., a lift on a van for a wheel-chair).

It

is possible that a patient reported items in another direct non-medical cost category (i.e.,
glasses, exercise equipment, etc) that were not captured using the above methodology.
The second limitation of the direct non-medical cost estimate was due to patients failing
to report direct non-medical expenditures. A patient may not have associated their
Parkinson’s condition as the source of a non-medical expense. For example, a patient
may have purchased handrails for their bathtub because of poor balance due to their
Parkinson’s disease, but when reporting expenses in the other medical expenses category,
the patient failed to associate the poor balance with their Parkinson’s disease state.
A data limitation of this study related to the indirect costs was the frequency of
missing daily wage rate data for morbidity costs related to missed work days. Missing
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daily wage rates was a limitation because it was necessary to know daily wage rates to
estimate morbidity costs due missed work days. In order to make an estimate of the
morbidity costs due to missed work, the Bureau of Labor Statistics (BLS) wage data were
used to estimate the daily wage rate for patients who reported missing work due to
Parkinson’s disease.35 To overcome this limitation and make an estimate of daily lost
wages due to Parkinson’s disease, the demographics (age, race and gender) of patients in
this study were used to determine the daily wage amount that their labor would have
earned. This daily wage amount was calculated for each of the individuals reporting
missed work days and allowed for an estimate or morbidity costs due to missed work
days.
There were limitations of the sources of data used in this study. For the MEPS data,
the first limitation is that sample size precludes some analysis.178 Specifically, analysis at
the state level is not possible and single year analyses of rare diseases are not possible
due to the sample size limitations.178 The second limitation of the MEPS-HC data is due
to responder bias. Household respondents may not accurately report information related
to their health (i.e., diagnosis) and their healthcare (i.e., type of health plan).178 One final
limitation related to the data sources of this study is that caregiver costs are not collected
by the MEPS and thus reported cost estimates underestimate the true cost.
The other data sources, National Vital Statistics Survey (NVSS) and Bureau of Labor
Statistics (BLS), also had some limitations. Both the NVSS and the BLS reported limited
race category information.35'38 The race categories reported included white, black and
other. In 2002, the NVSS began to expand the categories of race to include Asian and
American Indian. However, BLS only incorporated wage information for the Asian race
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category, making it difficult to obtain an exact estimate of lost wages. While the majority
of patients with Parkinson’s disease are white, it is important to note this data limitation.
Three limitations of the study methodology need to be noted. The first of the study
methodology limitations is related to the way in which morbidity and mortality costs
were estimated in this study. This study used the human capital approach to calculate the
indirect cost of Parkinson’s disease. According to the human capital method, a person
generates a stream of earnings valued at market earnings. The value of human life is
based on market earnings and therefore likely underestimates the value of children and
retired persons.34 Since a relatively large number of Parkinson’s disease patients are
elderly and retired, the cost estimates presented here for mortality and morbidity are
likely underestimated.
The second limitation is due to the methodology used to calculate wage for morbidity
costs. The BLS data provided an average wage based on gender, race and age for people
in the United States. The BLS data could be a source of bias because the wage data are
averaged for the United States as a whole and averages for individual regions (Northeast,
West, South and Mid-West) of the country were not available. The average wage an
individual earns may differ depending on the region of the United States that an
individual resides. If wage data had been used based on each region in the United States,
the estimate presented here may have been different.
The third methodological limitation of this study was that it did not include an
estimate for intangible costs. The difficulty of measuring the intangible costs of any
disease has previously been established.31 However, it would be reasonable to expect
that a chronic, progressive disease such as Parkinson’s disease would have high
intangible costs.
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Conclusions
The overall total cost of illness in 2003 was estimated by this study to be over six
billion dollars annually for the 625,143 patients with Parkinson’s disease. Mean annual
overall total costs (minus nursing home costs and mortality costs) for males with
Parkinson’s disease were $1,970 higher than females with Parkinson’s disease. Patients
with Parkinson’s disease who were widowed had the highest mean total cost of illness.
Patients living in the South and patients with less than a high-school education reported
higher mean overall total cost of illness for Parkinson’s disease. Also, patients under the
age of 65 had the highest mean overall cost of illness for Parkinson’s disease. However,
none of the selected demographic characteristics were found to be statistically significant
for predicting the overall cost of illness in Parkinson’s disease.
Statistically significant differences for the non-institutionalized were found among
patients with Parkinson’s disease for direct medical costs. Specifically, this study
concluded there are statistically significant differences in direct medical costs between
male and female patients with Parkinson’s disease. This study also concluded that there
are statistically significant differences in direct medical costs for patients who live in the
South compared to patients residing in the Northeast.
In this study, direct non-medical costs were the least frequently reported cost by
patients with Parkinson’s disease. Less than 10% (21) of patients with Parkinson’s
disease in this study reported having direct non-medical costs due to their illness. Of
those patients reporting direct non-medical costs, the majority were reporting costs
related to home modifications such as raised toilet seats and shower handrails. The
majority of these direct non-medical costs were low with the exception of one person
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who reported that because of their Parkinson’s disease they had made $35,000 in home
modifications.
For non-institutionalized patients with Parkinson’s disease, indirect costs, specifically
bed-days, made up a large percentage (26%) of the overall total cost estimate reported
here. Mean indirect costs were highest for patients living in the West and lowest for
patients living in the Northeast. Patients who live in the South comprised the largest
portion (60%) of patients reporting indirect costs due to morbidity. However, there were
no statistically significant differences in selected demographic characteristics and indirect
costs for patients with Parkinson’s disease.
The cost of illness presented here is the first one ever conducted at the national level
for Parkinson’s disease using the MEPS database. This study utilized a comprehensive
methodology to estimate the national cost of illness of Parkinson’s disease. By selecting
out only costs specific to Parkinson’s disease, the methodology used in this study
eliminated the possibility of including costs for co-morbid conditions. All components of
cost of illness for Parkinson’s disease were measured in this study with the exception of
intangible costs. The methodology used in this study gathered costs in all categories of
direct medical costs and included; prescription medications, office-based visits,
emergency room visits, inpatient stays, outpatient visits, home health visits, and nursing
home stays. Direct non-medical costs were also included in this cost of illness estimate as
well as indirect costs for morbidity (bed days and missed work days) and mortality.
None of the previous cost and burden of illness studies for Parkinson’s disease
measured all the direct medical costs that were measured in this study, and none of the
previous studies that measured a specific segment of direct medical costs were at the
national level 19>20"23*51-151-153 Direct non-medical costs were measured in only two of the
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previous studies of cost and burden of illness for Parkinson’s disease.23,151 Neither of the
previous cost studies for Parkinson’s disease that measured direct non-medical costs was
at the national level. Indirect costs for morbidity costs due to Parkinson’s disease were
measured by five previous studies; however, none of the previous studies included
mortality costs.19,20,23,151,152 Also, none of the previous morbidity estimates were at the
national level.
The estimate of approximately six billion dollars annually for non-institutionalized
patients is within the lower range of previous national estimates of the cost of Parkinson’s
disease.7,8 However, because those estimates lacked clear methodology, the
reproducibility and reliability of those estimates are questionable. The methodology
utilized and described in this study are reproducible, reliable, and comprehensive. As
with this study, future cost of illness studies should continue to follow the methodology
outlined in 1966 by Dr. Dorothy Rice.28

Recommendations for Future Research
The purpose of this study was to determine the cost of illness due to Parkinson’s
disease. This section proposes ideas for future research to advance the knowledge of the
cost of illness for Parkinson’s disease. First, each component of the cost of illness (direct
medical costs, direct non-medical costs, and indirect costs) will be discussed and
suggested methodological improvements for future research.
For direct medical costs, future research should focus on nursing home patients and
study the length of time between when the patient was diagnosed with Parkinson’s
disease to when they were admitted into the nursing home. Such a study would look at

gender differences in admissions, and marital status of the person being admitted to the
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nursing home. With regards to marital status and nursing home admissions for patients
with Parkinson’s disease, it would be useful to see if patients who are married are
admitted later in the Parkinson’s disease process than patients who are single, divorced,
or widowed. Finally, it would be useful to look at the region of the country where the
nursing home is located to see if there are any regional variations in costs and admissions
of patients with Parkinson’s disease.
One previous burden of illness study in North Carolina reported that informal
caregiver costs were a significant portion of the cost burden in the Parkinson’s
population.23 Due to the high frequency and cost of morbidity related to bed days
reported in this study, research to better estimate the caregiver costs for patients with
Parkinson’s disease should be conducted. It is likely that many of the people reporting
bed days for Parkinson’s disease received some type of informal or non-paid care. Since
the data sources used in this study did not include this type of information, it would be
useful to know the informal care costs for patients with Parkinson’s disease. This type of
informal care costs for patients with Parkinson’s disease would not only provide insight
into the costs, but also the sources (i.e., spouse, sibling, or children) of informal care.
Cost of illness studies provide valuable information when the methodologies used are
comprehensive and clearly stated as this study has demonstrated. An additional
recommendation for future research is to conduct another national cost of illness study
for Parkinson’s disease that compares costs for patients with Parkinson’s disease to
people without Parkinson’s disease. This type of study would provide insight into
healthcare resource utilization differences for patients with Parkinson’s disease compared
to people who do not have Parkinson’s.
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One final recommendation for future research is to examine cost differences between
different categories of services (i.e., prescription medications, home health services, etc.)
and selected demographic factors. The cost for each particular category of service would
be the dependent variable and the selected demographic factors would be the independent
variables. If significant cost differences were found in a particular demographic category
for a particular healthcare service, then patients, healthcare providers, and healthcare
insurers would have a better idea of what to expect once a diagnosis of Parkinson’s
disease is made.
Although this study answered the primary research question and subsequent objectives,
it has created other questions. Future research questions should therefore address the
following:
1. What are the demographic characteristics that are predictive of higher overall total
cost of illness for patients with Parkinson’s disease?
2. What are the other demographic characteristics that were not used in this study
that are predictive of higher direct medical costs for patients with Parkinson’s
disease?
3. What are the demographic characteristics that are predictive of higher indirect cost
of illness for patients with Parkinson’s disease?
4. Based on gender, which specific component(s) of direct medical costs were
significantly higher for patients with Parkinson’s disease?
5.

Based on region, which specific component(s) of direct medical costs were
significantly higher for patients with Parkinson’s disease?

6. Based on region, which specific component(s) of direct medical costs were
significantly higher for patients with Parkinson’s disease?
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7. What impact (cost-effectiveness, cost benefit, cost utility) will new medications
that have been approved since 2003 have on the burden of illness for patients with
Parkinson’s disease?
8. Will new medications approved since 2003 prove effective at reducing direct
medical costs (i.e., will nursing home costs be lowered) for Parkinson’s disease?
9. Will new medications approved since 2003 increase quality of life such that
patients with Parkinson’s disease require less informal care, thereby reducing lost
income and increasing productivity of informal care-givers?
10. What effect will increasing life expectancy have on the overall total cost, direct
medical costs, direct non-medical costs, and indirect costs of Parkinson’s disease?
11. What are the other costs of Parkinson’s disease (i.e. humanist costs) that were not
covered in this study?
Cost of illness studies provide valuable information and insight into disease states
when the methodologies used are comprehensive and clearly stated as this study has
demonstrated. While not as costly a disease state as Alzheimer’s, Parkinson’s disease is a
more costly disease when compared to Multiple Sclerosis, a disease state with a similar
prevalence. This study has provided an initial and crucial stepping stone in
understanding the costs associated with Parkinson’s disease. Future research of the cost
of illness of Parkinson’s disease will now have a reliable baseline foundation from which
to work.
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e n clo se d stum ped e n v elo p e. Please in d icate p erm issio n below:

S incerely,

her n u AwffegD/V
K acitetiitc A nderson
G rad u ate S tudent
H eallh S cience A dm in istratio n Program
T h e U niversity o f T ennessee H ealth S cience
8 4 " M o n ro e A venue, S uite 21)5M
M em phis, T N 38 1 6 3
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(Tin IRS me n it »»rijrtl to nytH to iM tig e to rto provide addilima! jnfonnslioii o n ce n ta jlh pnpo«I.J

Submission requires original and 2 copies.

OS NOTWRITE BELOWTHIS L«£

IRBACTION:

Approved w^proviBO(e)_

Apprtnuad.

■Ulxu U

Referred For Bond Rwiew

.1

Ln7)U"ifclMitndtrtyr&b..

At*j***A-#M *UM6 ‘
HI..HU&).

Consent Required: N o _

W CFft .

^ _______ ______

Vm __

Not Applicable___

Writtei___

Sflmd___

m

Date

(Rw. 11/2003)
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APPENDIX C. LISTING OF ALL VARIABLES
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MEPS HC - 077A - Prescribed Medicines Data 2003
DUPERSID - 8 character variable that uniquely identifies each person
PERWT03F - final person level weight
RXICD1X - the first reported medical condition associated with the prescribed medicines
RXICD2X - the second reported medical condition associated with the prescribed
medicines
RXICD3X - the third reported medical condition associated with the prescribed
medicines
RXNAME - prescription name reported by the pharmacist
RXRECIDX - uniquely identifies each prescription medication record on file
RXXP03X - sum of payments for prescribed medicines, sums all the expenditures from
various sources of payment
PSU9603 - variance estimation PSU for all years of MEPS-HC (1996-2003)
STRA9603 - variance estimation stratum for all years of MEPS-HC (1996-2003)
MEPS HC- 077C - Other Medical Expenses 2003
DUPERSID - 8 character variable that uniquely identifies each person
EVNTIDX - event identification number
OMOTHOS - other medical expenses that do not fall into the OMTYPE categories
OMOTHOX - edited other medical expenses not included in OMTYPE
OMTYPE - other medical expenses (glasses, orthopedic items, ambulance services,
hearing devices, bathroom aids, medical equipment, diabetic equipment, prostheses,
alterations to home, and disposable supplies)
OMTYPEX - other medical expenses (edited)
OMXP03X - sum of all 12 sources of payments
PERWT03F - final person level weight
VARPSU03 - variance estimation PSU
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VARSTR03 - variance estimation stratum

MEPS HC - 077D - Hospital Inpatient Stays Data 2003
ANYOPER - any operations or surgeries performed
DUPERSID - 8 character variable that uniquely identifies each person
EVNTIDX - event identification number
IPDXP03X - sum of doctor payments for inpatient stays
IPFXP03X - sum of facility payments for inpatient stays
IPICD1X - first medical condition linked to patient stay
IPICD2X - second medical condition linked to patient stay
IPICD3X - third medical condition linked to patient stay
IPICD4X - fourth medical condition linked to patient stay
NUMNIGHX - number of nights in hospital
PERWT03F - final person level weight
RSNINHOS - reason in hospital
SPECCOND - was hospital stay related to condition
VARPSU03 - variance estimation PSU
VARSTR03 - variance estimation stratum
MEPS HC - 077E - Emergency Room Visits Data 2003
DUPERSID - 8 character variable that uniquely identifies each person
ERDXP03X - doctor sum payments (ERDSF03X-ERDOT03X)
ERFXP03X - facility sum payments (ERFSP03X-ERFOT03X)
ERICD1X - first medical condition linked to emergency room visit
ERICD2X - second medical condition linked to emergency room visit
ERICD3X - third medical condition linked to emergency room visit
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EVNTIDX - event identification number

PERWT03F - final person level weight
VARPSU03 - variance estimation PSU
VARSTR03 - variance estimation stratum
VSTCTGRY - best category for care patient received
VSTRELCN - was this visit related to specific condition
MEPS HC - 077F - Outpatient Visits Data 2003
DUPERSID - 8 character variable that uniquely identifies each person
EVNTIDX - event identification number
MEDPRESC - any medicine prescribed for patient this visit
MEDPTYPE - type of medical care provider seen by patient on this visit
OPICD1X - first medical condition linked to outpatient department visit
OPICD2X - second medical condition linked to outpatient department visit
OPICD3X - third medical condition linked to outpatient department visit
OPICD4X - fourth medical condition linked to outpatient department visit
OPDXP03X - sum of doctor payments (OPDSF03-OPDOT03X)
OPFXP03X - sum of facility payments (OPFSF03X-OPFOT03X)
PERWT03F - final person level weight
VARPSU03 - variance estimation PSU
VARSTR03 - variance estimation stratum
VSTCTGRY - best category for care patient received
VSTRELCN - was this visit related to specific condition
MEPS HC - 077H - Home - Health Visits Data 2003
D U P E R S ID - 8 character variable that uniquely identifies each person
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EVNTIDX - event identification number

HHXP03X - sum of payments for home health visits
PERWT03F - final person level weight
VARPSU03 - variance estimation PSU
VARSTR03 - variance estimation stratum
MEPS HC - 073 - Full Year Population Characteristics Data 2003
VARPSU03 - variance estimation PSU
VARSTR03 - variance estimation stratum
DUPERSID - 8 character variable that uniquely identifies each person
AGE03X - age (December 31, 2003)
HIDEG03 - highest educational degree completed (December 31, 2003)
RACEX - ethnic/racial origin
RACETHNX - ethnicity category of the person
HISPANX - Hispanic ethnicity
HISPCAT - specific Hispanic ethnicity group
COMBINEDRACE - This variable was created by combining RACE01X, RACETHNX,
HISPANX, and HISPCAT to get a detailed race of the person
SEX - gender
TTLP03X - person's total income
MARRY03X - marital status as of December 31, 2003
REGION03X - census region were the person lived as of December 31, 2003
POVCAT03 - poverty level as of December 31, 2003
MEPS HC - 074 - Jobs File Data 2003
DUPERSID - 8 character variable that uniquely identifies each person
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OCCPCODX - condensed occupation code

JOBTYPE - self-employed or work for someone else
JSTOPD - job stop date - day
JSTOPM - job stop date - month
JSTOPY - job stop date - year
JSTRTD - job start date -day
JSTRTM - job start date - month
JSTRTY- job start date - year
HRLYWAGE - how much person makes per hour
MAKEAMT - how much does person make
Y CHANGE - why change in full or part-time status
WHY LEFT - reason why not at job now
RETIRJOB - person retired from job
SICKPAY - is there paid sick leave
PAYDRVST - is there paid sick leave for doctor visits
WORKSTAT - foil or part-time
HRSPRWK - number of hours worked per week
APXHRDAY - approximate number of hours worked per day
DW - daily wage rate
HRSPRDY - number of hours worked per day
WKLYAMT - usual weekly gross income
MEPS HC - 078 - Medical Conditions Data 2003
PERWT03F - final person level weight
VARPSU03 - variance estimation PSU
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VARSTR03 - variance estimation stratum

DUPERSID - 8 character variable that uniquely identifies each person
COND1DX - condition id
ICD9CODX - ICD -9 code for condition
CONDBEGD - day condition started
CONDBEGM - month condition started
CONDBEGY - year condition started
MISSWORK - was condition associated with missed work days
INBEDFLG - flag, associated with bed days
MEPS NHC - 00IP - Nursing Home Component 1996
DUPERSID - 8 character variable that uniquely identifies each person
AGEY - age (December 31, 1996)
SEX - gender
BRACE - racial background
BRACEOS - other specify race
PARKNSON - did person have Parkinson's disease
BHISPAN - is sample person Hispanic
EDULEV - level of education
BMRKSAD - marital status at admission
SADDD - admission date (day)
SADMM - admission date (month)
SADYY - admission date year
MEPS NHC - 00IF - Nursing Home Component 1996
B A S E ID - nursing home identifier
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NUM95ADY - number of admissions in 1999
MEPS NHC - 002 - Nursing Home Component 1996
PERSNUM - person number
SFID - original sampled facility identification
PERSNUM - person number
ORIGPERS - original identification for this person
AKADXMMB - key admission date (month)
AKADXDDB - key admission date day
AKADXYYB - key admission date year
ALIVE - vital status
HISPANX - Hispanic decent
SADMMB - original admission date (month)
SADDDB - admission date (day)
SADYYB - admission date (year)
DODMMX - date of death (month)
DODDDX - date of death (day)
DODYYX - date of death (year)
AGEXY - end date age
STRATM7Y - strata for variance estimation
PSU - PSU for variance estimation
MEPS NHC - 003 - Nursing Home Component 1996
NHID - nursing home identification
TOTPREV - total patient revenues
TOTPDAY - total patient days
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TOTPEXP - total patient expenses

TOTNPREV - total non-patient revenues
MEPS NHC - 003 - Nursing Home Component 1996
STRATM7Y - strata for variance estimation
FRAKEWT - final full year facility weight (ranked)
PSU - PSU for variance estimation
MEPS NHC - 007 - Nursing Home Component 1996
SFID - original facility identification
EXPTOTBX - basic expenditures summed
EXPTOTAX - ancillary expenditures summed
EXPTOTX - total expenditures
DIEMTOT - perdiem of EXPTOTX
PSU - PSU for variance estimation
STRATUM7Y - strata for variance estimation
NVSS - Deaths Final Data for 2003
AGE - age of person at the time of death
GENDER - was person who died male or female
RACE - race of person who died (white, black, or other)
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APPENDIX D. FORMULAS FOR COST CALCULATIONS

222

Formula for Costs in Other Medical Expenses Event File (HC-077C)
Step One: Add together all reported events for the Other Medical Expenses Event file.
OMXP03X

+

OMXP03X

+

OMXP03X

=

Unweighted Patient Total for
Other Medical Expenses

Where: OMXP03X = sum of all payments for Other Medical Expenses.
Step Two: Multiply unweighted cost variable total by POOLWT to get amount that
Parkinson’s patients would spend on Other Medical Expenses.
OMXP03 XUWPT

X

POOLWT
(person weight)

=

OMXP03XWPT

Step Three: Add together all weighted totals for to arrive at a national estimate for other
medical expenses.
£ (OMXP03XWPT)

=

OMXP03XWOT
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Formula for Costs in Hospital Inpatient Stay Event File (HC-077D)
Step One: Add together all reported events for the specific event file.
IPFXP03X

+

IPFXP03X

+

IPFXP03X

=

IPFXP03UWPT

Where: EPFXP03X = sum of facility payments for inpatient stays and IPDXP03X = sum
of doctor payments for inpatient stays.
Step Two: Multiply unweighted cost variable total by POOLWT to get amount that
Parkinson’s patients would spend on Flospital Inpatient Stays.
IPFXP03UWPT

X

POOLWT
=
(person weight)

IPFXP03WPT

Step Three: Add together all weighted totals for Hospital Inpatient Stays to arrive at a
national estimate.
£ (IPFXP03 XWPT)

=

IPFXP03WOT
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Formula for Costs in Emergency Room Events File (HC-077E)
Step One: Add together all reported events for the specific event file.
ERFXP03X

+

ERDXP03X

+

ERDXP03X

=

ERDXP03 XUWPT

Where: ERFXP03X = sum of facility payments for Emergency Room Visits and
ERDXP03X = sum of doctor payments for Emergency Room Visits.
Step Two: Multiply unweighted cost variable total by POOLWT to get amount that
Parkinson’s patients would spend on Emergency Room Visits.
ERDXP03 XUWPT

X

POOLWT
=
(person weight)

ERDXP03 XWPT

Step Three: Add together all weighted totals for Emergency Room visits to arrive at a
national estimate.
£ (ERDXP03XWPT)

=

ERDXP03XWOT
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Formula for Costs in Outpatient Visits Event File (HC-077F)
Step One: Add together all reported events for the specific event file.
OPDXP03X

+

OPDXP03X

+

OPDXP03X

=

OPFXP03 XUWPT

Where: OPDXPOIX = sum of doctor payments for outpatient visits and OPFXPOIX =
sum of facility payments for Outpatient Visits.
Step Two: Multiply unweighted cost variable total by POOLWT to get amount that
Parkinson’s patients would spend on Outpatient Visits.
OPFXP03 XUWPT

X

POOLWT
=
(person weight)

OPFXP03 XWPT

Step Three: Add together all weighted totals for Outpatient Visits to arrive at a national
estimate.
OPFXP03 XWPT

=

OPFXP03XWOT
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Formula for Costs in Office Based Provider Visits (HC-077G)
Step One: Add together all reported events for the specific event file.
OBSF03X

+

OBSF03X

+

OBSF03X

=

OBSF03XUWPT

Where: OBSF03X = sum of payments for Office Based Provider Visits.
Step Two: Multiply unweighted cost variable total by POOLWT to get amount that
Parkinson’s patients would spend on Office Based Provider Visits.
OBSF03XUWPT

X

POOLWT
=
(person weight)

OBSF03XWPT

Step Three: Add together all weighted totals for to arrive at a national estimate.
£ (OBSF03XWPT)

=

OBSF03XWOT
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Formula for Costs in Home Health Visits Event File (HC-077H)
Step One: Add together all reported events for the specific event file
HHXP03X

+

HHXP03X

+

HHXP03X

=

HHXP03 XUWPT

Where: HHXP03X = sum of payments for home health visits.
Step Two: Multiply unweighted cost variable total by POOLWT to get amount that
Parkinson’s patients would spend on Home Health Visits.
HHXP03UWPT

X

POOLWT
(person weight)

=

HHXP03XWPT

Step Three: Add together all weighted totals for to arrive at a national estimate.
£ (HHXP03XWPT) =

HHXP03XWOT
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Formula for Nursing Home Costs (NHC-003 and NHC-007)
Step One: Add together all reported events for the specific event file
EXPTOTX

+

EXPTOTX

+

EXPTOTX

-

EXPTOTXUWPT

Where: EXPTOTX = sum of all payments for Nursing Home Expenses.
Step Two: Multiply unweighted cost variable total by POOLWT to get amount that
Parkinson’s patients would spend on Nursing Home costs.
EXPTOTXUWPT

X

POOLWT
=
(person weight)

EXPTOTXWPT

Step Three: Add together all weighted totals for to arrive at a national estimate.
£ (EXPTOTXWPT)

=

EXPTOTXWOT
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Formula for Overall Direct and Indirect Cost of Parkinson’s Disease
The following formula was used to determine the overall direct and indirect cost of
Parkinson’s disease.

Overall Total
Cost for
Prescription
Medications

Overall Total
Cost for Inpatient
Visits

+

Overall Total
Cost for Home
Health Visits

+

Overall Total
Cost for
Outpatient Visits

Overall Total
Cost for Office
Based Visits
+

Overall Total
Cost for
Morbidity

—

Overall Total
Cost for Nursing
Home

Overall Total
Cost for
Parkinson’s
disease
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+

Overall Total
Cost for
Emergency Room
Visits

Overall Total
Cost for Other
Medical
Expenses

Overall Total
Cost for
Mortality

+

+

+
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